dcth-10q_20170930.htm

0001564590-17-023836.txt : 20171114 0001564590-17-023836.hdr.sgml : 20171114 20171114173018 ACCESSION NUMBER: 0001564590-17-023836 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC. CENTRAL INDEX KEY: 0000872912 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 061245881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16133 FILM NUMBER: 171203168 BUSINESS ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 489-2100 MAIL ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: DELCATH SYSTEMS INC DATE OF NAME CHANGE: 19990607 10-Q 1 dcth-10q_20170930.htm 10-Q dcth-10q_20170930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-16133

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware		06-1245881
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1633 Broadway, Suite 22C

(Address of principal executive offices)

(212) 489-2100

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer	☐

Non-accelerated filer ☐	(Do not check if a smaller reporting company)	Smaller reporting company	☒

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act . ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 13, 2017, 2,591,509 shares of the Company’s common stock, $0.01 par value, were outstanding.

DELCATH SYSTEMS, INC.

Table of Contents

		Page
PART I—FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016	3
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2017 and 2016	4
	Condensed Consolidated Statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2017	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	41
Item 4.	Controls and Procedure	43

PART II—OTHER INFORMATION

Item 1.	Legal Proceedings	44
Item 1A.	Risk Factors	44
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 3.	Defaults upon Senior Securities	44
Item 4.	Mine Safety Disclosure	44
Item 5.	Other Information	44
Item 6.	Exhibits	45

SIGNATURES		47

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

(in thousands, except share data)

	September 30,			December 31,
	2017			2016
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	2,495		$	4,409
Restricted cash		8,362			27,287
Accounts receivables, net		298			403
Inventories		1,164			660
Prepaid expenses and other current assets		385			698
Deferred financing costs		529			699
Total current assets		13,233			34,156
Property, plant and equipment, net		1,253			1,083
Total assets	$	14,486		$	35,239

Liabilities and Stockholders' Deficit
Current liabilities
Accounts payable	$	1,891		$	594
Accrued expenses		3,755			3,407
Series C preferred shares		494			—
Convertible notes payable, net of debt discount		9,736			13,343
Warrant liability		16			18,751
Total current liabilities		15,892			36,095
Deferred revenue		—			30
Other non-current liabilities		444			604
Total liabilities		16,336			36,729

Commitments and Contingencies		—			—

Stockholders' deficit
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively		—			—
Common stock, $.01 par value; 500,000,000 shares authorized; 1,426,153 and 11,805 shares issued and 1,425,862 and 11,750 shares outstanding at September 30, 2017 and December 31, 2016, respectively*		14			—
Additional paid-in capital		303,808			277,790
Accumulated deficit		(305,587	)		(279,188	)
Treasury stock, at cost; 1 share at September 30, 2017 and December 31, 2016, respectively^*		(51	)		(51	)
Accumulated other comprehensive income		(34	)		(41	)
Total stockholders' deficit		(1,850	)		(1,490	)
Total liabilities and stockholders' deficit	$	14,486		$	35,239

^*reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

See accompanying Notes to Condensed Consolidated Financial Statements.

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share data)

	Three months ended September 30,						Nine months ended September 30,
	2017			2016			2017			2016
Revenue	$	684		$	435		$	2,011		$	1,316
Cost of goods sold		172			112			527			373
Gross profit		512			323			1,484			943

Operating expenses:
Selling, general and administrative		2,860			2,361			7,807			7,025
Research and development		2,279			2,686			7,119			5,975
Total operating expenses		5,139			5,047			14,926			13,000
Operating loss		(4,627	)		(4,724	)		(13,442	)		(12,057	)
Change in fair value of the warrant liability, net		27			8,680			1,227			9,171
Gain on warrant extinguishment		—			—			9,613			—
Loss on debt settlements		(2,952	)		—			(2,952	)		—
Interest expense		(5,042	)		(4,963	)		(20,324	)		(6,584	)
Other income (expense)		(2	)		3			5			(15	)
Net loss	$	(12,596	)	$	(1,004	)	$	(25,873	)	$	(9,485	)
Other comprehensive loss:
Foreign currency translation adjustments		(15	)		(2	)		7			(12	)
Comprehensive loss	$	(12,611	)	$	(1,006	)	$	(25,866	)	$	(9,497	)

Common share data:
Basic and diluted loss per share*	$	(9.36	)	$	(230.99	)	$	(34.99	)	$	(2,232.30	)

Weighted average number of basic and diluted common shares outstanding*		1,401,413			4,349			754,421			4,249

*reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

See accompanying Notes to Condensed Consolidated Financial Statements.

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Stockholders’ Deficit)

(Unaudited)

(in thousands, except share data)

	Common Stock Issued															Accumulated
	$0.01 Par Value				Treasury Stock											Other
	No. of Shares		Amount		No. of Shares			Amount			Additional Paid in Capital		Accumulated Deficit			Comprehensive loss			Total
Balance at January 1, 2017		11,805	$	—		(1	)	$	(51	)	$	277,790	$	(279,188	)	$	(41	)	$	(1,490	)
Compensation expense for issuance of stock options		—		—		—			—			48		—			—			48
Compensation expense for issuance of restricted stock		261		—		—			—			84		—			—			84
Issuance of common stock for payments made in shares on convertible note payable		1,413,790		14		—			—			25,852		—			—			25,866
Series B preferred stock dividend														(526	)					(526	)
Warrants exercised		297		—		—			—			15		—			—			15
Fair value of warrants exercised				—		—			—			19		—			—			19
Net loss		—		—		—			—			—		(25,873	)		—			(25,873	)
Total comprehensive loss		—		—		—			—			—		—			7			7
Balance at September 30, 2017		1,426,153	$	14		(1	)	$	(51	)	$	303,808	$	(305,587	)	$	(34	)	$	(1,850	)

^*reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

See accompanying Notes to Condensed Consolidated Financial Statements.

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	Nine months ended September 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(25,873	)	$	(9,485	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense		48			138
Restricted stock compensation expense		84			228
Depreciation expense		198			232
Loss on disposal of equipment		20			1
Warrant liability fair value adjustment		(1,227	)		(9,171	)
Gain on warrant extinguishment		(9,613	)		—
Non-cash interest income		16			(1	)
Deferred revenue		(30	)		31
Debt discount and deferred finance costs amortization		20,315			6,567
Loss on debt settlements		2,952			—
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets		276			610
Increase in accounts receivable		(94	)		(94	)
Decrease (increase) in inventories		(338	)		190
Increase in accounts payable and accrued expenses		1,767			312
Decrease in other non-current liabilities		(160	)		(155	)
Net cash used in operating activities		(11,659	)		(10,597	)

Cash flows from investing activities:
Purchase of property, plant and equipment		(372	)		(245	)
Increase in restricted cash		—			(1,087	)
Net cash used in investing activities		(372	)		(1,332	)

Cash flows from financing activities:
Increase in restricted cash		—			(29,200	)
Net proceeds from the release of restricted cash		7,901			—
Release of restricted cash for extinguishment of Series C Warrants		7,876			—
Cash paid to extinguish of Series C Warrants		(7,876	)		—
Net proceeds from sale of Series B and Series C preferred shares		2,278			—
Release of restricted cash for redemption of Series A and Series B preferred shares		2,360			—
Redemption of Series A and Series B preferred shares		(2,360	)		—
Net proceeds from convertible debt financing		—			31,436
Net proceeds from sale of stock and exercise of warrants		15			704
Net cash provided by financing activities		10,194			2,940
Foreign currency effects on cash and cash equivalents		(77	)		71
Net decrease in cash and cash equivalents		(1,914	)		(8,918	)

Cash and cash equivalents:
Beginning of period		4,409			12,607
End of period	$	2,495			3,689

Supplemental non-cash activities:
Conversion of convertible notes to common stock	$	26,199		$	—
Fair value of warrants issued	$	—		$	28,133
Fair value of warrants exercised	$	19		$	245

See accompanying Notes to Condensed Consolidated Financial Statements.

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(1)

General

The interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and nine months ended September 30, 2017 and 2016 should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”), which has been filed with the Securities Exchange Commission (“SEC”), as amended by that certain Amendment No. 1 to Form 10-K for the year ended December 31, 2016, filed with the SEC on July 14, 2017 and can also be found on the Company’s website (www.delcath.com). In these notes the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred and fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-three hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

Description of Business

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is in commercial development under the trade name Delcath Hepatic CHEMOSAT^® Delivery System for Melphalan (CHEMOSAT^®), where it has been used at major medical centers to treat a wide range of cancers of the liver.

Our primary research focus is on ocular melanoma liver metastases (mOM) and intrahepatic cholangiocarcinoma (ICC), a type of primary liver cancer, and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need.

Our clinical development program for CHEMOSAT and Melphalan/HDS is comprised of The FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial), a Global Phase 3 clinical trial that is investigating overall survival in mOM, and a registration trial for intrahepatic cholangiocarcinoma (ICC) we plan to initiate in 2017. Our clinical development plan (CDP) also includes a commercial registry for CHEMOSAT non-clinical commercial cases performed in Europe and sponsorship of select investigator initiated trials (IITs) in colorectal cancer metastatic to the liver (mCRC) and pancreatic cancer metastatic to the liver.

Liquidity and Operating Matters

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $305.6 million at September 30, 2017. As shown in the accompanying financial statements during the three and nine months ended September 30, 2017, the Company incurred net losses of $12.6 million and $25.9 million, respectively and during the nine months ended September 30, 2017 used $11.7 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. As a result of issuing $35.0 million in senior secured convertible notes in June 2016 and effecting a reverse stock split on November 6, 2017 management believes that in its current reduced operating mode its capital resources will be adequate to fund operations through at least January 2018. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to clinical research, product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel.

Basis of Presentation

These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2017 and 2016; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.

Significant Accounting Policies

A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K filed for the period ended December 31, 2016.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018. Due to the nature of the Company’s revenue generating activites and the small number of customer contracts, the Company does not anticipate that this guidance will materially impact its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

(2)	Inventories

Inventories consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Raw materials	$	328	$	346
Work-in-process		660		214
Finished goods		176		100
Total inventories	$	1,164	$	660

(3)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Insurance premiums	$	61	$	501
Taxes		53		—
Security Deposit		50		50
Other¹		221		147
Total prepaid expenses and other current assets	$	385	$	698

¹Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at September 30, 2017 and December 31, 2016.

(4)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

(in thousands)	September 30, 2017			December 31, 2016
Buildings and land	$	574		$	556
Enterprise hardware and software		1,648			1,532
Leaseholds		1,659			1,504
Equipment		960			940
Furniture		182			354
Property, plant and equipment, gross		5,023			4,886
Accumulated depreciation		(3,770	)		(3,803	)
Property, plant and equipment, net	$	1,253		$	1,083

Depreciation expense for the three and nine months ended September 30, 2017 was approximately $0.1 million and $0.2 million, respectively, as compared to approximately $0.1 million and $0.2 million, respectively, for the same periods in 2016.

(5)	Accrued Expenses

Accrued expenses consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Clinical trial expenses		1,410		1,365
Compensation, excluding taxes	$	1,132	$	933
Professional fees		448		286
Short-term portion of lease restructuring		221		216
Other¹		544		607
Total accrued expenses	$	3,755	$	3,407

¹Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.

(6)	Restructuring Expenses

In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of September 30, 2017, the total remaining lease restructuring liability for its leased office space was approximately $0.7 million, of which approximately $0.3 million and $0.4 million were included in Accrued expenses and Other non-current liabilities on the condensed consolidated balance sheets, respectively.

The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2017:

(in thousands)	Lease Liability
Reserve balance at December 31, 2016	$	820
Charges		—
Payments/Utilizations		(155	)
Reserve balance at September 30, 2017	$	665

(7)	Convertible Notes Payable

On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes are secured pursuant to a Security Agreement which creates a first priority security interest in all of the personal property (other than Excluded Collateral (as defined in the Security Agreement) of the Company of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future.

The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable, if applicable, in arrears for each calendar month on the first (1st) business day of each calendar month after any such interest accrues after an Event of Default.

Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. An additional $6.6 million was released during the three months ended March 31, 2017. Under the terms of warrant repurchase agreements signed in April 2017 and discussed in more detail below, $7.9 million was returned to the holders in exchange for the extinguishment of the Series C Warrants. During the three months ended September 30, 2017, an additional $2.1 million was released to the Company and $2.4 million was returned to the holders in order to redeem the Series A and Series B Preferred Shares discussed in more detail in Note 8. The remaining cash proceeds of $7.3 million are being held in restricted accounts.

In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire appoximately 20,000 shares of Common Stock. The provisions in the Series C Warrants required the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants. On April 2, 2017 the Company entered into separate warrant repurchase agreements (the “Warrant Repurchase Agreements”) with each of the investors named on the Schedule of Buyers attached to the SPA. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case were paid to the respective investor, in exchange for cancellation of the Warrants issued to each investor under the SPA. As a result of the extinguishment, the Company recognized a gain of $9.6 million, representing the difference between the fair value of the liability as of the extinguishment date of $17.5 million related to the Series C Warrants and the $7.9 million in cash returned to the Note holders to extinguish the liability.

The Company has agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall, at the election of the Company, automatically be converted into shares of Common Stock at a conversion rate defined in the agreement. If we cannot meet the equity conditions, we could be required to repay some or all of the amounts due under the notes in cash, and we may not have the funds available to make one or more of such payments when due. At any time after the issuance of the Notes, the Notes will be convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $1,536.50, subject to adjustment as provided in the Notes.

Restructuring Agreement

On August 28, 2017, the Company entered into a Restructuring Agreement (the “Agreement”) with one of the institutional investors (the “Investor”) who was a party to the SPA. As of the date the Agreement was entered into, the Investor held $11,444,637 aggregate principal amount of Notes of which there was $10,092,857 aggregate Restricted Principal, (as defined in the Notes) of Notes (the “Restricted Notes”), secured by such aggregate cash amount held in a collateral account of the Company in the same amount (the “Restricted Cash”) and (y) $1,351,780 principal of Notes (the “Unrestricted Notes”), (ii) 4,200 shares of Series A Preferred Stock and (iii) 2,006 shares of Series B Convertible Preferred Stock.

Pursuant to the Agreement, (a) on the date thereof the Company and the Investor took the following actions (the “Initial Restructuring”): (i) the Investor released restrictions on $1,650,000 of Restricted Cash (the “Initial Release”), (ii) the Investor consented to the use of additional Restricted Cash to effect redemptions of the Series A Preferred Shares and the Series B Preferred Shares, (iii) the Investor cancelled $1,200,000 aggregate principal of the Notes (such portion of the Notes, the “Cancellation Note”), (iv) the Company redeemed all the Series A Preferred Shares outstanding for a cash payment to the Investor of $4.20 and (v) the Company redeemed the Series B Preferred Shares for a cash payment to the Investor of $2,006,000 and (b) upon the consummation of a reverse stock split of our Common Stock of at least twenty to one (the “Reverse Stock Split Event”, and such date, the “Reverse Stock Split Date”) by September 15, 2017, the Company and the Investor shall have taken the following actions (the “Additional Restructuring”, and together with the Initial Restructuring, the “Restructuring”): (i) the Investor shall consent to the use of Restricted Cash to effect redemptions of $4,000,000 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Redemption Notes”), (ii) the Company shall redeem the Redemption Notes for a redemption price of $6,436,852.80 (the “Redemption Price”) and (iii) the Company shall exchange (the “Exchange”), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, $2,436,852.80 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Exchange Notes”, and together with the Redemption Notes, the “Restructured Notes”) for new warrants to purchase 114,286 shares of its Common Stock (the “New Warrants”, as exercised, the “New Warrant Shares”). The New Warrants expire on the 42 month anniversary of the date of issuance and bear an exercise price of $122.50 per share (which shall be adjusted to the new lower purchase price per share if there is a subsequent “down round” financing). The Investor, in lieu of an exercise of the New Warrants pursuant to a cash payment of the aggregate exercise price of the number of New Warrants being exercised, may exercise the New Warrants, in whole or in part, by electing instead to receive upon such exercise two shares and one hundred and twenty-five thousandths of a share of the Company’s Common Stock for each Warrant Share exercised pursuant to this provision.. The transactions set forth herein were being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended (the “1933

Act”) and Rule 144(d)(3)(ii) of the 1933 Act. As a result of not having effected a reverse stock split by September 15, 2017, the Additional Restructuring did not occur.

Amendment to Restructuring Agreement

As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,551 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75^th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period, (iv) the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes and (v) the conversion floor price on the notes is $0.05 and not subject to adjustments.

The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows:

	Number of Shares of Common Stock		Number of Shares of Preferred Stock		Applicable Conversion Price		Reduction in Principal
January 12, 2017		11,753		—	$	126.00	$	1,478,318
January 26 - February 1, 2017¹		4,857		—	$	112.00		544,000
February 10, 2017		43,882		—	$	70.00		3,045,817
February 23 - March 2, 2017¹		2,571		—	$	49.00		126,000
March 13, 2017		117,297		—	$	38.50		4,417,830
April 10, 2017		169,061		—	$	21.00		3,621,286
May 9, 2017		109,367		—	$	17.50		1,913,915
June 7 / July 2, 2017 Exchange Agreement²		689,796		4,200	$	6.09		4,200,000
July 7, 2017		114,286		—	$	17.50		2,000,000
August 4, 2017		38,906		—	$	24.50		1,015,848
August 28, 2017 Restructuring Agreement³		117,171		—	$	10.50		1,200,000
Total		1,418,948					$	23,563,014

¹During the periods referenced above, the Company and the holders of the Notes agreed to a temporary reduction in the conversion price in order to encourage voluntary conversion of Notes by the holders thereof.

² On July 2, 2017, the Company entered into an exchange agreement with one of its investors which had purchased Notes, for $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock. The Series A Preferred Stock shares were issued to address a short-term valuation issue for 689,796 common shares delivered to the Notes holders to close an installment period. Through the Series A Preferred Shares placement, the Company was able to value the open installment shares such that the amount of debt remaining under the Notes was reduced by $4.2 million. Additionally, the Company recognized a loss on debt settlement of $1.0 million related to this transcation.

³On August 28, 2017, the Company entered into a restructuring agreement with one of its investors which had purchased Notes. The restructuring agreement included a provision to exchange 117,171 shares for $1.2 million aggregate principal amount of such Notes. Additionally, the Company recognized a loss on debt settlement of $2.0 million related to this transaction. The restructuring agreement is discussed in more detail above.

As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants, the Company has recognized a beneficial conversion feature of $4.4 million. The original issue discount, the beneficial conversion feature, and the fair value of the issuance of the Series C Warrants are collectively considered the debt discount. The Company recorded a debt discount in the amount of $35.0 million which is being amortized over the life of the Notes using the effective interest method. As of September 30, 2017, $33.3 million of the debt discount has been amortized to interest expense. In addition to the debt discounts listed above, the Notes also include put options in the event of default and change in control as defined in the Notes. The value of such options was zero as the probability for such events was remote as of the issuance date and at September 30, 2017.

All debt issuance costs are accounted for as a deferred asset and will be amortized over the life of the Notes. As of September 30, 2017, the Company had incurred approximately $1.8 million in debt issuance costs and had amortized approximately $1.2 million of those costs.

The following table summarizes the convertible notes outstanding at September 30, 2017:

(in thousands)
Convertible notes payable, principal	$	11,437
Debt discounts		(1,701	)
Net convertible note payable	$	9,736

(8)	Stockholders’ Equity

Stock Issuances

Reverse Stock Split

On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-three hundred fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.]

On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

In addition, shareholders of the Company also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000. The previously discussed reverse stock split had no impact on the increase in authorized shares.

Recent Preferred Stock Issuances

Series A Preferred Stock

“Series A Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series A Preferred Stock”). On July 2, 2017, we entered into an exchange agreement (the “Exchange”) with one of our investors which had purchased certain senior secured convertible notes (the “Notes”), convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock (the “Series A Preferred Shares”). The Exchange was made in reliance upon the exemption from registration provided by Rule 3(a)(9) of the Securities Act of 1933, as amended. The Series A Preferred Shares were entitled to the whole number of votes equal to $4.2 million divided by $1,288.00 (the closing bid price on June 13, 2016, the date of issuance of the Notes as adjusted for the reverse stock split effected in July 2016,) or 3,261 votes. The Series A Preferred Stock had no dividend, liquidation or other preferential rights to our common stock, and each share of Series A Preferred Stock was redeemed for the amount of $0.001, paid in cash pursuant to the Restructuring Agreement signed on August 28, 2017 and discussed in further detail in Note 7.

Series B Preferred Stock

On June 29, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series B Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series B Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series B Preferred Stock”). On July 11, 2017, we entered into a securities purchase agreement with existing holders of Notes pursuant to which the investors purchased $2,360,000 of Series B Preferred Stock for a cash purchase price of $2,000,000 in a private placement. The Series B Preferred Stock was entitled to the whole number of votes equal to $2.0 million divided by $65.35 (the closing bid price on July 5, 2017, the date of the original securities purchase agreement for the Series B Preferred Stock), or 30,607 votes. The Series B Preferred Stock had no dividend, liquidation or other preferential rights (but had the redemption rights described below) to our common stock and could have been converted into shares of our common stock at a price equal to $53.55 per share upon the earlier of the date of closing to the extent that the holder thereof reallocated shares of our common stock reserved for issuance under its Notes to conversion of the Series B Preferred Shares and otherwise upon receipt of shareholder approval of the Reverse Stock Split. The Series B Preferred Stock allowed for optional redemption by the Company at any time after issuance or the holders at any time after the tenth business day prior to the maturity date. In the instance of a Financing, the Company was required to redeem the Series B Preferred Stock. The $360,000 difference between the redemption amount and the cash purchase price of the Series B Preferred Stock, as well as all issuance costs related to the Series B Preferred Stock, have been recorded as a deemed dividend. The Series B Preferred Stock was redeemed for $2,360,000 pursuant to the Restructuring Agreement signed on August 28, 2017 with one investor and upon a redemption notice from the second investor as discussed in further detail in Note 7.

Series C Preferred Stock

On September 12, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series C Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock which was filed with the State of Delaware on September 20, 2017. On September 21, 2017, we entered into a securities purchase agreement with two of our investors which had purchased Notes, convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $0.5 million aggregate purchase price for 590 shares of Series C Preferred Stock. The purchase of the Series C Preferred Stock is being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended. The Series C Preferred Stock shall be entitled to 1,484,061 votes and may only vote on approval of a reverse split of our outstanding common stock. The Series C Preferred Stock has no dividend, liquidation or other preferential rights to our common stock, and each share of Series C Preferred Stock shall be redeemable for the amount of $1,000.00, payable in cash per share at our written election, and must be redeemed by us no later than December 21, 2017. Because the Series C Preferred Stock is mandatorily redeemable, it has been recorded as a liability with the difference between the purchases price and the fair value being recognized over the term of the instrument. Additionally, all expenses related to the issuance of the Series C Preferred Stock are recognized as a debt discount and have been amortized over the term of the instrument. Per the terms of the October 22, 2017 Amendment to the Restructuring Agreement, the Series C Preferred Stock was redeemed for $590,000 on November 6, 2017.

Warrants

subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At September 30, 2017, the 2013 Warrants were exercisable at $39,424.00 per share with approximately 100 warrants outstanding. The 2013 Warrants have a five-year term.

In February 2015, the Company completed the sale of approximately 440 shares of its common stock and the issuance of warrants to purchase 197 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2017, the February 2015 Warrants were exercisable at $49.00 per share with approximately 100 warrants outstanding. The February 2015 Warrants have a five-year term.

In July 2015, the Company completed the sale of approximately 1,715 Units consisting of approximately 1,715 shares of its common stock, Series A Warrants to purchase up to approximately 1,140 common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 1,715 common shares (“Series B Warrants”) and 1,140 Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the three months ended March 31, 2016, approximately 285 Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 1,140 Series B Warrants expired on January 29, 2016 and the remaining liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 285 Series A Warrants were issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2017, the Series A Warrants were exercisable at $49.00 with approximately 500 warrants outstanding. The Series A Warrants have a five-year term. There were approximately 285 July 2015 Series A Warrants exercised during the nine months ended September 30, 2017 for proceeds of approximately $15,000.

In October 2016, the Company completed the sale of approximately 1,215 shares of its common stock and the issuance of warrants to purchase 425 common shares (the “October 2016 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $1.2 million, with net cash proceeds after related expenses from this transaction of $1.1 million. Of those proceeds, the Company allocated an estimated fair value of $0.3 million to the October 2016 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At September 30, 2017, the October 2016 Warrants were exercisable at $49.00 per share with 200 warrants outstanding. The October 2016 Warrants have a five-year term.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 34 and 573 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 304 shares, from 269 to 573 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of September 30, 2017 there were 55 shares available to grant under the 2009 Stock Incentive Plan.

A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options and Restricted Stock granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee. Options granted under the Plans expire over varying terms, but not more than ten years from the date of grant.

recognized compensation expense of approximately $24,000 and $0.1 million, respectively. There were 43 stock options awards granted during the nine months ended September 30, 2017. There were no stock option awards granted during the same period in 2016.

For the three and nine months ended September 30, 2017, the Company recognized compensation expense of approximately $20,000 and $0.1 million, respectively, relating to restricted stock granted to employees. For the same periods in 2016, the Company recognized compensation expense of approximately $38,000 and $0.2 million, respectively. There were 264 shares of restricted stock granted during the nine months ended September 30, 2017. There were approximately no shares of restricted stock awards granted for the same period in 2016.

(9)	Fair Value Measurements

Derivative Warrant Liability

As disclosed in Note 8 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q, the Company allocated part of the proceeds of public offerings in 2013, 2015 and 2016 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes discussed in further detail in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. The valuation of the October 2013, February 2015, July 2015 Series A, June 2016 Series C and October 2016 warrants (collectively, the “Warrants”) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the three and nine months ended September 30, 2017, the Company recorded pre-tax derivative warrant income of approximately $27,000 and $1.2 million, respectively. The resulting derivative warrant liabilities totaled approximately $16,000 at September 30, 2017. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at September 30, 2017 was determined by using option pricing models with the following assumptions:

	October 2016 Warrants		July 2015 Series A Warrants		February 2015 Warrants		October 2013 Warrants
Expected volatility		142.46%		165.32%		181.24%		227.68%
Risk-free interest rates		1.77%		1.59%		1.53%		1.33%
Expected life (in years)		4.02		2.81		2.38		1.08

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820.

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1		Level 2		Level 3		Balance at September 30, 2017
Liabilities
Derivative instrument liabilities	$	—	$	—	$	16	$	16

For the periods ended September 30, 2017 and 2016, there were no transfers in or out of Level 1, 2 or 3 inputs.

The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2017:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)	Warrant Liability
Balance at December 31, 2016	$	18,751
Total change in the liability included in earnings		(1,227	)
Extinguishment of convertible note warrant		(17,489	)
Fair value of warrants issued		—
Fair value of warrants exercised		(19	)
Balance at September 30, 2017	$	16

(10)	Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. Additionally, for the periods ended September 30, 2017, the deemed dividend related to the Series B Preferred Stock (as discussed further in Note 8) is included with net loss to determine both the basic and diluted loss per share.

The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive:

	September 30,
	2017		2016
Stock options		155		118
Unvested restricted shares		289		54
Warrants		953		21,221
Total		1,397		21,394

(11)

Taxes

As discussed in Note 13 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. During the third quarter of 2015, the Internal Revenue Service commenced an examination of the Company’s federal income tax return for the year ended December 31, 2013. The examination was completed in the third quarter of 2017 and no changes were made to the reported amounts. Accordingly, there was no effect on the financial statements as a result of the examination. The Company has not been audited by the international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

(12)	Subsequent Events

As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,550 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75^th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period, (iv) the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes and (v) the conversion floor price on the notes is $0.05 and not subject to adjustments.

The exercise price for the warrants issued in conjunction with the amended restructuring agreement is $122.50. The warrants contain a cashless exercise provision pursuant to which the warrants may be exercised for 382,650 shares of the Company’s common stock on or after the 75^th day subsequent to the date of consummation of offering hereunder. On the 136^th day subsequent to the date of consummation of the offering hereunder, there shall be a “true up” with regard to the issuance of shares upon exercise such that the difference between 382,650 shares and the number of shares that would be issuable if the exercise price were lowered to the average price per share of the variable weighted average price of our common stock for the five trading days commencing on the date which is 76 days after the date of consummation of the offering hereunder, but not lower than 33% of the variable weighted average price of a share of our common stock on the 81^st date following the date of consummation of the offering hereunder. In lieu of the “true up”, on or before the 135^th date following the date of consummation of the offering hereunder, we may buy out that provision for $6,138,349.80.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2016 included in the Company’s 2016 Annual Report on Form 10-K to provide an understanding of its results of operations, financial condition and cash flows.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q for the period ended September 30, 2017 contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity and results of operations. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should,” and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this Quarterly Report on Form 10-Q for the period ending September 30, 2017 that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Exchange Act and Section 27A of the Securities Act. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in this Quarterly Report on Form 10-Q for the period ended September 30, 2017 in Part II, Item 1A under “Risk Factors” as well as in Part I, Item 3 “Quantitative and Qualitative Disclosures About Market Risk,” our Annual Report on Form 10-K for the period ended December 31, 2016 in Item 1A under “Risk Factors” as well as in Item 7A “Quantitative and Qualitative Disclosures About Market Risk,” and the risks detailed from time to time in our future SEC reports. These forward-looking statements include, but are not limited to, statements about:

•

our estimates regarding sufficiency of our cash resources, anticipated capital requirements and need for additional financing;

•

the commencement of future clinical trials and the results and timing of those clinical trials;

•

our ability to successfully commercialize CHEMOSAT/Melphalan/HDS, generate revenue and successfully obtain reimbursement for the procedure and System;

•

the progress and results of our research and development programs;

•

submission and timing of applications for regulatory approval and approval thereof;

•

our ability to successfully source certain components of the system and enter into supplier contracts;

•

our ability to successfully manufacture CHEMOSAT/Melphalan/HDS;

•

our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate partners; and

•

our estimates of potential market opportunities and our ability to successfully realize these opportunities.

Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

Overview

The following section should be read in conjunction with Part I, Item 1: Condensed Consolidated Financial Statements of this report as well as Part I, Item 1: Business; and Part II, Item 8: Financial Statements and Supplementary Data of the Company’s 2016 Annual Report on Form 10-K.

About Delcath

The direction and focus of our CDP for CHEMOSAT and Melphalan/HDS is informed by prior clinical development conducted between 2004 and 2010, non-clinical, commercial CHEMOSAT cases performed on patients in Europe, and prior regulatory experience with the FDA. Experience gained from this research, development, early European commercial and United States regulatory activity has led to the implementation of several safety improvements to our product and the associated medical procedure.

In the United States, Melphalan/HDS is considered a combination drug and device product, and is regulated as a drug by the FDA. The FDA has granted us six orphan drug designations, including three orphan designations for the use of the drug melphalan for the treatment of patients with mOM, HCC and ICC. Melphalan/HDS has not been approved for sale in the United States.

In Europe, the current version of our CHEMOSAT product is regulated as a Class IIb medical device and received its CE Mark in 2012. We are in an early phase of commercializing the CHEMOSAT system in select markets in the European Union (EU) where the prospect of securing adequate reimbursement for the procedure is strongest. In 2015 national reimbursement coverage for CHEMOSAT procedures was awarded in Germany. In 2016, coverage levels were negotiated between hospitals in Germany and regional sickness funds. Coverage levels determined via this process are expected to be renegotiated annually.

Currently there are few effective treatment options for certain cancers in the liver. Traditional treatment options include surgery, chemotherapy, liver transplant, radiation therapy, interventional radiology techniques, and isolated hepatic perfusion. We believe that CHEMOSAT and Melphalan/HDS represents a potentially important advancement in regional therapy for primary liver cancer and certain other cancers metastatic to the liver. We believe that CHEMOSAT and Melphalan/HDS is uniquely positioned to treat the entire liver either as a standalone therapy or as a complement to other therapies.

Cancers in the Liver – A Significant Unmet Need

Cancers of the liver remain a major unmet medical need globally. According to the American Cancer Society’s (ACS) Cancer Facts & Figures 2017 report, cancer is the second leading cause of death in the United States, with an estimated 600,920 deaths and 1,688,780 new cases expected to be diagnosed in 2017. Cancer is one of the leading causes of death worldwide, accounting for approximately 8.2 million deaths and 14.1 million new cases in 2012 according to GLOBOCAN. The financial burden of cancer is enormous for patients, their families and society. The Agency for Healthcare Quality and Research estimates that the direct medical costs (total of all healthcare expenditures) for cancer in the U.S. in 2014 was $87.8 billion. The liver is often the life-limiting organ for cancer patients and one of the leading causes of cancer death. Patient prognosis is generally poor once cancer has spread to the liver.

Liver Cancers—Incidence and Mortality

There are two types of liver cancers: primary liver cancer and metastatic liver disease. Primary liver cancer (hepatocellular carcinoma or HCC, including intrahepatic bile duct cancers or ICC) originates in the liver or biliary tissue and is particularly prevalent in populations where the primary risk factors for the disease, such as hepatitis-B, hepatitis-C, high levels of alcohol consumption, aflatoxin, cigarette smoking and exposure to industrial pollutants, are present. Metastatic liver disease, also called liver metastasis, or secondary liver cancer, is characterized by microscopic cancer cell clusters that detach from the primary site of disease and travel via the blood stream and lymphatic system into the liver, where they grow into new tumors. These metastases often continue to grow even after the primary cancer in another part of the body has been removed. Given the vital biological functions of the liver, including processing nutrients from food and filtering toxins from the blood, it is not uncommon for metastases to settle in the liver. In many cases patients die not as a result of their primary cancer, but from the tumors that metastasize to their liver. In the United States, metastatic liver disease is more prevalent than primary liver cancer.

Ocular Melanoma

Ocular melanoma is one of the cancer histologies with a high likelihood of metastasizing to the liver. Based on third party research conducted in 2016, we estimate that up to 4,700 cases of ocular melanoma are diagnosed in the United States and Europe annually, and that approximately 55% of these patients will develop metastatic disease. Of metastatic cases of ocular melanoma, we estimate that approximately 90% of patients will develop liver involvement. Once ocular melanoma has spread to the liver, current evidence suggests median overall survival for these patients is generally six to eight months. Currently there is no standard of care (SOC) for patients with ocular melanoma liver metastases. According to our 2016 research, we estimate that approximately 2,000 patients with ocular melanoma liver metastases in the United States and Europe may be eligible for treatment with the Melphalan/HDS.

Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC)

Hepatobiliary cancers – including HCC and ICC – are among the most prevalent and lethal forms of cancer. According to GLOBOCAN, an estimated 78,500 new cases of primary liver cancers are diagnosed in the United States and Europe annually. According to the ACS, approximately 40,710 new cases of HCC and ICC will be diagnosed in the United States in 2017. Approximately 75-90% of these patients are diagnosed with HCC. Excluding patients who are eligible for surgical resection or certain focal treatments, we estimate that approximately 15,000 patients with HCC in the United States and Europe may be eligible for treatment with Melphalan/HDS. We estimate that an additional 9,300 patients diagnosed with ICC may also be eligible for treatment with Melphalan/HDS. According to the ACS, the overall five-year survival rate for liver cancer patients in the United States is approximately 18%. For patient diagnosed with a localized stage of disease, the ACS estimates 5-year survival at 31%. The ACS estimates that 5-year survival for all cancers is 68%. Globally, with 782,000 new cases in 2012, HCC was the fifth most common cancer in men and the ninth in women according to GLOBOCAN. GLOBOCAN estimates indicate that HCC was responsible for 746,000 deaths in 2012 (9.1% of the total cancer deaths), making it the second most common cause of death from cancer worldwide.

The prognosis for primary liver cancer is very poor, as indicated by an overall ratio of mortality to incidence of 0.95. The American Cancer Society’s Cancer Facts & Figures 2017 outlines the treatment options for HCC as follows: “Early stage liver cancer can sometimes be successfully treated with surgery to remove part of the liver (partial hepatectomy); however, few patients have sufficient healthy liver tissue for this option. Liver transplantation may be possible in individuals with small tumors who are not candidates for partial hepatectomy. Other treatment options include tumor ablation (destruction) or embolization (blocking blood flow). Few options exist for patients diagnosed at an advanced stage. Sorafenib (Nexavar^®) is a targeted drug approved for the treatment of HCC in patients who are not candidates for surgery and do not have severe cirrhosis.”

Based on third party research, we estimate that up to 15,000 of the 65,000 patients diagnosed annually in the United States and Europe could be eligible candidates for treatment with the Melphalan/HDS. The FDA has granted orphan drug status to the Melphalan/HDS for treatment of patients with unresectable HCC. We believe that there is a large unmet medical need in first line therapy for patients with HCC, with Sorafenib the only currently approved systemic therapy in the United States, Europe and certain Asian markets.

ICC is the second most common primary liver tumor and accounts for 3% of all gastrointestinal cancers and 15% of HCC cases diagnosed in the United States and Europe annually. Outside of resection, which is the only cure for ICC, there is currently no standard of care. Based on third party research, we believe that 90% of ICC patients are not candidates for surgical resection, and that approximately 20-30% of these may be candidates for certain focal interventions. We estimate that approximately 9,300 ICC patients in the United States and Europe annually could be candidates for treatment with Melphalan/HDS, which we believe represents a significant market opportunity.

About CHEMOSAT and Melphalan/HDS

CHEMOSAT and Melphalan/HDS administer concentrated regional chemotherapy to the liver. This “whole organ” therapy is performed by isolating the circulatory system of the liver, infusing the liver with chemotherapeutic agent, and then filtering the blood prior to returning it to the patient. During the procedure, known as percutaneous hepatic perfusion (PHP^® therapy), three catheters are placed percutaneously through standard interventional radiology techniques. The catheters temporarily isolate the liver from the body’s circulatory system, allow administration of the chemotherapeutic agent melphalan hydrochloride directly to the liver, and collect blood exiting the liver for filtration by our proprietary filters. The filters absorb chemotherapeutic agent in the blood, thereby reducing systemic exposure to the drug and related toxic side effects, before the filtered blood is returned to the patient’s circulatory system.

PHP therapy is performed in an interventional radiology suite in approximately two to three hours. Patients remain in an intensive care or step-down unit overnight for observation following the procedure. Treatment with CHEMOSAT and Melphalan/HDS is repeatable, and a new disposable CHEMOSAT and Melphalan/HDS is used for each treatment. Patients treated in clinical settings are permitted up to six treatments. In non-clinical commercial settings patients have received up to eight treatments. In the United States, melphalan hydrochloride for injection will be included with the system. In Europe, the system is sold separately and used in conjunction with melphalan hydrochloride commercially available from a third party. In our clinical trials, melphalan hydrochloride for injection is provided to both European and United States clinical trial sites.

Risks associated with the CHEMOSAT and Melphalan/HDS Procedure

As with many cancer therapies, treatment with CHEMOSAT and Melphalan/HDS is associated with toxic side effects and certain risks, some of which are potentially life threatening. An integrated safety population comprised of patients treated during our prior clinical development using early versions of the Melphalan/HDS showed these risks to include grade 3 or 4 bone marrow suppression and febrile neutropenia, as well as risks of hepatic injury, severe hemorrhage, gastrointestinal perforation, stroke, and myocardial infarction in the setting of an incomplete cardiac risk assessment. Deaths due to certain adverse reactions within this integrated safety population were not observed to occur again during the clinical trials following the adoption of related protocol amendments.

Procedure and Product Refinements

The trials that comprised this integrated safety population used early versions of the device and procedure. As a consequence of these identified risks and experience gained in non-clinical, commercial usage in Europe, we have continued to develop and refine both the CHEMOSAT and Melphalan/HDS and the PHP procedure. The procedure refinements have included modifications to the pre, peri and post procedure patient management and monitoring, as well as the use of the following: prophylactic administration of proton pump inhibitors, prophylactic platelet transfusions, prophylactic hydration at key pre-treatment intervals, use of vasopressor agents coupled with continuous monitoring for maintenance of blood pressure and prophylactic administration of growth factors to reduce risk of serious myelosuppression. In addition, in 2012 we introduced the Generation Two version of the CHEMOSAT system, which offered improved hemofiltration and other product enhancements.

Reports from treating physicians in both Europe and the United States using the Generation Two CHEMOSAT and Melphalan/HDS in a non-clinical, commercial setting have suggested that these product improvements and procedure refinements have improved the safety profile. In 2016, physicians in Europe and the United States also presented the results of research that signaled an improved safety profile as well as efficacy in multiple tumor types at several major medical conferences.

Phase 3—Melanoma Metastases Trial

In February 2010, we concluded a randomized Phase 3 multi-center study for patients with unresectable metastatic ocular or cutaneous melanoma exclusively or predominantly in the liver. In the trial, patients were randomly assigned to receive PHP treatments with melphalan using the Melphalan/HDS, or to a control group providing best alternative care (BAC). Patients assigned to the PHP arm were eligible to receive up to six cycles of treatment at approximately four to eight week intervals. Patients randomized to the BAC arm were permitted to cross-over into the PHP arm at radiographic documentation of hepatic disease progression. A majority of the BAC patients did in fact cross over to the PHP arm. Secondary objectives of the study were to determine the response rate, safety, tolerability and overall survival.

On April 21, 2010, we announced that our randomized Phase 3 clinical trial of PHP with melphalan using Melphalan/HDS for patients with unresectable metastatic ocular and cutaneous melanoma in the liver had successfully achieved the study’s primary endpoint of extended hepatic progression-free survival (hPFS). An updated summary of the results was presented at the European Multidisciplinary Cancer Congress organized by the European Cancer Organization and the European Society of Medical Oncology in September 2011. Data submitted in October 2012 to the FDA in Delcath’s New Drug Application (NDA) comparing treatment with the PHP with melphalan (the treatment group) to BAC (the control group), showed that patients in the PHP arm had a statistically significant longer median hPFS of 7.0 months compared to 1.7 months in the BAC control group, according to the Independent Review Committee (IRC) assessment. This reflects a 4-fold increase of hPFS over that of the BAC arm, with 50% reduction in the risk of progression and/or death in the PHP treatment arm compared to the BAC control arm. Results of this study were published in Annals of Surgical Oncology, a prestigious medical journal in December 2015.

Phase 2 Multi-Histology, Unresectable Hepatic Tumor Trial

Also in 2010, we concluded a separate multi-arm Phase 2 clinical trial of PHP with melphalan using an early version of the Melphalan/HDS in patients with primary and metastatic liver cancers, stratified into four arms: neuroendocrine tumors (carcinoid and pancreatic islet cell tumors), ocular or cutaneous melanoma, metastatic colorectal adenocarcinoma (mCRC), and HCC. In the metastatic neuroendocrine (mNET) cohort (n=24), the objective tumor response rate was 42%, with 66% of patients achieving hepatic tumor shrinkage and durable disease stabilization. In the mCRC cohort, there was inconclusive efficacy possibly due to advanced disease status of the patients. Similar safety profiles were seen across all tumor types studied in the trial.

Phase 2 Multi-Histology Clinical Trial - HCC Cohort

In the HCC cohort (n=8) of our Phase 2 Multi-Histology trial, a positive signal in hepatic malignancies was observed in 5 patients. Among these patients, one patient received four treatments, achieved a partial response lasting 12.22 months, and survived 20.47 months. Three other patients with stable disease received 3-4 treatments, with hPFS ranging 3.45 to 8.15 months, and overall survival (OS) ranging 5.26 to 19.88 months. There was no evidence of extrahepatic disease progression. The observed duration of hPFS and OS in this limited number of patients exceeded that generally associated with this patient population. We believe these results constitute a promising signal that warrants further clinical investigation.

Prior United States Regulatory Experience

Based on the results from our prior clinical development in August 2012, we submitted an NDA under Section 505(b)(2) of the Federal Food Drug Cosmetic Act (FFDCA) seeking an indication for the percutaneous intra-arterial administration of melphalan for use in the treatment of patients with metastatic melanoma in the liver, and subsequently amended the indication to ocular melanoma metastatic to the liver. Data submitted to the Food and Drug Administration (FDA) used the early clinical trial versions of the system along with early clinical procedure techniques. Our NDA was accepted for filing by the FDA on October 15, 2012, and was designated for standard review with an initial Prescription Drug User Fee Act (PDUFA) goal date of June 15, 2013. On April 3, 2013, the FDA extended its PDUFA goal date to September 13, 2013.

On May 2, 2013 we announced that an Oncologic Drug Advisory Committee (ODAC) panel convened by the FDA voted 16 to 0, with no abstentions, that the benefits of treatment with the early version of Melphalan/HDS did not outweigh the risks associated with the procedure. A significant portion of FDA’s presentation to the ODAC panel was focused on the FDA’s assessment of treatment related risks, including the analysis of treatment-related deaths that occurred during clinical trials. The FDA also expressed concerns about hypotension (low blood pressure) during the procedure, length of hospital stay, as well as risks of stroke, heart attack, renal failure, and bone marrow suppression. We believe that the protocol amendments and other procedure refinements instituted during clinical trials and subsequently in commercial, non-clinical usage in Europe, including changes to the way blood pressure is managed and monitored, may help address these procedure related risks. Collection of adequate safety data on all aspects of the procedure is a major focus of the clinical trials in our current CDP.

Briefing materials presented to the 2013 ODAC panel by both the FDA and Delcath are available on our website at http://delcath.com/clinical-bibliography.

2013 Complete Response Letter

In September 2013 the FDA issued a complete response letter (CRL) in response to our NDA. The FDA issues a CRL after the review of a file has been completed and questions remain that preclude approval of the NDA in its current form. The FDA comments included, but were not limited to, a statement that Delcath must perform another "well-controlled randomized trial(s) to establish the safety and efficacy of Melphalan/HDS using overall survival as the primary efficacy outcome measure," and which "demonstrates that the clinical benefits of Melphalan/HDS outweigh its risks." The FDA also required that the additional clinical trial(s) be conducted using the product the Company intends to market, and that certain clinical, clinical pharmacology, human factors and product quality elements of the CRL be addressed.

In January 2016, we announced the conclusion of a SPA with the FDA on the design of a new Phase 3 clinical trial of Melphalan/HDS to treat patients with hepatic dominant ocular melanoma. This SPA provides agreement that our new Phase 3 trial design adequately addresses objectives that, if met, would support the submission for regulatory approval of Melphalan/HDS. However, final determinations for marketing application approval are made by FDA after a complete review of a marketing application and are based on the entire data in the application. The SPA agreement also represents the satisfactory resolution of a substantial number of the FDA’s CRL non-clinical trial related requirements in that without these successful resolutions, the SPA request would not have been permitted to be filed.

Current Clinical Development Program

The focus of our current CDP is to generate clinical data for the CHEMOSAT and Melphalan/HDS in various disease states and validate the safety profile of the current version of the product and treatment procedure. We believe that the improvements we have made to CHEMOSAT and Melphalan/HDS and to the PHP procedure have addressed the severe toxicity and procedure-related risks observed during the previous Phase 2 and 3 clinical trials. The CDP is also designed to support clinical adoption of and reimbursement for CHEMOSAT in Europe, and to support regulatory approvals in various jurisdictions, including the United States.

(the FOCUS Trial) - NCT02678572

In January 2016, we initiated a new pivotal Phase 3 clinical trial in hepatic dominant ocular melanoma with the first patient enrolled in February 2016 looking at overall survival of patients (length of time from treatment to death). Called the FOCUS Trial, this new global Phase 3 trial will evaluate the safety, efficacy and pharmacokinetic profile of Melphalan/HDS versus best alternative care in 240 patients with hepatic dominant OM. The primary endpoint is a comparison of overall survival between the two study arms. Secondary and exploratory endpoints include progression-free survival, overall response rate and Quality of Life (QoL) measures. In the FOCUS trial's treatment phase, patients randomized to the Melphalan/HDS arm will receive up to six treatments at intervals of six to eight weeks for up to 12 months. Tumor response will be assessed in both study arms every 12 weeks until evidence of hepatic disease progression. For patients progressing to the follow-up phase, disease assessment scans will continue every 12 weeks for up to two years.

The FOCUS Trial is being conducted at leading cancer centers in the United States and Europe. The Moffitt Cancer Center in Tampa, Florida was activated as a participating center in January 2016 with Jonathan Zager, M.D., FACS, Professor of Surgery in the Cutaneous Oncology and Sarcoma Departments and a Senior Member at Moffitt Cancer Center, serving as the trial's lead investigator. In October 2016 we announced the addition of several prestigious cancer centers in the United States and Europe. We intend to include approximately 40 leading cancer centers in the United States and Europe in the FOCUS Trial.

The FOCUS Trial is being conducted under a SPA we concluded with the FDA in January 2016. Under the terms of the SPA, the FOCUS Trial is the only Phase 3 trial required for submission of an NDA. However, final determinations for marketing application approval are made by FDA after a complete review of a marketing application and are based on the entire data in the application.

There currently is no SOC for the treatment of hepatic dominant ocular melanoma. The Melphalan/HDS has been granted orphan drug status by FDA for treatment of patients with ocular melanoma. Based on the strength of the efficacy data in this disease observed in our prior Phase 3 clinical trial and the reports of an improved safety profile observed in non-clinical trial experience in Europe, we are confident that this program can address the concerns raised by the FDA in its CRL. We believe that ocular melanoma liver metastases represent a significant unmet medical need, and that pursuit of an indication in this disease state represents the fastest path to potential approval of the Melphalan/HDS in the United States.

Percutaneous Hepatic Perfusion (PHP) vs. Cisplatin/Gemcitabine in Patients with Intrahepatic Cholangiocarcinoma - NCT03086993

In March 2017 we announced another SPA agreement with the FDA for the design of a new pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC) titled A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma (Pivotal ICC Trial). Under the SPA, the Pivotal ICC Trial will enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe. The primary endpoint is overall survival (OS) and secondary and exploratory endpoints include safety, progression-free survival (PFS), overall response rate (ORR) and quality-of-life measures. This Pivotal ICC Trial is designed to be cost effective and pursued in a financially prudent manner when financial resources permit. The SPA agreement for this trial indicates that the pivotal trial design adequately addresses objectives that, if met, would support regulatory requirements for approval of Melphalan/HDS in ICC. However, final determinations for marketing application approval are made by FDA after a complete review of a marketing application and are based on the entire data in the application.

Phase 2 Hepatocellular Carcinoma (HCC) & Intrahepatic Cholangiocarcinoma (ICC) Program

In 2014 we initiated a Phase 2 clinical trial program in Europe and the United States, with the goal of obtaining an efficacy and safety signal for Melphalan/HDS in the treatment of HCC and ICC. Due to differences in treatment practice patterns between Europe and the United States, we established separate European and United States trial protocols for the HCC Phase 2 program with different inclusion and exclusion patient selection criteria:

Protocol 201 NCT02406508 – Conducted in the United States, this trial is intended to assess the safety and efficacy of Melphalan/HDS followed by sorafenib. The trial will evaluate overall response rate via modified Response Evaluation Criteria in Solid Tumors (mRECIST), progression free survival, characterize the systemic exposure of melphalan and assess patient quality of life. This trial is now closed to enrollment.

Protocol 202 NCT02415036 – Conducted in Europe, this trial is intended to assess the safety and efficacy of Melphalan/HDS without sorafenib. The trial will also evaluate overall response rate via mRECIST criteria, progression free survival, characterize the systemic exposure of melphalan and assess patient quality of life. This trial is now closed to enrollment.

ICC Cohort – In 2015 we expanded Protocol 202 to include a cohort of patients with ICC. The trial for this cohort is being conducted at the same centers participating in the Phase 2 HCC trial. This trial has completed enrollment and data collection for the ICC cohort is ongoing. We will announce results for this cohort once the data are fully mature.

ICC Retrospective Data Collection - The original goal to obtain an efficacy signal for the Phase 2 ICC cohort has been satisfied by the result of multicenter patient outcomes identified in the retrospective data collection of our commercial ICC cases conducted by our European investigators. These promising outcomes and observations were discussed with Key Opinion Leaders (KOL) at a Delcath-organized medical advisory panel meeting and led to the agreement that PHP^® therapy does, indeed, "demonstrate an efficacy signal in ICC and is worthy of full clinical investigation." Data from this retrospective data collection provided important scientific support during our negotiations with the FDA for our SPA for the Pivotal ICC Trial. Data for the retrospective data collection are being submitted for publication by the European investigators, and details of these findings will be announced when publicly available.

With the objectives of identifying an efficacy signal worthy of further clinical investigation now met, we have terminated enrollment in our Phase 2 program and will close the Phase 2 trials in order to focus available resources on the FOCUS Trial and the ICC Pivotal trial.

Clinical trials are long, expensive and highly uncertain processes and failure can unexpectedly occur at any stage of clinical development. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator treatment or required prior therapy.

A substantial portion of the Company’s operating expenses consist of research and development expenses incurred in connection with its clinical trials. See the Company’s Consolidated Financial included in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 29, 2017.

European Investigator Initiated Trials

In addition to the clinical trials in our CDP, we are supporting data generation in other areas. We are currently conducting one Investigator Initiated Trial (IITs) in colorectal carcinoma metastatic to the liver (mCRC) at Leiden University Medical Center in the Netherlands. We are planning two additional IITs – one for colorectal carcinoma metastatic to the liver at Heidelberg University in Heidelberg, Germany and one for pancreatic carcinoma metastatic to the liver at Spire Hospital in Southampton, England. We continue to evaluate other IITs as suitable opportunities present in Europe. We believe IITs will serve to build clinical experience at key cancer centers, and will help support efforts to obtain full reimbursement in Europe.

European Clinical Data Generation

On April 2, 2015, we announced the activation of our prospective patient registry in Europe to collect uniform essential patient safety, efficacy, and QoL information using observational study methods. This registry will gather data in multiple tumor types from commercial cases performed by participating cancer centers in Europe. A prospective registry is an organized system that uses observational study methods to collect defined clinical data under normal conditions of use to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure. Registry data is non-randomized, and as such cannot be used for either registration approval, promotional or competitive claims. However, we believe the patient registry will provide a valuable data

repository from a commercial setting that can be used to identify further clinical development opportunities, support clinical adoption and reimbursement in Europe. Cancer centers in Germany, the United Kingdom, and the Netherlands are participating in the registry and patient enrollment has begun.

Recent Data Presentations

In September 2017 we announced that results of a single institution study were presented at the Cardiology and Interventional Radiology of Europe (CIRSE) annual meeting, held in Copenhagen, Denmark on September 16-20, 2017.

The study, Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion (PHP) with Melphalan, was conducted by a team at the Leiden University Medical Center (LUMC) in Leiden, The Netherlands and presented by T.S. Meijer, MD. The study prospectively evaluated filtration efficiency and hematologic side effects in seven patients who received a total of ten PHP procedures with the GEN2 CHEMOSAT system. Pharmacokinetic sampling was conducted at several points during the PHP procedure, and filtration efficiency was calculated at several discrete points. Blood tests were conducted following each procedure to determine hematologic side effect Grade Levels until the blood values normalized.

Results of the study showed the GEN2 CHEMOSAT system had an overall efficiency of 86%, with efficiency highest at the time of highest concentration of melphalan in the blood and declining as melphalan blood concentration declined. Peak efficiency was 95.4% in samples taken after 10 minutes of filtration, 85.9% at the end of the drug infusion period, and 77.5% at the end of the saline washout period. Researchers noted these results were superior to and more consistent than prior experience published with the first generation CHEMOSAT system. Hematologic side effects were mainly Grade 1 and 2 with some Grade 3 and 4 side effects emerging post-procedure, including 40% of treatment cycles showing Grade 4 thrombocytopenia, 80% showing Grade 3 or 4 leucopenia, and 70% showing lymphocytopenia. All patients were asymptomatic and all lab results normalized in three weeks. Other adverse events were managed, and there was no mortality, no severe bleeding complications, and no hypotensive cardiac or cerebral events. Researchers concluded that the GEN2 CHEMOSAT system appears to have higher melphalan filter efficiency, more consistent performance, and appears safe but needs further validation.

In July 2017, the Journal of Cancer Research and Clinical Oncology published an analysis of clinical findings from 29 Hannover Medical School patients who were treated with percutaneous hepatic perfusion (PHP®) therapy with Melphalan/HDS as last-line therapy for primary and secondary liver tumors. Hannover Medical School physicians treated 29 patients with a total of 54 PHP procedures. Patients received as many as five treatments each, with an average of two per patient. Nineteen patients were diagnosed with unresectable liver metastases that arose from solid tumors, including 11 cases of ocular melanoma, and the remaining 10 patients had hepatocellular or cholangiocarcinoma.

Across all patients, the overall response rate (ORR) was 19.2 percent, with ocular melanoma patients experiencing the highest ORR (33.3 percent). As has been published previously, high tumor volumes negatively impact overall survival (OS). Median OS was 261 days for the entire patient group. Two patients with cholangiocarcinoma and one patient with ocular melanoma had the longest survival with 566, 465, and 477 days respectively. Overall, PHP with Melphalan/HDS was well tolerated. Complications including thrombocytopenia, cardiovascular events, ulcerous bleeding, and edema were reported. These results are summarized in the Journal of Cancer Research and Clinical Oncology article, “Safety and Efficacy of Chemosaturation in Patients with Primary and Secondary Liver Tumors.”

In February 2017, we announced that the American Journal of Clinical Oncology published a single-center retrospective review, in which authors found that investigational PHP with Melphalan/HDS offers promising results with a doubling of overall survival and significantly longer progression-free survival (PFS) and hPFS than other targeted therapies. The review, “Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma,” was written by a team from the Moffitt Cancer Center who analyzed clinical outcomes of three different non-randomized approaches used to treat 30 patients with liver metastases primarily resulting from ocular melanoma and skin melanoma. A third of the patients received PHP using melphalan delivered via the Delcath Hepatic Delivery System (Melphalan/HDS), 12 received chemoembolization (CE) and six received radioembolization with yttrium-90 (Y90). Two patients crossed over once their cancer progressed – one from PHP to Y90 and one from CE to PHP.

The paper’s authors concluded that patients who received PHP with Melphalan/HDS had significantly longer median hPFS at 361 days compared to 54 days for Y90 and 80 days for CE, as well as a longer median PFS at 245 days compared to 54 days for Y90 and 52 days for CE. Median overall survival was also longest for PHP at 608 days compared to 295 days for Y90 and 265 days for CE. The authors noted that further studies, including a randomized controlled trial, would be needed to confirm whether clinically superior outcomes can be achieved with PHP compared to other liver-targeted treatments.

Side effects following all treatments were similar, with most complications recorded as anorexia, abdominal pain, fatigue and nausea. Laboratory irregularities, such as thrombocytopenia and abnormal liver function tests, were seen immediately after treatment in some patients, but returned to baseline within a few days.

Also in February 2017, we announced results of a retrospective, multicenter study presented at the Regional Cancer Therapies 12th International Symposium in an oral presentation titled, "Percutaneous Hepatic Perfusion for Unresectable Metastatic Ocular Melanoma to the Liver: A Multi-Institutional Report of Outcomes." This analysis demonstrated that 45.7 percent of patients with ocular melanoma that metastasized to the liver who underwent PHP using Melphalan/HDS experienced a complete or partial response. The study further showed that among those who responded to treatment, overall survival was projected to be more than three years. The analysis was conducted by teams from Moffitt Cancer Center in Tampa, Fla., and the University of Southampton in the United Kingdom. The presentation was led by Dr. Alexandra Gangi of the Moffitt Cancer Center.

The analysis reviewed outcomes of 49 patients treated between 2008 and 2016 with Melphalan/HDS at either the Moffitt Cancer Center or the University of Southampton. Patients underwent a total of 115 PHP treatments. The median number of treatments per patient was two, with patients receiving one-to-six treatments.

Hepatic response to PHP was evaluable in 46 patients, among whom 45.7 percent showed complete or partial response, and 37.0 percent had stable disease. Median overall survival was not reached, but was projected to be 657 days (1.8 years). Among patients with a complete or partial response, overall survival was projected to be 1,207 days. Most common side effects following treatment were anemia, thrombocytopenia and neutropenia.

Market Access & Commercial Clinical Adoption

European Union

Our market access and clinical adoptions efforts are focused on the key target markets of Germany, United Kingdom and the Netherlands, which represent a majority of the total potential liver cancer market (primary and metastatic) in the EU and where progress in securing reimbursement for CHEMOSAT treatments offers the best near-term opportunities. We also continue to support clinical adoption of CHEMOSAT in Spain, France and Italy. We employ a combination of direct and indirect sales channels to market and sell CHEMOSAT in these markets. Our European Headquarters is in Galway, Ireland.

Since launching CHEMOSAT in Europe, over 500 treatments have been performed at over 25 leading European cancer centers. Physicians in Europe have used CHEMOSAT to treat patients with a variety of cancers in the liver, primarily ocular melanoma liver metastases, and other tumor types, including cutaneous melanoma, hepatocellular carcinoma, cholangiocarcinoma, and liver metastases from colorectal cancer, breast, pancreatic and neuroendocrine. In 2017, SPIRE Southampton Hospital in the U.K. and the Medical University of Hannover in Germany each surpassed 100 treatments with CHEMOSAT since initiating procedures. In 2017, we announced our first patient to receive eight CHEMOSAT treatments, and have seen the average number of repeat treatments performed on a per patient basis consistently increase.

European Reimbursement

A critical driver of utilization growth for CHEMOSAT in Europe is the expansion of reimbursement mechanisms for the procedure in our priority markets. In Europe, there is no centralized pan-European medical device reimbursement body. Reimbursement is administered on a regional and national basis. Medical devices are typically reimbursed under Diagnosis Related Groups (DRG) as part of a procedure. Prior to obtaining permanent DRG reimbursement codes, in certain jurisdictions, the Company is actively seeking interim reimbursement from existing mechanisms that include specific interim reimbursement schemes, new technology payment programs as well as existing DRG codes. In most EU countries, the government provides healthcare and controls reimbursement levels. Since the EU has no jurisdiction over patient reimbursement or pricing matters in its member states, the methodologies for determining reimbursement rates and the actual rates may vary by country.

Germany

In October 2015, we announced that the Institut fϋr das Entgeltsystem im Krankenhaus (InEk), the German federal reimbursement agency, established a national Zusatzentgeld (ZE) reimbursement code for procedures performed with CHEMOSAT in Germany. The ZE diagnostic-related group (DRG) code is a national reimbursement code that augments existing DRG codes until a specific new DRG code can be created, and will replace the previous Neue Untersuchungs und Behandlungsmethoden (NUB) procedure that required patients in Germany to apply individually for reimbursement of their CHEMOSAT treatment. With the establishment of a ZE code for CHEMOSAT, the procedure is now permanently represented in the DRG catalog in Germany. In 2016, coverage levels were negotiated between hospitals in Germany and regional sickness funds. Coverage levels determined via this process are renegotiated annually.

United Kingdom

In May 2014, NICE, a non-departmental public body that provides guidance and advice to improve health and social care in the UK, completed a clinical review of CHEMOSAT. The NICE review indicated that as the current body of evidence on the safety and efficacy of PHP with CHEMOSAT for primary or metastatic liver cancer is limited, the procedure should be performed within the context of research by clinicians with specific training in its use and techniques. Delcath expects to consult again with the Interventional Procedures Advisory Committee at the National Institute for Clinical Excellence (NICE) in England, to provide recent clinical evidence with a view to moving existing Interventional Procedural Guidance from research to specialist status. This would enable greater scope for commercialization because it would allow more use by NHS clinicians of the therapy. It might also pave the way for a full Medical Technology Assessment as a way towards longer term reimbursement with the NHS.

In the short term, public patients will continue to be treated in the UK through clinical trials. Private patients will continue to be treated through the established private treatment pathway such as private insurance coverage or self-pay.

Netherlands

In the Netherlands CHEMOSAT has been performed at the Netherlands Cancer Institute in 2013 and at Leiden University Medical Centre since 2014. In June 2017 the Medical Oncology National Treatment Guidelines for Uveal Melanoma were updated and now include recommendations to consider CHEMOSAT in the treatment of liver metastases. An application to the Dutch Health Care Institute (ZIN) to approve CHEMOSAT as a treatment option for ocular melanoma liver metastases and also an application for reimbursement Dutch Health Care Authority (NZA) for the formulation of a reimbursement code (DBC) has been made. These applications are currently under review by the respective bodies.

Spain

In April 2016, we announced that the General and Digestive Surgery team at HM Sanchinarro University Hospital had activated the hospital's CHEMOSAT program. The Sanchinarro team successfully performed three procedures with CHEMOSAT, using the procedure to treat patients with peripheral cholangiocarcinoma and neuroendocrine tumors liver metastases. HM Sanchinarro University Hospital is the second center in Spain to offer CHEMOSAT treatments.

Turkey

In April 2016 we announced the activation of the Hacettepe University Clinic in Ankara, Turkey as a CHEMOSAT treatment center. Hacettepe University Clinic successfully completed its first CHEMOSAT treatments in March 2016, and the center represents the first CHEMOSAT commercial location to be activated outside of the European Union. We believe that Hacettepe University can serve as an important hub for CHEMOSAT treatment to patients in Turkey and throughout the region.

Distribution Partners

As a result of the Company’s strategy to prioritize resources on the key direct markets of Germany, the Netherlands and the United Kingdom, the Company expects that its distribution strategy will play a lesser role in its current commercial activities. In Spain, the Company has determined that there was no benefit to continuing with an indirect model and therefore terminated its relationship with its distributor in Spain and is now represented in Spain through a sales agency. The Company is represented in Turkey through a distribution partner.

Regulatory Status

Our products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA. Foreign regulatory agencies, the FDA and comparable regulatory agencies in state and local jurisdictions impose extensive requirements upon the clinical development, pre-market clearance and approval, manufacturing, labeling, marketing, advertising and promotion, pricing, storage and distribution of pharmaceutical and medical device products. Failure to comply with applicable foreign regulatory agency or FDA requirements may result in Warning Letters, fines, civil or criminal penalties, suspension or delays in clinical development, recall or seizure of products, partial or total suspension of production or withdrawal of a product from the market.

United States Regulatory Environment

In the United States, the FDA regulates drug and device products under the FFDCA, and its implementing regulations. The Delcath Melphalan/HDS is subject to regulation as a combination product, which means it is composed of both a drug product and device product. If marketed individually, each component would therefore be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction over its

pre-market review and regulation based on a determination of its primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of the Melphalan/HDS, the primary mode of action is attributable to the drug component of the product, which means that the Center for Drug Evaluation and Research, has primary jurisdiction over its pre-market development and review.

The process required by the FDA before drug product candidates may be marketed in the United States generally involves the following:

•

submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated annually;

•

completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations;

•

performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication;

•

submission to the FDA of an NDA after completion of all pivotal clinical trials;

•

a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review;

•

satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the product is produced and tested to assess compliance with current good manufacturing practice, or cGMP, regulations; and

•

FDA review and approval of an NDA prior to any commercial marketing or sale of the drug in the United States.

The development and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product will be granted on a timely basis, if at all.

The results of preclinical tests (which include laboratory evaluation as well as GLP studies to evaluate toxicity in animals) for a particular product candidate, together with related manufacturing information and analytical data, are submitted as part of an IND to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. IND submissions may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional review board, or IRB, for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive good clinical practice regulations and regulations for informed consent and privacy of individually identifiable information. Similar requirements to the United States IND are required in the European Economic Area (EEA) and other jurisdictions in which we may conduct clinical trials.

Orphan Drug Exclusivity

Some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Pursuant to the Orphan Drug Act, the FDA grants orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. The orphan designation is granted for a combination of a drug entity and an indication and therefore it can be granted for an existing drug with a new (orphan) indication. Applications are made to the Office of Orphan Products Development at the FDA and a decision or request for more information is rendered in 60 days. NDAs for designated orphan drugs are exempt from user fees, obtain additional clinical protocol assistance, are eligible for tax credits up to 50% of research and development costs, and are granted a seven-year period of exclusivity upon approval. The FDA cannot approve the same drug for the same condition during this period of exclusivity, except in certain circumstances where a new product demonstrates superiority to the original treatment. Exclusivity begins on the date that the marketing application is approved by the FDA for the designated orphan drug, and an orphan designation does not limit the use of that drug in other applications outside the approved designation in either a commercial or investigational setting.

The FDA has granted Delcath six orphan drug designations. In November 2008, the FDA granted Delcath two orphan drug designations for the drug melphalan for the treatment of patients with cutaneous melanoma as well as patients with ocular melanoma. In May 2009, the FDA granted Delcath an additional orphan drug designation of the drug melphalan for the treatment of patients with neuroendocrine tumors. In August 2009, the FDA granted Delcath an orphan drug designation of the drug doxorubicin for the treatment of patients with primary liver cancer. In October 2013, the FDA granted Delcath an orphan drug designation of the drug melphalan for the treatment of HCC. In July 2015, the FDA granted Delcath an orphan drug designation of the drug melphalan for the treatment of cholangiocarcinoma, which includes ICC.

The granting of orphan drug designations does not mean that the FDA has approved a new drug. Companies must still pursue the rigorous development and approval process that requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product will be granted at all or on a timely basis.

Intellectual Property and Other Rights

Our success depends in part on our ability to obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary rights against infringers, and operate without infringing on the proprietary rights of third parties. Because of the length of time and expense associated with developing new products and bringing them through the regulatory approval process, the health care industry places considerable emphasis on obtaining patent protection and maintaining trade secret protection for new technologies, products, processes, know-how, and methods. The Company currently holds eight U.S. utility patents, one U.S. design patent, six pending U.S. utility patent applications (one of which has been allowed), four issued foreign counterpart utility patents (including the validation of one European patent in two European countries, and the validation of another European patent in four European countries), six issued foreign counterpart design patents, and eight pending foreign counterpart patent applications (one of which has been allowed).

In July 2017, one of our pending patent applications for our chemotherapy filtration system was approved by the U.S. Patent Office. When appropriate, the Company actively pursues protection of our proprietary products, technologies, processes, and methods by filing United States and international patent and trademark applications. We seek to pursue additional patent protection for technology invented through research and development, manufacturing, and clinical use of the CHEMOSAT and Melphalan/HDS that will enable us to expand our platform beyond the treatment of cancers in the liver.

There can be no assurance that the pending patent applications will result in the issuance of patents, that patents issued to or licensed by us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently broad to protect our technology or provide us with a competitive advantage.

To maintain our proprietary position, we also rely on trade secrets and proprietary technological experience to protect proprietary manufacturing processes, technology, and know-how relating to our business. We rely, in part, on confidentiality agreements with our marketing partners, employees, advisors, vendors and consultants to protect our trade secrets and proprietary technological expertise. In addition, we also seek to maintain our trade secrets through maintenance of the physical security of the premises where our trade secrets are located. There can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach, that others will not independently develop equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets and proprietary knowledge.

Certain of our United States and foreign patents have already expired and other patents relating to the CHEMOSAT and Melphalan/HDS will expire in the future. In certain circumstances, United States patent law allows for the extension of a patent’s duration for a period of up to five years after FDA approval. The Company intends to seek extension for one of our patents after FDA approval if it has not expired prior to the date of approval. In addition to our proprietary protections, the FDA has granted Delcath five orphan drug designations that provide us a seven-year period of exclusive marketing beginning on the date that our NDA is approved by the FDA for the designated orphan drug. While the exclusivity only applies to the indication for which the drug has been approved, the Company believes that it will provide us with added protection once commercialization of an orphan drug designated product begins.

There has been and continues to be substantial litigation regarding patent and other intellectual property rights in the pharmaceutical and medical device areas. If a third party asserts a claim against Delcath, the Company may be forced to expend significant time and money defending such actions and an adverse determination in any patent litigation could subject us to significant liabilities to third parties, require us to redesign our product, require us to seek licenses from third parties, and, if licenses are not available, prevent us from manufacturing, selling or using our system. Additionally, Delcath plans to enforce its intellectual property rights vigorously and may find it necessary to initiate litigation to enforce our patent rights or to protect our trade secrets or know-how. Patent litigation can be costly and time consuming and there can be no assurance that the outcome will be favorable to us.

Delcath Systems, Inc. Patents and Patent Applications

Patents Issued in the United States

Patent No.	Title	Issuance Date	Owned or Licensed	Expiration Date
7,022,097	Method For Treating Glandular Diseases and Malignancies	04/04/2006	Owned	06/24/2023
9,707,331	Apparatus For Removing Chemotherapy Compounds from Blood	07/18/2017	Owned	09/17/2034
D708749	Dual Filter	07/08/2014	Owned	07/08/2028
9,314,561	Filter and Frame Apparatus and Method of Use	04/19/2016	Owned	02/07/2034
9,541,544	A Method of Selecting Chemotherapeutic Agents for an Isolated Organ or Regional Therapy	01/10/2017	Owned	08/28/2033
8,679,057	Recovery Catheter Assembly	03/25/2014	Licensed	03/04/2031
9,265,914	Recovery Catheter Assembly	02/23/2016	Licensed	04/05/2031
9,108,029	Recovery Catheter Assembly and Method	08/18/2015	Licensed	02/09/2034

Patent Applications in the United States

Application No.	Application Title	Filing Date	Owned or Licensed
15/651,141	Apparatus For Removing Chemotherapy Compounds from Blood	07/17/2017	Owned
15/071,896	Filter and Frame Apparatus and Method of Use	03/16/2016	Owned
15/346,239	A Method of Selecting Chemotherapeutic Agents for an Isolated Organ or Regional Therapy	11/08/2016	Owned
14/995,677	Recovery Catheter Assembly	01/14/2016	Licensed
14/797,108	Recovery Catheter Assembly and Method	07/11/2015	Licensed

Foreign Patents

Patent No.	Title	Issuance Date	Owned or Licensed	Expiration Date
84.098	Dual Filter (Argentina)	06/29/2012	Owned	06/29/2027
343454	Dual Filter (Australia)	07/23/2012	Owned	06/25/2022
146201	Dual Filter (Canada)	05/15/2013	Owned	05/15/2023
ZL 201230277905.5	Dual Filter (China)	03/20/2013	Owned	06/22/2022
001333173	Dual Filter (Europe)	06/27/2012	Owned	06/25/2037
1456186	Dual Filter Cartridge for Fluid Filtration (Japan)	10/26/2012	Owned	10/26/2032

2797644	Filter and Frame Apparatus and Method of Use (Albania)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Austria)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Belgium)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Bulgaria)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Croatia)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Cyprus)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Czech Republic)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Denmark)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Estonia)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Finland)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (France)	04/12/2017	Owned	12/29/2032
602012031191.6	Filter and Frame Apparatus and Method of Use (Germany)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Great Britain)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Greece)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Hungary)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Iceland)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Ireland)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Italy)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Latvia)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Lithuania)	04/12/2017	Owned	12/29/2032

2797644	Filter and Frame Apparatus and Method of Use (Luxembourg)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Macedonia)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Malta)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Monaco)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Netherlands)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Norway)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Poland)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Portugal)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Romania)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (San Marino)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Serbia)		Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Slovakia)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Slovenia)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Spain)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Sweden)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Switzerland)	04/12/2017	Owned	12/29/2032
2797644	Filter and Frame Apparatus and Method of Use (Turkey)	04/12/2017	Owned	12/29/2032
2011224640	Recovery Catheter Assembly (Australian)	08/20/2015	Licensed	03/04/2031
ZL201180022704.3	Recovery Catheter Assembly (China)	08/26/2015	Licensed	03/04/2031
1183257	Recovery Catheter Assembly (Hong Kong)	08/12/2016	Licensed	03/04/2031
5982081	Recovery Catheter Assembly (Japan)	08/05/2016	Licensed	03/04/2031

Foreign Patent Applications

Application No.	Title	Filing Date	Owned or Licensed
12847108.3	Apparatus For Removing Chemotherapy Compounds from Blood (Europe)	11/07/2012	Owned
17176952.4	Apparatus For Removing Chemotherapy Compounds from Blood (Europe)	11/07/2012	Owned
17165333.0	Filter and Frame Apparatus and Method of Use (Europe)	12/29/2012	Owned
15104220.7	Filter and Frame Apparatus and Method of Use (Hong Kong)	07/07/2017	Owned
2015210390	Recovery Catheter Assembly (Australia)	03/04/2011	Licensed
2793561	Recovery Catheter Assembly (Canada)	09/05/2012	Licensed
201510452193.9	Recovery Catheter Assembly (China)	11/06/2012	Licensed
11709548.9	Recovery Catheter Assembly (Europe)	03/04/2011	Licensed
2016-081587	Recovery Catheter Assembly (Japan)	09/06/2012	Licensed

Other Regulatory Requirements

Products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including recordkeeping, annual product quality review and reporting requirements. Adverse event experience with the product must be reported to the FDA in a timely fashion and pharmacovigilance programs to proactively look for these adverse events are mandated by the FDA. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Following such inspections, the FDA may issue notices on Form 483 and Untitled Letters or Warning Letters that could cause us or our third-party manufacturers to modify certain activities. A Form 483 Notice, if issued at the conclusion of an FDA inspection, can list conditions the FDA investigators believe may have violated cGMP or other FDA regulations or guidelines. In addition to Form 483 Notices and Untitled Letters or Warning Letters, failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may require us to recall our products from distribution or withdraw any potential approvals of an NDA for that product.

The FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, dissemination of off-label information, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved label. Further, if there are any modifications to the drug, including changes in indications, labeling, or manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new or supplemental NDA, which may require us to develop additional data or conduct additional preclinical studies and clinical trials. Failure to comply with these requirements can result in adverse publicity, Warning Letters, corrective advertising and potential civil and criminal penalties.

Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties, in particular in oncology. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers’ communications regarding off-label use.

European Regulatory Environment

In the EEA, the CHEMOSAT system is subject to regulation as a medical device. The EEA is composed of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein. Under the EU Medical Devices Directive (Directive No 93/42/ECC of 14 June 1993, as last amended), drug delivery products such as the CHEMOSAT system is governed by the EU laws on pharmaceutical products only if they are (i) placed on the market in such a way that the device and the pharmaceutical product form a single integral unit which is intended exclusively for use in the given combination, and (ii) the product is not reusable. In such cases, the drug delivery product is governed by the EU Code on Medicinal Products for Human Use (Directive 2001/83/EC, as last amended), while the essential requirements of the EU Medical Devices Directive apply to the safety and performance-related device features of the product. Because we do not intend to place the CHEMOSAT system on the EEA market as a single integral unit with melphalan, the product is governed solely by the EU Medical Devices Directive, while the separately marketed drug is governed by the EU Code relating to Medicinal Products for Human Use and other EU legislation applicable to drugs for human use.

Before we may commercialize a medical device in the EEA, we must comply with the essential requirements of the EU Medical Devices Directive. Compliance with these requirements entitles a manufacturer to affix a CE conformity mark, without which the products cannot be commercialized in the EEA. To demonstrate compliance with the essential requirements and obtain the right to affix the CE conformity mark, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. In April 2011, we obtained authorization to affix a CE Mark for the Generation One CHEMOSAT system and began European commercialization with this version of the CHEMOSAT system in early 2012. In April 2012, the Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system, and since this time all procedures in Europe have been performed with this version of the system

The Medical Devices Directive establishes a classification system placing devices into Class I, IIa, IIb, or III, depending on the risks and characteristics of the medical device. For certain types of low risk medical devices (i.e., Class I devices which are non-sterile and do not have a measuring function), the manufacturer may issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the EU Medical Devices Directives. Other devices are subject to a conformity assessment procedure requiring the intervention of a Notified Body, which is an organization designated by a Member State of the EEA to conduct conformity assessments.

CHEMOSAT is regulated as a Class IIb medical device. As a Class IIb medical device, the Notified Body is not required to carry out an examination of the product’s design dossier as part of its conformity assessment prior to commercialization. The Company must continue to comply with the essential requirements of the EU Medical Devices Directive (Directive 93/42 EC) and is subject to a conformity assessment procedure requiring the intervention of a Notified Body. The conformity assessment procedure for Class IIb medical devices requires the manufacturer to apply for the assessment of its quality system for the design, manufacture and inspection of its medical devices by a Notified Body. The Notified Body will audit the system to determine whether it conforms to the provisions of the Medical Devices Directive. If the Notified Body’s assessment is favorable it will issue a Full Quality Assurance Certificate, which enables the manufacturer to draw a Declaration of Conformity and affix the CE mark to the medical devices covered by the assessment. Thereafter, the Notified Body will carry out periodic audits to ensure that the approved quality system is applied by the manufacturer.

A manufacturer without a registered place of business in a Member State of the European Union which places a medical device on the market under its own name must designate an authorized representative established in the European Union who can act before, and be addressed by, the Competent Authorities on the manufacturer’s behalf with regard to the manufacturer’s obligations under the EU Medical Devices Directive. We appointed such a representative prior to establishing our infrastructure in the EEA and expect that we will not need a third party representative in the future.

In the EEA, we must also comply with the Medical Device Vigilance System, which is designed to improve the protection of health and safety of patients, users and others by reducing the likelihood of recurrence of incidents related to the use of a medical device. Under this system, incidents are defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health. When a medical device is suspected to be a contributory cause of an incident, its manufacturer or authorized representative in the EU must report it to the Competent Authority of the Member State where the incident occurred. Incidents are generally investigated by the manufacturer. The manufacturer’s investigation is monitored by the Competent Authority, which may intervene, or initiate an independent investigation if considered appropriate. An investigation may conclude in the adoption of a Field Safety Corrective Action (FSCA). An FSCA is an action taken by a manufacturer to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An FSCA may include device recall, modification exchange and destruction. FSCAs must be notified by the manufacturer or its authorized representative to its customers and/or the end users of the medical device via a Field Safety Notice.

In the EEA, the off-label promotion of a pharmaceutical product is strictly prohibited under the EU Community Code on Medicinal Products, which provides that all information provided within the context of the promotion of a drug must comply with the information contained in its approved summary of product characteristics. Our product instructions and indication reference the chemotherapeutic agent melphalan hydrochloride. However, no melphalan labels in the EEA reference our product, and the labels vary from country to country with respect to the approved indication of the drug and its mode of administration. In the exercise of their professional judgment in the practice of medicine, physicians are generally allowed, under certain conditions, to use or prescribe a product in ways not approved by regulatory authorities. Physicians intending to use our device must obtain melphalan separately for use with the CHEMOSAT system and must use melphalan independently at their discretion.

In the EEA, the advertising and promotion of our products is also subject to EEA Member States laws implementing the EU Medical Devices Directive, Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, as well as other EEA Member State legislation governing the advertising and promotion of medical devices. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on our promotional activities with health care professionals.

Failure to comply with the EEA Member State laws implementing the Medical Devices Directive, with the EU and EEA Member State laws on the promotion of medicinal products or with other applicable regulatory requirements can result in enforcement action by the EEA Member State authorities, which may include any of the following: fines, imprisonment, orders forfeiting products or prohibiting or suspending their supply to the market, or requiring the manufacturer to issue public warnings, or to conduct a product recall.

The European Commission reviewed the medical devices legislative framework in 2012 with the aim of simplifying it and ensuring a more uniform application of the provisions contained in the medical devices directives across the EEA. We do not believe the adopted regulatory changes will impact our business at this time, though future changes to the medical device legislation may adversely affect our business, financial condition and results of operations or restrict our operations.

Other International Regulations

The CHEMOSAT device has received registrations in the following countries: Australia, New Zealand, Argentina, Taiwan, and Singapore. With limited resources and our attention focused on European commercial and clinical adoption efforts, pursuing other markets at this time is not practical. We will continue to evaluate commercial opportunities in these and other markets when resources are available and at an appropriate time.

Competition

The healthcare industry is characterized by extensive research, rapid technological progress and significant competition from numerous healthcare companies and academic institutions. Competition in the cancer treatment industry is intense. We believe that the primary competitive factors for products addressing cancer include safety, efficacy, ease of use, reliability and price. We also believe that physician relationships, especially relationships with leaders in the medical and surgical oncology communities, are important competitive factors. We also believe that the current global economic conditions and new healthcare reforms could put competitive pressure on us, including reduced selling prices and potential reimbursement rates, and overall procedure rates. Certain markets in Europe are experiencing the effects of continued economic weakness, which is affecting healthcare budgets and reimbursement.

The CHEMOSAT and Melphalan/HDS competes with all forms of liver cancer treatments, including surgery, systemic chemotherapy, focal therapies and palliative care. In the disease states we are targeting there are also numerous clinical trials sponsored by third-parties, which can compete for potential patients in the near term and may ultimately lead to new competitive therapies.

For ocular melanoma liver metastases, there are currently no approved or effective treatment options, and patients are generally treated with a variety of focal and regional techniques. There are numerous companies developing and marketing devices for the performance of focal therapies, including Covidian, Biocompatibles, Merit, CeleNova, SirTex, AngioDynamics, and many others.

For HCC, sorafenib (Nexavar, Onyx Pharmaceuticals) remains the only targeted drug approved for the treatment of HCC in patients who are not candidates for surgery.

Several therapies have been recently approved for unresectable or metastatic cutaneous melanoma, which may encompass liver metastases. Dabrafenib (Tafinlar™, GlaxoSmithKline), is indicated as single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, and in combination with trametinib in unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Furthermore, trametinib (MEKINIST™, GlaxoSmithKline) is indicated as single agent (in addition to in combination with dabrafinib) for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Previously approved melanoma therapies such as the biologic ipilimumab (Yervoy™, Bristol Myers Squibb) and the B-RAF targeted drug vemurafenib (Zelboraf™, Genentech) may also make up the competitive landscape for the treatment of metastatic liver disease.

Many of these treatments are approved in Europe and other global markets.

Many of our competitors have substantially greater financial, technological, research and development, marketing and personnel resources. In addition, some of our competitors have considerable experience in conducting clinical trials, regulatory, manufacturing and commercialization capabilities. Our competitors may develop alternative treatment methods, or achieve earlier product development, in which case the likelihood of us achieving meaningful revenues or profitability will be substantially reduced.

Manufacturing and Quality Assurance

We manufacture certain components including our proprietary filter media, and assemble and package the CHEMOSAT and Melphalan/HDS at our facility in Queensbury, New York. We have established our European headquarters and distribution facility in Galway, Ireland where we intend to conduct final manufacturing and assembly in the future. Delcath currently utilizes third-parties to manufacture some components of the CHEMOSAT and Melphalan/HDS. The CHEMOSAT and Melphalan/HDS and its components must be manufactured and sterilized in accordance with approved manufacturing and pre-determined performance specifications. In addition, certain components will require sterilization prior to distribution and Delcath relies on third-party vendors to perform the sterilization process.

We are committed to providing high quality products to our customers. To honor this commitment, Delcath has implemented updated quality systems throughout our organization. Delcath’s quality system starts with the initial product specification and continues through the design of the product, component specification process and the manufacturing, sale and servicing of the product. These systems are designed to enable us to satisfy the various international quality system regulations including those of the FDA with respect to products sold in the United States and those established by the International Standards Organization (ISO) with respect to products sold in the EEA. The Company is required to maintain ISO 13485 certification for medical devices to be sold in the EEA, which requires, among other items, an implemented quality system that applies to component quality, supplier control, product design and manufacturing operations. On February 17, 2011, we announced that we had achieved ISO 13485 certification for our Queensbury manufacturing facility. On December 28, 2011, we announced that we had achieved ISO 13485 certification for our Galway, Ireland facility.

Intellectual Property and Other Rights

Our success depends in part on our ability to obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary rights against infringers, and operate without infringing on the proprietary rights of third parties. Because of the length of time and expense associated with developing new products and bringing them through the regulatory approval process, the health care industry places considerable emphasis on obtaining patent protection and maintaining trade secret protection for new technologies, products, processes, know-how, and methods. The Company currently holds nine United States utility patents, one United States design patent, five pending United States utility patent applications, eleven issued foreign counterpart utility patents, six issued foreign counterpart design patents, and eight pending foreign counterpart patent applications (one of which has been allowed). We presently have issued utility and design patents with claims related to certain features of the current version of CHEMOSAT and Melphalan/HDS in the United States and Japan and a design patent protection in Argentina, Australia, Canada, China and Europe.

When appropriate, the Company actively pursues protection of our proprietary products, technologies, processes, and methods by filing United States and international patent and trademark applications. We seek to pursue additional patent protection for technology invented through research and development, manufacturing, and clinical use of the CHEMOSAT and Melphalan/HDS that will enable us to expand our platform beyond the treatment of cancers in the liver. There can be no assurance that the pending patent applications will result in the issuance of patents, that patents issued to or licensed by us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently broad to protect our technology or provide us with a competitive advantage.

Certain of our United States and foreign patents have already expired and other patents relating to the CHEMOSAT and Melphalan/HDS will expire in 2017. In certain circumstances, United States patent law allows for the extension of a patent’s duration for a period of up to five years after FDA approval. The Company intends to seek extension for one of our patents after FDA approval if it has not expired prior to the date of approval. In addition to our proprietary protections, the FDA has granted Delcath five orphan drug designations that provide us a seven-year period of exclusive marketing beginning on the date that our NDA is approved by the FDA for the designated orphan drug. While the exclusivity only applies to the indication for which the drug has been approved, the Company believes that it will provide us with added protection once commercialization of an orphan drug designated product begins.

Employees

During 2016, Delcath added 7 employees to support clinical trial implementations in the EU and United States and to meet the demands of commercial sales. As of September 30, 2017, Delcath had 46 full-time employees. None of our employees is represented by a union and we believe relationships with our employees are good.

Stock Relisting

On September 13, 2017 the Company announced the delisting of its shares from the NASDAQ Capital Market. As a result of the shareholder non-approval of its reverse stock split on September 7, 2017 by the requisite vote required under Delaware law, the Company did not meet the requirements for continued listing on the Nasdaq Capital Market. After conversations with both the NASDAQ and OTC Markets, the Company was able to effect the change in listing to the OTC Markets more quickly than anticipated. The Company's common stock commenced trading on the OTCQB on September 15, 2017 under the symbol "DCTH".

Reverse Stock Split

Board of Directors

On September 21, 2017 the Company disclosed that Harold Koplewicz, M.D. resigned as a member of the Board of Directors of Delcath Systems, Inc. (the “Company”), effective September 15, 2017. The decision of Dr. Koplewicz to resign is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

On November 14, 2017, the Company appointed Simon Pedder as a director to take the seat vacated by Dr. Koplewiz.

Results of Operations for the three and nine months ended September 30, 2017; Comparisons of Results of Operations for the three and nine months ended September 30, 2016

Three months ended September 30, 2017 and September 30, 2016

Revenue

The Company recorded approximately $0.7 million in revenue related to product sales for the three months ended September 30, 2017 and $0.4 million in revenue related to product sales for the three months ended September 30, 2016. Although sales remain modest, the increase continues to be driven by the establishment of ZE diagnostic-related group reimbursement for CHEMOSAT procedures in Germany.

Cost of Goods Sold

For the three months ended September 30, 2017, the Company recorded cost of goods sold of approximately $0.2 million compared to $0.1 million for the three months ended September 30, 2016. The increase in cost of goods sold is commensurate with the increase in sales.

Selling, General and Administrative Expenses

For the three month period ended September 30, 2017 selling, general and administrative expenses were $2.9 million compared to $2.4 million for the three months ended September 30, 2016. The increase is due primarily to an increase in independent audit fees due to additional testing over the Company’s internal control over financial reporting and an increase in costs associated with the Company’s shareholder meetings as a result of the efforts to secure approval for a reverse stock split.

Research and Development Expenses

For the three month periods ended September 30, 2017 and 2016, research and development expenses decreased to $2.3 million from $2.7 million, primarily due to efforts in opening centers in 2016 in order to support the enrollment of our Phase 3 trial which is discussed in further detail in the Current Clinical Development Program section above.

Other Income/Expense and Interest Expense

Other income (expense) increase is related to foreign currency exchange gains and losses.

Interest expense is related to:

1. the restructuring lease liability discussed in Note 6 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q;

2. the amortization of debt discounts and debt issuance costs discussed in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q; and

3. original issuance discounts related to the issuance of Series C preferred stock discussed in Note 8 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

Interest income is from a money market account and interest earned on operating accounts.

Derivative Instrument Income

For the three months ended September 30, 2017 derivative instrument income decreased to approximately $27,000 from $8.7 million for the three months ended September 30, 2016. The decrease of $8.7 million is due to the extinguishment of the Series C Warrants and the mark-to-market adjustments to the Warrant liability as discussed in more detail in Note 7 and Note 9 to the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

Net Loss

The Company recorded a net loss for the three months ended September 30, 2017, of $12.6 million, an increase of $11.6 million, or 1,153.9%, compared to a net loss of $1.0 million for the same period in 2016. This increase in net loss is primarily due to an $8.7 million change in the fair value of the warrant liability and a $3.0 million loss on settlement of the convertible note debt, both non-cash items.

Nine months ended September 30, 2017 and September 30, 2016

Revenue

The Company recorded approximately $2.0 million in revenue related to product sales for the nine months ended September 30, 2017 and $1.3 million in revenue related to product sales for the nine months ended September 30, 2016. Although sales remain modest, the increase continues to be driven by the establishment of ZE diagnostic-related group reimbursement for CHEMOSAT procedures in Germany.

Cost of Goods Sold

For the nine months ended September 30, 2017, the Company recorded cost of goods sold of approximately $0.5 million compared to $0.4 million for the nine months ended September 30, 2016. The increase in cost of goods sold is commensurate with the increase in sales.

Selling, General and Administrative Expenses

For the nine months ended September 30, 2017 the Company recorded selling, general and administrative expenses of approximately $7.8 million compared to $7.0 million for the same period in 2016. The increase is due primarily to an increase in Delaware corporate taxes, in independent audit fees due to additional testing over the Company’s internal control over financial reporting and an increase in costs associated with the Company’s shareholder meetings as a result of the efforts to secure approval for a reverse stock split.

Research and Development Expenses

For the nine months ended September 30, 2017 and 2016, research and development expenses increased to $7.1 million from $6.0 million, primarily due to the ongoing efforts of our Phase 3 trial which is discussed in further detail in the Current Clinical Development Program section above.

Other Income/Expense and Interest Expense

Other income (expense) increase is related to foreign currency exchange gains and losses.

Interest expense is related to:

1. the restructuring lease liability discussed in Note 6 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q;

Interest income is from a money market account and interest earned on operating accounts.

Derivative Instrument Income

For the nine months ended September 30, 2017 derivative instrument income decreased to $1.2 million from $9.2 million for the nine months ended September 30, 2016. The decrease of $7.9 million is due to the extinguishment of the Series C Warrants and the mark-to-market adjustments to the Warrant liability as discussed in more detail in Note 7 and Note 9 to the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

Net Loss

The Company recorded a net loss for the nine months ended September 30, 2017, of $25.9 million, an increase of $16.4 million, or 172.8%, compared to a net loss of $9.5 million for the same period in 2016. This increase in net loss is primarily due to a $13.7 million increase in interest expense primarily related to the amortization of debt discounts and a $3.0 million loss settlement of the convertible note debt, offset by a $9.6 million gain on the extinguishment of the June 2016 Series C Warrants, both non-cash items, discussed further in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. Additionally, there was a $1.9 million increase in operating expenses and a $7.9 million change in the fair value of the warrant liability, a non-cash item, offset by a $0.5 million increase in gross profit.

Liquidity and Capital Resources

The Company’s future results are subject to substantial risks and uncertainties. Delcath has operated at a loss for its entire history and anticipates that losses will continue over the coming years. There can be no assurance that Delcath will ever generate significant revenues or achieve profitability. The Company expects to use cash, cash equivalents and investment proceeds to fund its clinical and operating activities. Delcath’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining approvals and complying with regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments.

At September 30, 2017, the Company had cash and cash equivalents totaling $2.5 million, as compared to cash and cash equivalents totaling $4.4 million and $3.7 million at December 31, 2016 and September 30, 2016, respectively. In addition, the Company has $8.4 million in restricted cash primarily related to the Convertible Notes discussed further in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. During the nine months ended September 30, 2017 the Company used $11.7 million of cash in its operating activities, which compares to $10.6 million used for operating activities during the comparable period in 2016. As a result of issuing $35.0 million in senior secured convertible notes in June 2016 and effecting a reverse stock split on November 6, 2017 management believes that in its current reduced operating mode its capital resources will be adequate to fund operations through at least January 2018.

Our consolidated financial statements as of September 30, 2017 have been prepared under the assumption that we will continue as a going concern for the next twelve months. We expect to incur significant expenses and operating losses for the foreseeable future. These factors raise substantial doubt about our ability to continue as a going concern. Because Delcath’s business does not generate positive cash flow from operating activities, the Company will need to obtain substantial additional capital in order to fund clinical trial research and support development efforts relating to Ocular Melanoma liver metastases, ICC, HCC or other indications, and to fully commercialize the product. The Company believes it will be able to raise additional capital in the event it is in its best interest to do so. The Company anticipates raising such additional capital by either borrowing money, selling shares of Delcath’s capital stock, or entering into strategic alliances with appropriate partners. To the extent additional capital is not available when needed or on acceptable terms, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of its business. Further, the Company’s assumptions relating to its cash requirements may differ materially from its actual requirements because of a number of factors, including significant unforeseen delays in the regulatory approval process, changes in the timing, scope, focus and direction of clinical trials and costs related to commercializing the product.

The Company has funded its operations through a combination of private placements of its securities, and public offerings in 2000, 2003, 2009, 2010, 2011, 2012, 2013, 2015, and 2016 including registered direct offerings in 2007, 2009 and 2013, “at the market” equity offering programs in 2012 and 2013, and by a private placement of convertible notes in 2016 and preferred stock in 2017. For a detailed discussion of the Company’s various sales of securities see Note 8 to the Company’s financial statements contained in this Quarterly Report on Form 10-Q.

In October 2015, the Company filed a registration statement on Form S-3 with the SEC, which was declared effective on October 20, 2015 and allows the Company to offer and sell, from time to time in one or more offerings, up to $76.0 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deems prudent or necessary to raise capital at a later date. The Company is not currently eligible to use its Form S-3.

The Company intends to use the net proceeds from any future offerings for general corporate purposes, including, but not limited to, funding of clinical trials, obtaining regulatory approvals, commercialization of its products, capital expenditures and working capital.

Application of Critical Accounting Policies

The Company’s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). Certain accounting policies have a significant impact on amounts reported in the financial statements. A summary of those significant accounting policies can be found in Note 3 to the Company’s audited financial statements contained in the 2016 Annual Report on Form 10-K.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The Company may be minimally exposed to market risk through changes in market interest rates that could affect the interest earned on its cash balances.

The Company measures all derivatives, including certain derivatives embedded in contracts, at fair value and recognizes them on the balance sheet as an asset or a liability, depending on the Company’s rights and obligations under the applicable derivative contract.

In October 2013, the Company completed the sale of 234 shares of its common stock and the issuance of warrants to purchase approximately 106 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At September 30, 2017, the 2013 Warrants were exercisable at $39,424.00 per share with approximately 100 warrants outstanding. The 2013 Warrants have a five-year term.

In February 2015, the Company completed the sale of 440 shares of its common stock and the issuance of warrants to purchase 197 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At September 30, 2017, the February 2015 Warrants were exercisable at $49.00 per share with approximately 100 warrants outstanding. The February 2015 Warrants have a five-year term.

In July 2015, the Company completed the sale of 1,715 Units consisting of 1,715 shares of its common stock, Series A Warrants to purchase up to 1,140 common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to 1,715 common shares (“Series B Warrants”) and 0.4 million Series A Warrants per unit pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the 2015 Series A Warrants and Series B Warrants. The exercise price of both series of warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. During the three months ended March 31, 2016, approximately 285 Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 1,140 Series B Warrants expired on January 29, 2016 and the remaining liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 285 Series A Warrants were issued. At September 30, 2017, the Series A Warrants were exercisable at $49.00 with approximately 500 million warrants outstanding. The Series A Warrants have a five-year term. There were approximately 285 July 2015 Series A Warrants exercised during the nine months endedSeptember 30, 2017 for proceeds of approximately $15,000.

In June 2016, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase approximately 19,430 additional shares of the Company’s common stock. The Company allocated an estimated fair value of $27.8 million to the Series C Warrants. On April 2, 2017 the Company entered into warrant repurchase agreements with each of the investors named on the Schedule of Buyers attached to the SPA. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case are to be paid to the respective investor, in exchange for cancellation of the Series C Warrants issued to each investor under the SPA.

The proceeds allocated to the 2013 Warrants, February 2015 Warrants, the July 2015 Series A Warrants, and the October 2016 Warrants (the “Warrants”) were initially classified as derivative instrument liabilities that are subject to mark-to-market adjustments each period. As a result, for the nine months ended September 30, 2017, the Company recorded pre-tax derivative instrument income

of $1.2 million. The fair value of the Warrants totaled $0.02 million at September 30, 2017. Management expects that the warrants outstanding at September 30, 2017 will either be exercised or expire worthless. The fair value of the Warrants at September 30, 2017 was determined by using option pricing models assuming the following:

	October 2016 Warrants		July 2015 Series A Warrants		February 2015 Warrants		October 2013 Warrants
Expected volatility		142.46%		165.32%		181.24%		227.68%
Risk-free interest rates		1.77%		1.59%		1.53%		1.33%
Expected life (in years)		4.02		2.81		2.38		1.08

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Delcath’s management, with the participation of its Chief Executive Officer, evaluated the effectiveness of the design and operation of its disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act). Based on that evaluation, the Company’s Chief Executive Officer concluded that Delcath’s disclosure controls and procedures as of September 30, 2017 (the end of the period covered by this Quarterly Report on Form 10-Q), have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the Company’s Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Controls

There was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 1.

Legal Proceedings

Not Applicable.

Item 1A.

Risk Factors

Delcath’s 2016 Annual Report on Form 10-K, in Part 1 – Item 1A. "Risk Factors," contains a detailed discussion of factors that could materially adversely affect our business, operating results and/or financial condition. There have been no material changes in these risk factors since such disclosure.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

On July 11, 2017, we entered into an Amended and Restated Securities Purchase Agreement (the “Amended Purchase Agreement”) with certain institutional investors for the sale by the Company of 2,360 shares of Series B Preferred Stock (the “Series B Preferred Stock”) at a purchase price of $1,000 per share, in a private placement. The aggregate gross proceeds for the sale of the Series B Preferred Stock is $2.0 million. The Company intends to use the proceeds from the transaction for general corporate purposes. The restricted shares of Series B Preferred Stock have no registration rights and thus will not be eligible for legend removal for a period of at least six months from the date of closing. This Amended Purchase Agreement amends the July 5, 2017 Securities Purchase Agreement (the “Purchase Agreement”) into which we entered with certain institutional investors (the “Investors”) for the sale by the Company of 2,360 shares of Series B Preferred Stock in a registered direct offering. The Series B Preferred Stock shall be entitled to the whole number of votes equal to $2.0 million divided by $65.35 (the closing bid price on July 5, 2017, the date of sale of the Series B Preferred Stock), or 30,607 votes. The Series B Preferred Stock has no liquidation or other rights which are preferential to our common stock. The Series B Preferred Stock was redeemed for $2,360,000 in August 2017.

On September 21, 2017, we entered into a securities purchase agreement (the “SPA”) with two of our investors which had purchased certain senior secured convertible notes (the “Notes”), convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $0.5 million aggregate purchase price for 590 shares of Series C Preferred Stock (the “Series C Preferred Shares”). The purchase of the Series C Preferred Stock is being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended. The Series C Preferred Shares shall be entitled to 1,484,061 votes and may only vote on approval of a reverse split of our outstanding common stock. The Series C Preferred Stock has no dividend, liquidation or other preferential rights to our common stock, and each share of Series C Preferred Stock shall be redeemable for the amount of $1,000.00, payable in cash, per share at our written election, and must be redeemed by us no later than December 21, 2017. The Series C Preferred Stock was redeemed for $590,000 in November 2017.

Item 3.

Defaults upon Senior Securities

Not Applicable.

Item 4.

Mine Safety Disclosures

Not Applicable.

Item 5.

Other Information

Not Applicable.

Item 6.

Exhibits

Exhibit No.		Description

10.1	⁽¹⁾	Securities Purchase Agreement, dated as of June 6, 2016

10.2	⁽²⁾	Form of Senior Secured Convertible Note

10.3	⁽³⁾	Form of Warrant

10.4	⁽⁴⁾	Form of Security and Pledge Agreement

31.1	**	Certification by Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	**	Certification by Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	***	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	***	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

**	Filed herewith.

***	Furnished herewith.

(1)	Filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

(2)	Filed as Exhibit A to the Securities Purchase Agreement filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

(3)	Filed as Exhibit B to the Securities Purchase Agreement filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

(4)	Filed as Exhibit C to the Securities Purchase Agreement filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

DELCATH SYSTEMS, INC.

Exhibit Index

Exhibit No.		Description

10.1	⁽¹⁾	Securities Purchase Agreement, dated as of June 6, 2016

10.2	⁽²⁾	Form of Senior Secured Convertible Note

10.3	⁽³⁾	Form of Warrant

10.4	⁽⁴⁾	Form of Security and Pledge Agreement

31.1	**	Certification by Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	**	Certification by Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	***	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	***	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

**	Filed herewith.

***	Furnished herewith.

(1)	Filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

(2)	Filed as Exhibit A to the Securities Purchase Agreement filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

(3)	Filed as Exhibit B to the Securities Purchase Agreement filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

(4)	Filed as Exhibit C to the Securities Purchase Agreement filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 7, 2016 and incorporated by reference

DELCATH SYSTEMS, INC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

November 14, 2017	DELCATH SYSTEMS, INC.
	(Registrant)

	/s/ Jennifer K. Simpson
	Jennifer K. Simpson
	President and Chief Executive Officer
	(Principal Executive Officer)


	/s/ Barbra C. Keck
	Barbra C. Keck
	Chief Financial Officer
	(Principal Financial Officer)

EX-31.1 2 dcth-ex311_7.htm EX-31.1 dcth-ex311_7.htm

Exhibit 31.1

DELCATH SYSTEMS, INC.

PRINCIPAL EXECUTIVE OFFICER’S CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jennifer K. Simpson, Chief Executive Officer, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2017

	/s/ Jennifer K. Simpson
	Jennifer K. Simpson
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 dcth-ex312_8.htm EX-31.2 dcth-ex312_8.htm

Exhibit 31.2

DELCATH SYSTEMS, INC.

PRINCIPAL FINANCIAL OFFICER’S CERTIFICATION

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Barbra C. Keck, Principal Financial Officer, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2017

	/s/ Barbra C. Keck
	Barbra C. Keck
	Chief Financial Officer
	(Principal Financial Officer)

EX-32.1 4 dcth-ex321_6.htm EX-32.1 dcth-ex321_6.htm

Exhibit 32.1

DELCATH SYSTEMS, INC.

PRINCIPAL EXECUTIVE OFFICER’S CERTIFICATION

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jennifer K. Simpson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2017

	/s/ Jennifer K. Simpson
	Jennifer K. Simpson
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-32.2 5 dcth-ex322_9.htm EX-32.2 dcth-ex322_9.htm

Exhibit 32.2

DELCATH SYSTEMS, INC.

PRINCIPAL FINANCIAL OFFICER’S CERTIFICATION

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Barbra C. Keck, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2017

	/s/ Barbra C. Keck
	Barbra C. Keck Chief Financial Officer
	(Principal Financial Officer)

EX-101.INS 6 dcth-20170930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure dcth:Lease dcth:Installment dcth:Investor utr:D dcth:Vote dcth:Input dcth:Conversion 0000872912 2017-01-01 2017-09-30 0000872912 2017-11-13 0000872912 2017-09-30 0000872912 2016-12-31 0000872912 2016-07-20 2016-07-21 0000872912 us-gaap:SubsequentEventMember 2017-11-05 2017-11-06 0000872912 2017-07-01 2017-09-30 0000872912 2016-07-01 2016-09-30 0000872912 2016-01-01 2016-09-30 0000872912 us-gaap:CommonStockMember 2016-12-31 0000872912 us-gaap:TreasuryStockMember 2016-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000872912 us-gaap:RetainedEarningsMember 2016-12-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0000872912 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000872912 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0000872912 us-gaap:CommonStockMember 2017-09-30 0000872912 us-gaap:TreasuryStockMember 2017-09-30 0000872912 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000872912 us-gaap:RetainedEarningsMember 2017-09-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0000872912 dcth:SeriesCWarrantsMember 2017-01-01 2017-09-30 0000872912 dcth:SeriesCWarrantsMember 2016-01-01 2016-09-30 0000872912 dcth:SeriesAAndSeriesBPreferredSharesMember 2017-01-01 2017-09-30 0000872912 dcth:SeriesAAndSeriesBPreferredSharesMember 2016-01-01 2016-09-30 0000872912 2015-12-31 0000872912 2016-09-30 0000872912 us-gaap:SubsequentEventMember dcth:OTCQBMember 2017-11-05 2017-11-06 0000872912 us-gaap:SubsequentEventMember dcth:OTCQBMember 2017-11-06 0000872912 dcth:SeniorSecuredConvertibleNoteMember 2016-06-30 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2017-09-30 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2016-12-31 0000872912 us-gaap:ComputerEquipmentMember 2017-09-30 0000872912 us-gaap:ComputerEquipmentMember 2016-12-31 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2017-09-30 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2016-12-31 0000872912 us-gaap:EquipmentMember 2017-09-30 0000872912 us-gaap:EquipmentMember 2016-12-31 0000872912 us-gaap:FurnitureAndFixturesMember 2017-09-30 0000872912 us-gaap:FurnitureAndFixturesMember 2016-12-31 0000872912 us-gaap:PropertySubjectToOperatingLeaseMember 2017-01-01 2017-09-30 0000872912 us-gaap:FacilityClosingMember dcth:SubLease1Member 2014-05-20 2014-05-22 0000872912 us-gaap:FacilityClosingMember dcth:SubLease2Member 2014-08-16 2014-08-18 0000872912 us-gaap:PropertySubjectToOperatingLeaseMember 2017-09-30 0000872912 us-gaap:PropertySubjectToOperatingLeaseMember us-gaap:AccruedLiabilitiesMember 2017-09-30 0000872912 us-gaap:PropertySubjectToOperatingLeaseMember us-gaap:OtherNoncurrentLiabilitiesMember 2017-09-30 0000872912 us-gaap:PropertySubjectToOperatingLeaseMember 2016-12-31 0000872912 dcth:SeniorSecuredConvertibleNoteMember dcth:SecuritiesPurchaseAgreementMember 2016-06-06 0000872912 dcth:SeriesCWarrantsMember dcth:SecuritiesPurchaseAgreementMember 2016-06-06 0000872912 dcth:SeniorSecuredConvertibleNoteMember dcth:SeriesCWarrantsMember dcth:SecuritiesPurchaseAgreementMember 2016-06-05 2016-06-06 0000872912 dcth:SeniorSecuredConvertibleNoteMember dcth:SecuritiesPurchaseAgreementMember 2017-09-30 0000872912 dcth:SeniorSecuredConvertibleNoteMember dcth:SecuritiesPurchaseAgreementMember 2017-01-01 2017-09-30 0000872912 dcth:SecuritiesPurchaseAgreementMember dcth:SeniorSecuredConvertibleNoteMember 2016-06-05 2016-06-06 0000872912 dcth:SecuritiesPurchaseAgreementMember dcth:SeniorSecuredConvertibleNoteMember 2016-12-01 2016-12-31 0000872912 dcth:SecuritiesPurchaseAgreementMember dcth:SeniorSecuredConvertibleNoteMember us-gaap:CashMember 2017-01-01 2017-09-30 0000872912 dcth:SecuritiesPurchaseAgreementMember dcth:SeniorSecuredConvertibleNoteMember 2017-01-01 2017-03-31 0000872912 dcth:SecuritiesPurchaseAgreementMember dcth:SeniorSecuredConvertibleNoteMember 2017-07-01 2017-09-30 0000872912 dcth:SecuritiesPurchaseAgreementMember dcth:SeniorSecuredConvertibleNoteMember dcth:SeriesAAndSeriesBPreferredSharesMember 2017-07-01 2017-09-30 0000872912 dcth:SeniorSecuredConvertibleNoteMember dcth:SecuritiesPurchaseAgreementMember dcth:SeriesCWarrantsMember 2016-06-06 0000872912 dcth:SecuritiesPurchaseAgreementMember dcth:WarrantRepurchaseAgreementsMember 2017-04-01 2017-04-02 0000872912 dcth:SeniorSecuredConvertibleNoteMember dcth:SecuritiesPurchaseAgreementMember 2016-06-12 2016-06-13 0000872912 dcth:RestructuringAgreementMember us-gaap:NotesPayableOtherPayablesMember us-gaap:InvestorMember 2017-08-28 0000872912 dcth:RestructuringAgreementMember dcth:RestrictedNotesMember us-gaap:NotesPayableOtherPayablesMember us-gaap:InvestorMember 2017-08-28 0000872912 dcth:RestructuringAgreementMember dcth:UnrestrictedNotesMember us-gaap:NotesPayableOtherPayablesMember us-gaap:InvestorMember 2017-08-28 0000872912 dcth:RestructuringAgreementMember us-gaap:InvestorMember us-gaap:SeriesAPreferredStockMember 2017-08-28 0000872912 dcth:RestructuringAgreementMember us-gaap:InvestorMember dcth:SeriesBConvertiblePreferredStockMember 2017-08-28 0000872912 us-gaap:InvestorMember dcth:RestructuringAgreementMember 2017-08-27 2017-08-28 0000872912 us-gaap:InvestorMember dcth:CancellationNoteMember dcth:RestructuringAgreementMember 2017-08-27 2017-08-28 0000872912 us-gaap:SeriesBPreferredStockMember us-gaap:InvestorMember dcth:RestructuringAgreementMember 2017-08-27 2017-08-28 0000872912 us-gaap:InvestorMember dcth:AdditionalRestructuringMember 2017-09-14 2017-09-15 0000872912 us-gaap:InvestorMember dcth:RedemptionNotesMember dcth:AdditionalRestructuringMember 2017-09-15 0000872912 us-gaap:InvestorMember dcth:ExchangeNotesMember dcth:AdditionalRestructuringMember 2017-09-15 0000872912 us-gaap:InvestorMember dcth:ExchangeNotesMember dcth:AdditionalRestructuringMember dcth:NewWarrantsMember 2017-09-14 2017-09-15 0000872912 us-gaap:InvestorMember dcth:AdditionalRestructuringMember dcth:NewWarrantsMember 2017-09-14 2017-09-15 0000872912 us-gaap:InvestorMember dcth:AdditionalRestructuringMember dcth:NewWarrantsMember 2017-09-15 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:SeniorSecuredConvertibleNoteMember 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:SeniorSecuredConvertibleNoteMember 2017-10-09 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember 2017-10-09 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2017-10-09 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:SeniorSecuredConvertibleNoteMember 2017-10-11 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:SeniorSecuredConvertibleNoteMember 2017-10-09 2017-10-11 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember dcth:SeniorSecuredConvertibleNoteMember 2017-10-11 0000872912 us-gaap:CommonStockMember 2017-01-11 2017-01-12 0000872912 us-gaap:CommonStockMember 2017-01-26 2017-02-01 0000872912 us-gaap:CommonStockMember 2017-02-09 2017-02-10 0000872912 us-gaap:CommonStockMember 2017-02-23 2017-03-02 0000872912 us-gaap:CommonStockMember 2017-03-12 2017-03-13 0000872912 us-gaap:CommonStockMember 2017-04-09 2017-04-10 0000872912 us-gaap:CommonStockMember 2017-05-08 2017-05-09 0000872912 us-gaap:CommonStockMember dcth:ExchangeAgreementMember 2017-07-01 2017-07-02 0000872912 us-gaap:CommonStockMember 2017-07-06 2017-07-07 0000872912 us-gaap:CommonStockMember 2017-08-03 2017-08-04 0000872912 us-gaap:CommonStockMember dcth:RestructuringAgreementMember 2017-08-27 2017-08-28 0000872912 us-gaap:CommonStockMember 2017-01-11 2017-08-28 0000872912 us-gaap:PreferredStockMember dcth:ExchangeAgreementMember 2017-07-01 2017-07-02 0000872912 2017-01-12 0000872912 2017-02-01 0000872912 2017-02-10 0000872912 2017-03-02 0000872912 2017-03-13 0000872912 2017-04-10 0000872912 2017-05-09 0000872912 dcth:ExchangeAgreementMember 2017-07-02 0000872912 2017-07-07 0000872912 2017-08-04 0000872912 dcth:RestructuringAgreementMember 2017-08-28 0000872912 2017-01-11 2017-01-12 0000872912 2017-01-26 2017-02-01 0000872912 2017-02-09 2017-02-10 0000872912 2017-02-23 2017-03-02 0000872912 2017-03-12 2017-03-13 0000872912 2017-04-09 2017-04-10 0000872912 2017-05-08 2017-05-09 0000872912 dcth:ExchangeAgreementMember 2017-07-01 2017-07-02 0000872912 2017-07-06 2017-07-07 0000872912 2017-08-03 2017-08-04 0000872912 dcth:RestructuringAgreementMember 2017-08-27 2017-08-28 0000872912 2017-01-11 2017-08-28 0000872912 us-gaap:SeriesAPreferredStockMember dcth:ExchangeAgreementMember 2017-07-01 2017-07-02 0000872912 dcth:RestructuringAgreementMember 2017-08-27 2017-08-28 0000872912 dcth:RestructuringAgreementMember us-gaap:CommonStockMember 2017-08-27 2017-08-28 0000872912 dcth:SeniorSecuredConvertibleNoteMember 2017-09-30 0000872912 us-gaap:MinimumMember 2016-07-18 2016-07-19 0000872912 us-gaap:MaximumMember 2016-07-18 2016-07-19 0000872912 2016-07-21 0000872912 2016-07-18 0000872912 2016-07-19 0000872912 us-gaap:SeriesAPreferredStockMember 2017-06-29 0000872912 dcth:SeniorSecuredConvertibleNoteMember us-gaap:SeriesAPreferredStockMember 2017-07-01 2017-07-02 0000872912 us-gaap:SeriesAPreferredStockMember 2017-07-01 2017-07-02 0000872912 us-gaap:SeriesAPreferredStockMember 2017-07-02 0000872912 us-gaap:SeriesBPreferredStockMember 2017-06-29 0000872912 us-gaap:SeriesBPreferredStockMember 2017-07-10 2017-07-11 0000872912 us-gaap:SeriesBPreferredStockMember 2017-07-11 0000872912 us-gaap:SeriesBPreferredStockMember dcth:RestructuringAgreementMember 2017-08-28 0000872912 us-gaap:SeriesBPreferredStockMember 2017-07-01 2017-09-30 0000872912 us-gaap:SeriesCPreferredStockMember 2017-09-12 0000872912 us-gaap:SeriesCPreferredStockMember 2017-09-20 2017-09-21 0000872912 us-gaap:SeriesCPreferredStockMember 2017-09-21 0000872912 us-gaap:SeriesCPreferredStockMember 2017-11-06 0000872912 2013-10-01 2013-10-31 0000872912 dcth:WarrantsTwoThousandAndThirteenMember 2013-10-01 2013-10-31 0000872912 dcth:WarrantsTwoThousandAndThirteenMember 2013-10-31 0000872912 dcth:WarrantsTwoThousandAndThirteenMember 2017-09-30 0000872912 dcth:WarrantsTwoThousandAndThirteenMember 2017-01-01 2017-09-30 0000872912 2015-02-01 2015-02-28 0000872912 dcth:WarrantsFebruaryTwoThousandAndFifteenMember 2015-02-01 2015-02-28 0000872912 dcth:WarrantsFebruaryTwoThousandAndFifteenMember 2015-02-28 0000872912 dcth:WarrantsFebruaryTwoThousandAndFifteenMember 2017-09-30 0000872912 dcth:WarrantsFebruaryTwoThousandAndFifteenMember 2017-01-01 2017-09-30 0000872912 2015-07-01 2015-07-31 0000872912 dcth:SeriesACommonStockWarrantsMember 2015-07-31 0000872912 dcth:SeriesBCommonStockWarrantsMember 2015-07-31 0000872912 dcth:SeriesACommonStockWarrantsMember 2015-07-01 2015-07-31 0000872912 dcth:SeriesAAndBCommonStockWarrantsMember 2015-07-31 0000872912 dcth:SeriesACommonStockWarrantsMember 2017-09-30 0000872912 dcth:SeriesACommonStockWarrantsMember 2017-01-01 2017-09-30 0000872912 dcth:SeriesBCommonStockWarrantsMember 2017-01-01 2017-09-30 0000872912 dcth:SeriesBCommonStockWarrantsMember 2017-09-30 0000872912 2016-10-01 2016-10-31 0000872912 dcth:WarrantsOctoberTwoThousandAndSixteenMember 2016-10-01 2016-10-31 0000872912 dcth:WarrantsOctoberTwoThousandAndSixteenMember 2016-10-31 0000872912 dcth:WarrantsOctoberTwoThousandAndSixteenMember 2017-09-30 0000872912 dcth:WarrantsOctoberTwoThousandAndSixteenMember 2017-01-01 2017-09-30 0000872912 dcth:StockIncentivePlan2004Member 2017-09-30 0000872912 dcth:StockIncentivePlan2009Member 2017-09-30 0000872912 dcth:StockIncentivePlan2009Member 2016-07-01 2016-07-31 0000872912 dcth:StockIncentivePlan2009Member 2016-07-31 0000872912 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000872912 us-gaap:RestrictedStockMember 2017-07-01 2017-09-30 0000872912 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000872912 us-gaap:RestrictedStockMember 2016-07-01 2016-09-30 0000872912 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0000872912 dcth:WarrantsOctoberTwoThousandAndSixteenMember 2017-01-01 2017-09-30 0000872912 dcth:WarrantsSeriesAJulyTwoThousandAndFifteenMember 2017-01-01 2017-09-30 0000872912 dcth:WarrantsFebruaryTwoThousandAndFifteenMember 2017-01-01 2017-09-30 0000872912 dcth:WarrantsOctoberTwoThousandAndThirteenMember 2017-01-01 2017-09-30 0000872912 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-09-30 0000872912 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000872912 dcth:UnvestedRestrictedStockMember 2017-01-01 2017-09-30 0000872912 dcth:UnvestedRestrictedStockMember 2016-01-01 2016-09-30 0000872912 us-gaap:WarrantMember 2017-01-01 2017-09-30 0000872912 us-gaap:WarrantMember 2016-01-01 2016-09-30 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SeriesCPreferredStockMember us-gaap:SubsequentEventMember 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:OnOrAfterSeventyFifthDaySubsequentToDateOfConsummationOfOfferingMember 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:AfterSeventySixDaysFromDateOfConsummationOfOfferingMember 2017-10-09 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:OnEightyFirstDateFollowingFromDateOfConsummationOfOfferingMember 2017-10-09 2017-10-10 0000872912 dcth:AmendmentToRestructuringAgreementMember us-gaap:SubsequentEventMember dcth:OnOrBeforeOneThirtyFifthDateFollowingFromDateOfConsummationOfOfferingMember 2017-10-10 DELCATH SYSTEMS, INC. 0000872912 --12-31 Smaller Reporting Company 2591509 2017 DCTH Q3 10-Q false 2017-09-30

2495000

4409000

8362000

27287000

298000

403000

1164000

660000

385000

698000

529000

699000

13233000

34156000

1253000

1083000

14486000

35239000

1891000

594000

3755000

3407000

494000 0

9736000

13343000

16000

18751000

15892000

36095000

30000

444000

604000

16336000

36729000

14000

303808000

277790000

-305587000

-279188000

51000

-34000

-41000

-1850000

-1490000

14486000

35239000

0.01

10000000

0.01

500000000

1426153

11805

1425862

11750

0.0625

0.0029

684000

435000

2011000

1316000

172000

112000

527000

373000

512000

323000

1484000

943000

2860000

2361000

7807000

7025000

2279000

2686000

7119000

5975000

5139000

5047000

14926000

13000000

-4627000

-4724000

-13442000

-12057000

-27000

-8680000

-1227000

-9171000

9613000

2952000 2952000

5042000

4963000

20324000

6584000

-2000

3000

5000

-15000

-12596000

-1004000

-25873000

-9485000

-15000

-2000

7000

-12000

-12611000

-1006000

-25866000

-9497000

-9.36

-230.99

-34.99

-2232.30

1401413

4349

754421

4249

11805

-1

-51000

277790000

-279188000

-41000

48000

261

84000

1413790

14000

25852000

25866000

526000

297 15000 15000 19000 19000

-25873000

7000

1426153

14000

-1

-51000

303808000

-305587000

-34000

48000

138000

84000

228000

198000

232000

-20000

-1000

-16000 1000 -30000 31000

20315000

6567000

-276000

-610000

94000

338000

-190000

1767000

312000

-160000

-155000

-11659000

-10597000

372000

245000

1087000

-372000

-1332000

0 29200000

7901000

7876000 0

7876000

2278000

2360000 0

2360000

31436000

15000

704000

10194000

2940000

-77000

71000

-1914000

-8918000

12607000

3689000

26199000

28133000

19000

245000

<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (7)</td> <td valign="top"> Convertible Notes Payable</td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes are secured pursuant to a Security Agreement which creates a first priority security interest in all of the personal property (other than Excluded Collateral (as defined in the Security Agreement) of the Company of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable, if applicable, in arrears for each calendar month on the first (1st) business day of each calendar month after any such interest accrues after an Event of Default. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. An additional $6.6 million was released during the three months ended March 31, 2017. Under the terms of warrant repurchase agreements signed in April 2017 and discussed in more detail below, $7.9 million was returned to the holders in exchange for the extinguishment of the Series C Warrants. During the three months ended September 30, 2017, an additional $2.1 million was released to the Company and $2.4 million was returned to the holders in order to redeem the Series A and Series B Preferred Shares discussed in more detail in Note 8. The remaining cash proceeds of $7.3 million are being held in restricted accounts. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire appoximately 20,000 shares of Common Stock. The provisions in the Series C Warrants required the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants. On April 2, 2017 the Company entered into separate warrant repurchase agreements (the “Warrant Repurchase Agreements”) with each of the investors named on the Schedule of Buyers attached to the SPA. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case were paid to the respective investor, in exchange for cancellation of the Warrants issued to each investor under the SPA. As a result of the extinguishment, the Company recognized a gain of $9.6 million, representing the difference between the fair value of the liability as of the extinguishment date of $17.5 million related to the Series C Warrants and the $7.9 million in cash returned to the Note holders to extinguish the liability.    <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall, at the election of the Company, automatically be converted into shares of Common Stock at a conversion rate defined in the agreement. If we cannot meet the equity conditions, we could be required to repay some or all of the amounts due under the notes in cash, and we may not have the funds available to make one or more of such payments when due. At any time after the issuance of the Notes, the Notes will be convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $1,536.50, subject to adjustment as provided in the Notes. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restructuring Agreement <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 28, 2017, the Company entered into a Restructuring Agreement (the “Agreement”) with one of the institutional investors (the “Investor”) who was a party to the SPA. As of the date the Agreement was entered into, the Investor held $11,444,637 aggregate principal amount of Notes of which there was $10,092,857 aggregate Restricted Principal, (as defined in the Notes) of Notes (the “Restricted Notes”), secured by such aggregate cash amount held in a collateral account of the Company in the same amount (the “Restricted Cash”) and (y) $1,351,780 principal of Notes (the “Unrestricted Notes”), (ii) 4,200 shares of Series A Preferred Stock and (iii) 2,006 shares of Series B Convertible Preferred Stock. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Agreement, (a) on the date thereof the Company and the Investor took the following actions (the “Initial Restructuring”): (i) the Investor released restrictions on $1,650,000 of Restricted Cash (the “Initial Release”), (ii) the Investor consented to the use of additional Restricted Cash to effect redemptions of the Series A Preferred Shares and the Series B Preferred Shares, (iii) the Investor cancelled $1,200,000 aggregate principal of the Notes (such portion of the Notes, the “Cancellation Note”), (iv) the Company redeemed all the Series A Preferred Shares outstanding for a cash payment to the Investor of $4.20 and (v) the Company redeemed the Series B Preferred Shares for a cash payment to the Investor of $2,006,000 and (b) upon the consummation of a reverse stock split of our Common Stock of at least twenty to one (the “Reverse Stock Split Event”, and such date, the “Reverse Stock Split Date”) by September 15, 2017, the Company and the Investor shall have taken the following actions (the “Additional Restructuring”, and together with the Initial Restructuring, the “Restructuring”): (i) the Investor shall consent to the use of Restricted Cash to effect redemptions of $4,000,000 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Redemption Notes”), (ii) the Company shall redeem the Redemption Notes for a redemption price of $6,436,852.80 (the “Redemption Price”) and (iii) the Company shall exchange (the “Exchange”), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, $2,436,852.80 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Exchange Notes”, and together with the Redemption Notes, the “Restructured Notes”) for new warrants to purchase 114,286 shares of its Common Stock (the “New Warrants”, as exercised, the “New Warrant Shares”). The New Warrants expire on the 42 month anniversary of the date of issuance and bear an exercise price of $122.50 per share (which shall be adjusted to the new lower purchase price per share if there is a subsequent “down round” financing). The Investor, in lieu of an exercise of the New Warrants pursuant to a cash payment of the aggregate exercise price of the number of New Warrants being exercised, may exercise the New Warrants, in whole or in part, by electing instead to receive upon such exercise two shares and one hundred and twenty-five thousandths of a share of the Company’s Common Stock for each Warrant Share exercised pursuant to this provision.. The transactions set forth herein were being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 144(d)(3)(ii) of the 1933 Act. As a result of not having effected a reverse stock split by September 15, 2017, the Additional Restructuring did not occur. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amendment to Restructuring Agreement <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,551 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period, (iv) the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes and (v) the conversion floor price on the notes is $0.05 and not subject to adjustments. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.56%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Applicable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reduction in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 12, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,753</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,478,318</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 26 - February 1, 20171</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544,000</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 10, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,882</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,045,817</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 23 - March 2, 20171</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,571</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,000</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 13, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,297</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,417,830</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 10, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,061</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,621,286</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 9, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,367</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,913,915</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 7 / July 2, 2017 Exchange Agreement2</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">689,796</td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.09</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200,000</td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 7, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,286</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000,000</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 4, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,906</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.50</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015,848</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 28, 2017 Restructuring Agreement3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,171</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200,000</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,418,948</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,563,014</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 During the periods referenced above, the Company and the holders of the Notes agreed to a temporary reduction in the conversion price in order to encourage voluntary conversion of Notes by the holders thereof. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 On July 2, 2017, the Company entered into an exchange agreement with one of its investors which had purchased Notes, for $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock. The Series A Preferred Stock shares were issued to address a short-term valuation issue for 689,796 common shares delivered to the Notes holders to close an installment period. Through the Series A Preferred Shares placement, the Company was able to value the open installment shares such that the amount of debt remaining under the Notes was reduced by $4.2 million. Additionally, the Company recognized a loss on debt settlement of $1.0 million related to this transcation. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 On August 28, 2017, the Company entered into a restructuring agreement with one of its investors which had purchased Notes. The restructuring agreement included a provision to exchange 117,171 shares for $1.2 million aggregate principal amount of such Notes. Additionally, the Company recognized a loss on debt settlement of $2.0 million related to this transaction. The restructuring agreement is discussed in more detail above. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants, the Company has recognized a beneficial conversion feature of $4.4 million. The original issue discount, the beneficial conversion feature, and the fair value of the issuance of the Series C Warrants are collectively considered the debt discount. The Company recorded a debt discount in the amount of $35.0 million which is being amortized over the life of the Notes using the effective interest method. As of September 30, 2017, $33.3 million of the debt discount has been amortized to interest expense. In addition to the debt discounts listed above, the Notes also include put options in the event of default and change in control as defined in the Notes. The value of such options was zero as the probability for such events was remote as of the issuance date and at September 30, 2017. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All debt issuance costs are accounted for as a deferred asset and will be amortized over the life of the Notes. As of September 30, 2017, the Company had incurred approximately $1.8 million in debt issuance costs and had amortized approximately $1.2 million of those costs. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the convertible notes outstanding at September 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, principal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discounts</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,701</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net convertible note payable</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,736</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018. Due to the nature of the Company’s revenue generating activites and the small number of customer contracts, the Company does not anticipate that this guidance will materially impact its consolidated financial statements. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;letter-spacing:0.05pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.    </div>

<div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant, and equipment consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings and land</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">556</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enterprise hardware and software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,648</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leaseholds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,659</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,504</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">960</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">940</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,023</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,770</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,803</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,253</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,083</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,410</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation, excluding taxes</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,132</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">933</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term portion of lease restructuring</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.42%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,755</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,407</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.</div>

<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.56%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Applicable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reduction in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 12, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,753</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,478,318</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 26 - February 1, 20171</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544,000</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 10, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,882</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,045,817</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 23 - March 2, 20171</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,571</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,000</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 13, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,297</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,417,830</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 10, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,061</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,621,286</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 9, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,367</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,913,915</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 7 / July 2, 2017 Exchange Agreement2</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">689,796</td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.09</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200,000</td> <td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 7, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,286</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000,000</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 4, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,906</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.50</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015,848</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.56%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 28, 2017 Restructuring Agreement3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,171</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200,000</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.56%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,418,948</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.68%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,563,014</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 During the periods referenced above, the Company and the holders of the Notes agreed to a temporary reduction in the conversion price in order to encourage voluntary conversion of Notes by the holders thereof. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 On July 2, 2017, the Company entered into an exchange agreement with one of its investors which had purchased Notes, for $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock. The Series A Preferred Stock shares were issued to address a short-term valuation issue for 689,796 common shares delivered to the Notes holders to close an installment period. Through the Series A Preferred Shares placement, the Company was able to value the open installment shares such that the amount of debt remaining under the Notes was reduced by $4.2 million. Additionally, the Company recognized a loss on debt settlement of $1.0 million related to this transcation. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 On August 28, 2017, the Company entered into a restructuring agreement with one of its investors which had purchased Notes. The restructuring agreement included a provision to exchange 117,171 shares for $1.2 million aggregate principal amount of such Notes. Additionally, the Company recognized a loss on debt settlement of $2.0 million related to this transaction. The restructuring agreement is discussed in more detail above. </div>

<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the convertible notes outstanding at September 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible notes payable, principal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discounts</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,701</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net convertible note payable</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,736</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Warrants at September 30, 2017 was determined by using option pricing models with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.56%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">October 2016 <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 2015 Series A <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">February 2015 <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">October 2013 <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142.46%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165.32%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181.24%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227.68%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rates</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.77%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.59%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.53%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.02</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.81</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.38</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.08</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative instrument liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,221</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,394</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>    </div>

0.0029

0.01

35000000

328000

346000

660000

214000

176000

100000

61000

501000

53000

50000

221000

147000

0.05 0.05

574000

556000

1648000

1532000

1659000

1504000

960000

940000

182000

354000

5023000

4886000

3770000

3803000

100000

1410000 1365000

1132000

933000

448000

286000

221000

216000

544000

607000

0.05 0.05 2

900000

700000

665000

300000

400000

820000

155000

35000000

0.01 32200000

2800000

0.00

0.15

3000000 3000000 7300000 6600000 2100000

2400000

20000

27800000

7900000

9600000

17500000

14 P7M

2016-06-13

1536.50

11444637

10092857

1351780

4200

2006

1650000 1200000

4.20

2006000

4000000

6436852.80

2436852.80

114286

P42M

122.50

2.125

279015

127551

590000

2.00

The maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018

2018-12-30

Until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period

The Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes

7300000

600000

0.05

11753

4857

43882

2571

117297

169061

109367

689796

114286

38906

117171

1418948

4200

126.00

112.00

70.00

49.00

38.50

21.00

17.50

6.09

17.50

24.50

10.50

1478318

544000

3045817

126000

4417830

3621286

1913915

4200000

2000000

1015848

1200000

23563014

4200

1000000

1200000

117171

2000000

35000000

33300000

4400000

1800000

1200000

11437000

1701000

9736000

0.1

0.05

0.01

170000000

500000000

0.01

4200000

4200

1288.00 3261

0.001

0.01

2360000

2000000

2000000 65.35 30607 53.55

2360000

360000

0.01

500000

590

1484061

1000.00

590000

234

106 7500000

6900000

1900000

39424.00

100

P5Y

440

197 2600000

2500000

800000

49.00

100

P5Y

1715

1140

1715

7000000

6000000

3400000

49.00

500

P5Y 285

800000

1140 2016-01-29

285

15000

1215

425 1200000

1100000

300000

49.00

200

P5Y

573

304

269

P10Y

3000

24000

48000

100000

20000

100000

38000

200000

264

1.4246

1.6532

1.8124

2.2768

0.0177

0.0159

0.0153

0.0133

P4Y7D

P2Y9M22D

P2Y4M17D

P1Y29D

16000

18751000

1227000

17489000

16000

155

118

289

953

21221

1397

21394

127550

590000

2017-10-11 0

122.50

382650

On the 136th day subsequent to the date of consummation of the offering hereunder, there shall be a “true up” with regard to the issuance of shares upon exercise such that the difference between 382,650 shares and the number of shares that would be issuable if the exercise price were lowered to the average price per share of the variable weighted average price of our common stock for the five trading days commencing on the date which is 76 days after the date of consummation of the offering hereunder, but not lower than 33% of the variable weighted average price of a share of our common stock on the 81st date following the date of consummation of the offering hereunder. 5 0.33 6138349.80 reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

EX-101.SCH 7 dcth-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Prepaid Expenses and Other Current Assets link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Property, Plant, and Equipment link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Restructuring Expenses link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Convertible Notes Payable link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Net Loss per Common Share link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Taxes link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - General (Policies) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Property, Plant, and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Restructuring Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Convertible Notes Payable (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Net Loss per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - General - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Inventories - Schedule of Inventories (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Prepaid Expenses and Other Current Assets - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Property, Plant, and Equipment - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Restructuring Expenses - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Convertible Notes Payable - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Parenthetical) (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Convertible Notes Payable - Summary of Convertible Notes Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Stockholders' Equity - Reverse Stock Split - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stockholders' Equity - Recent Preferred Stock Issuances - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Warrants (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 dcth-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 dcth-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 dcth-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Trading Symbol Trading Symbol Document Fiscal Period Focus Document Fiscal Period Focus Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Preferred stock redemption amount current. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Restricted cash Restricted Cash And Cash Equivalents At Carrying Value Accounts receivables, net Accounts Receivable Net Current Inventories Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Deferred financing costs Deferred Finance Costs Current Net Total current assets Assets Current Property, plant and equipment, net Property Plant And Equipment Net Total assets Assets Liabilities and Stockholders' Deficit Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Series C preferred shares Preferred Stock Redemption Amount Current Convertible notes payable, net of debt discount Convertible Notes Payable Current Warrant liability Derivative Liabilities Current Total current liabilities Liabilities Current Deferred revenue Deferred Revenue Noncurrent Other non-current liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and Contingencies Commitments And Contingencies Stockholders' deficit Stockholders Equity [Abstract] Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Preferred Stock Value Common stock, $.01 par value; 500,000,000 shares authorized; 1,426,153 and 11,805 shares issued and 1,425,862 and 11,750 shares outstanding at September 30, 2017 and December 31, 2016, respectively* Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Treasury stock, at cost; 1 share at September 30, 2017 and December 31, 2016, respectively* Treasury Stock Value Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Total stockholders' deficit Stockholders Equity Total liabilities and stockholders' deficit Liabilities And Stockholders Equity Statement [Table] Statement [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Statement [Line Items] Statement [Line Items] Preferred stock, par value (in dollars per share) Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock Shares Outstanding Common stock, par value (in dollars per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock Shares Authorized Common stock, shares issued (in shares) Common Stock Shares Issued Common stock, shares outstanding (in shares) Common Stock Shares Outstanding Treasury stock, at cost (in share) Treasury Stock Shares Reverse stock split ratio Stockholders Equity Note Stock Split Conversion Ratio1 Loss on debt settlement. Income Statement [Abstract] Revenue Sales Revenue Goods Net Cost of goods sold Cost Of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Selling, general and administrative Selling General And Administrative Expense Research and development Research And Development Expense Total operating expenses Operating Expenses Operating loss Operating Income Loss Change in fair value of the warrant liability, net Fair Value Adjustment Of Warrants Gain on warrant extinguishment Gains Losses On Extinguishment Of Debt Loss on debt settlements Loss On Debt Settlement Interest expense Interest Expense Other income (expense) Other Nonoperating Income Expense Net loss Net Income Loss Other comprehensive loss: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Foreign currency translation adjustments Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Common share data: Earnings Per Share Basic And Diluted [Abstract] Basic and diluted loss per share Earnings Per Share Basic And Diluted Weighted average number of basic and diluted common shares outstanding Weighted Average Number Of Share Outstanding Basic And Diluted Number of shares of stock issued during the period pursuant to the exercise of stock options. Value of stock issued pursuant to the exercise of warrants during the period. The fair value of warrants exercised during the period. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Issued [Member] Common Stock [Member] Treasury Stock [Member] Treasury Stock [Member] Additional Paid in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated Other Comprehensive loss [Member] Accumulated Other Comprehensive Income [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase Decrease In Stockholders Equity Roll Forward Balance Balance (in shares) Shares Outstanding Compensation expense for issuance of stock options Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Compensation expense for issuance of restricted stock Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Compensation expense for issuance of restricted stock (in shares) Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Issuance of common stock for payments made in shares on convertible note payable Stock Issued During Period Value Conversion Of Convertible Securities Issuance of common stock for payments made in shares on convertible note payable (in shares) Stock Issued During Period Shares Conversion Of Convertible Securities Series B preferred stock dividend Dividends Preferred Stock Cash Warrants exercised Stock Issued During Period Value Exercise Of Warrants Warrants Exercised (in shares) Stock Issued During Period Shares Exercise Of Warrants Fair value of warrants exercised Fair Value Of Warrants Exercised Net loss Total comprehensive loss Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Balance Balance (in shares) Common stock issued, par value Interest income earned on money market and operating accounts. Deferred revenues. Increase in restricted cash from financing activities. Release of restricted cash for extinguishment. Release of restricted cash for redemption. Statement Of Cash Flows [Abstract] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Series C warrants. Series C Warrants [Member] Series C Warrants [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A and series B preferred shares. Series A and Series B Preferred Shares [Member] Series A And Series B Preferred Shares [Member] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock option compensation expense Stock Option Plan Expense Restricted stock compensation expense Restricted Stock Expense Depreciation expense Depreciation Loss on disposal of equipment Gain Loss On Disposition Of Assets Warrant liability fair value adjustment Gain on warrant extinguishment Non-cash interest income Interest Income Earned On Money Market And Operating Accounts Deferred revenue Deferred Revenues Debt discount and deferred finance costs amortization Amortization Of Financing Costs And Discounts Loss on debt settlements Changes in assets and liabilities: Increase Decrease In Operating Capital [Abstract] Decrease in prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Increase in accounts receivable Increase Decrease In Accounts Receivable Decrease (increase) in inventories Increase Decrease In Inventories Increase in accounts payable and accrued expenses Increase Decrease In Accounts Payable And Accrued Liabilities Decrease in other non-current liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchase of property, plant and equipment Payments To Acquire Property Plant And Equipment Increase in restricted cash Increase In Restricted Cash Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Increase in restricted cash Increase In Restricted Cash From Financing Activities Net proceeds from the release of restricted cash Proceeds From Repayments Of Restricted Cash Financing Activities Release of restricted cash for extinguishment of Series C Warrants Release Of Restricted Cash For Extinguishment Cash paid to extinguish of Series C Warrants Payments For Repurchase Of Warrants Net proceeds from sale of Series B and Series C preferred shares Proceeds From Issuance Of Preferred Stock And Preference Stock Release of restricted cash for redemption of Series A and Series B preferred shares Release Of Restricted Cash For Redemption Redemption of Series A and Series B preferred shares Payments For Repurchase Of Preferred Stock And Preference Stock Net proceeds from convertible debt financing Proceeds From Convertible Debt Net proceeds from sale of stock and exercise of warrants Proceeds From Issuance Or Sale Of Equity Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Foreign currency effects on cash and cash equivalents Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations Net decrease in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents: Cash And Cash Equivalents At Carrying Value [Abstract] Beginning of period End of period Supplemental non-cash activities: Noncash Investing And Financing Items [Abstract] Conversion of convertible notes to common stock Debt Conversion Original Debt Amount1 Fair value of warrants issued Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues Fair value of warrants exercised Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Organization Consolidation And Presentation Of Financial Statements [Abstract] General Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Prepaid expenses and other current assets. Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] Prepaid Expenses And Other Current Assets Prepaid Expenses And Other Current Assets [Text Block] Property Plant And Equipment [Abstract] Property, Plant, and Equipment Property Plant And Equipment Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Restructuring And Related Activities [Abstract] Restructuring Expenses Restructuring And Related Activities Disclosure [Text Block] Convertible notes payable. Debt Disclosure [Abstract] Convertible Notes Payable Convertible Notes Payable [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Earnings Per Share [Abstract] Net Loss per Common Share Earnings Per Share [Text Block] Income Tax Disclosure [Abstract] Taxes Income Tax Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Disclosure of accounting policy for liquidity and operating matters. Liquidity and Operating Matters Liquidity And Operating Matters Policy [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of inventories Schedule Of Inventory Current Table [Text Block] Prepaid Expenses and Other Current Assets Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block] Components of property, plant and equipment Property Plant And Equipment [Text Block] Schedule of accrued expenses Schedule Of Accrued Liabilities Table [Text Block] Schedule of restructuring and related costs Schedule Of Restructuring And Related Costs [Text Block] Summary of Common Stock Shares Issued under Notes Schedule Of Debt Conversions [Text Block] Summary of Convertible Notes Outstanding Convertible Debt Table [Text Block] Schedule of fair value of the warrants Schedule Of Assumptions For Fair Value As Of Balance Sheet Date Of Interests Continued To Be Held By Transferor Servicing Assets Or Servicing Liabilities [Text Block] Assets and liabilities measured at fair value on a recurring basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Fair value measurements using significant unobservable inputs Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Net Loss per Common Share [Abstract] Anti-dilutive securities excluded from the computation of earnings per share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Entity Listings, Exchange Entity Listings Exchange [Axis] Exchange Exchange [Domain] OTCQB. OTCQB [Member] O T C Q B [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Senior secured convertible notes. Senior Secured Convertible Notes [Member] Senior Secured Convertible Note [Member] EX-101.PRE 11 dcth-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 13, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,591,509
Document Fiscal Year Focus	2017
Trading Symbol	DCTH
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)

Sep. 30, 2017

Dec. 31, 2016

Current assets

Cash and cash equivalents

$ 2,495,000

$ 4,409,000

Restricted cash

8,362,000

27,287,000

Accounts receivables, net

298,000

403,000

Inventories

1,164,000

660,000

Prepaid expenses and other current assets

385,000

698,000

Deferred financing costs

529,000

699,000

Total current assets

13,233,000

34,156,000

Property, plant and equipment, net

1,253,000

1,083,000

Total assets

14,486,000

35,239,000

Current liabilities

Accounts payable

1,891,000

594,000

Accrued expenses

3,755,000

3,407,000

Series C preferred shares

494,000

Convertible notes payable, net of debt discount

9,736,000

13,343,000

Warrant liability

16,000

18,751,000

Total current liabilities

15,892,000

36,095,000

Deferred revenue

30,000

Other non-current liabilities

444,000

604,000

Total liabilities

16,336,000

36,729,000

Commitments and Contingencies

Stockholders' deficit

Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively

Common stock, $.01 par value; 500,000,000 shares authorized; 1,426,153 and 11,805 shares issued and 1,425,862 and 11,750 shares outstanding at September 30, 2017 and December 31, 2016, respectively*

^[1]

14,000

Additional paid-in capital

303,808,000

277,790,000

Accumulated deficit

(305,587,000)

(279,188,000)

Treasury stock, at cost; 1 share at September 30, 2017 and December 31, 2016, respectively*

^[1]

(51,000)

Accumulated other comprehensive income

(34,000)

(41,000)

Total stockholders' deficit

(1,850,000)

(1,490,000)

Total liabilities and stockholders' deficit

$ 14,486,000

$ 35,239,000

[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical)	Sep. 30, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares
Preferred stock, par value (in dollars per share) \| $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	1,426,153	11,805
Common stock, shares outstanding (in shares)	1,425,862	11,750
Treasury stock, at cost (in share)	1	1

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Income Statement [Abstract]

Revenue

$ 684,000

$ 435,000

$ 2,011,000

$ 1,316,000

Cost of goods sold

172,000

112,000

527,000

373,000

Gross profit

512,000

323,000

1,484,000

943,000

Operating expenses:

Selling, general and administrative

2,860,000

2,361,000

7,807,000

7,025,000

Research and development

2,279,000

2,686,000

7,119,000

5,975,000

Total operating expenses

5,139,000

5,047,000

14,926,000

13,000,000

Operating loss

(4,627,000)

(4,724,000)

(13,442,000)

(12,057,000)

Change in fair value of the warrant liability, net

27,000

8,680,000

1,227,000

9,171,000

Gain on warrant extinguishment

9,613,000

Loss on debt settlements

(2,952,000)

Interest expense

(5,042,000)

(4,963,000)

(20,324,000)

(6,584,000)

Other income (expense)

(2,000)

3,000

5,000

(15,000)

Net loss

(12,596,000)

(1,004,000)

(25,873,000)

(9,485,000)

Other comprehensive loss:

Foreign currency translation adjustments

(15,000)

(2,000)

7,000

(12,000)

Comprehensive loss

$ (12,611,000)

$ (1,006,000)

$ (25,866,000)

$ (9,497,000)

Common share data:

Basic and diluted loss per share

^[1]

$ (9.36)

$ (230.99)

$ (34.99)

$ (2,232.30)

Weighted average number of basic and diluted common shares outstanding

^[1]

1,401,413

4,349

754,421

4,249

[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016
Reverse stock split ratio		0.0625
Subsequent Event [Member]
Reverse stock split ratio	0.0029

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive loss [Member]
Balance at Dec. 31, 2016	$ (1,490)		$ (51)	$ 277,790	$ (279,188)	$ (41)
Balance (in shares) at Dec. 31, 2016		11,805	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	48			48
Compensation expense for issuance of restricted stock	84			84
Compensation expense for issuance of restricted stock (in shares)		261
Issuance of common stock for payments made in shares on convertible note payable	25,866	$ 14		25,852
Issuance of common stock for payments made in shares on convertible note payable (in shares)		1,413,790
Series B preferred stock dividend	(526)				(526)
Warrants exercised	15			15
Warrants Exercised (in shares)		297
Fair value of warrants exercised	19			19
Net loss	(25,873)				(25,873)
Total comprehensive loss	7					7
Balance at Sep. 30, 2017	$ (1,850)	$ 14	$ (51)	$ 303,808	$ (305,587)	$ (34)
Balance (in shares) at Sep. 30, 2017		1,426,153	(1)

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016 $ / shares	Sep. 30, 2017 $ / shares	Dec. 31, 2016 $ / shares
Common stock issued, par value		$ 0.01	$ 0.01	$ 0.01
Reverse stock split ratio		0.0625
Subsequent Event [Member]
Reverse stock split ratio	0.0029

XML 19 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (25,873,000)	$ (9,485,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	48,000	138,000
Restricted stock compensation expense	84,000	228,000
Depreciation expense	198,000	232,000
Loss on disposal of equipment	20,000	1,000
Warrant liability fair value adjustment	(1,227,000)	(9,171,000)
Gain on warrant extinguishment	(9,613,000)	0
Non-cash interest income	16,000	(1,000)
Deferred revenue	(30,000)	31,000
Debt discount and deferred finance costs amortization	20,315,000	6,567,000
Loss on debt settlements	2,952,000	0
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	276,000	610,000
Increase in accounts receivable	(94,000)	(94,000)
Decrease (increase) in inventories	(338,000)	190,000
Increase in accounts payable and accrued expenses	1,767,000	312,000
Decrease in other non-current liabilities	(160,000)	(155,000)
Net cash used in operating activities	(11,659,000)	(10,597,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(372,000)	(245,000)
Increase in restricted cash	0	(1,087,000)
Net cash used in investing activities	(372,000)	(1,332,000)
Cash flows from financing activities:
Increase in restricted cash	0	(29,200,000)
Net proceeds from the release of restricted cash	7,901,000	0
Net proceeds from sale of Series B and Series C preferred shares	2,278,000	0
Net proceeds from convertible debt financing	0	31,436,000
Net proceeds from sale of stock and exercise of warrants	15,000	704,000
Net cash provided by financing activities	10,194,000	2,940,000
Foreign currency effects on cash and cash equivalents	(77,000)	71,000
Net decrease in cash and cash equivalents	(1,914,000)	(8,918,000)
Cash and cash equivalents:
Beginning of period	4,409,000	12,607,000
End of period	2,495,000	3,689,000
Supplemental non-cash activities:
Conversion of convertible notes to common stock	26,199,000	0
Fair value of warrants issued	0	28,133,000
Fair value of warrants exercised	19,000	245,000
Series A and Series B Preferred Shares [Member]
Cash flows from financing activities:
Release of restricted cash for redemption of Series A and Series B preferred shares	2,360,000	0
Redemption of Series A and Series B preferred shares	(2,360,000)	0
Series C Warrants [Member]
Cash flows from financing activities:
Release of restricted cash for extinguishment of Series C Warrants	7,876,000	0
Cash paid to extinguish of Series C Warrants	$ (7,876,000)	$ 0

XML 20 R9.htm IDEA: XBRL DOCUMENT

General

9 Months Ended

Sep. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

General

(1)

General

Description of Business

Liquidity and Operating Matters

Basis of Presentation

Significant Accounting Policies

Recent Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Inventories

(2)	Inventories

Inventories consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Raw materials	$	328	$	346
Work-in-process		660		214
Finished goods		176		100
Total inventories	$	1,164	$	660

XML 22 R11.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

9 Months Ended

Sep. 30, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Prepaid Expenses And Other Current Assets

(3)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Insurance premiums	$	61	$	501
Taxes		53		—
Security Deposit		50		50
Other¹		221		147
Total prepaid expenses and other current assets	$	385	$	698

XML 23 R12.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment

9 Months Ended

Sep. 30, 2017

Property Plant And Equipment [Abstract]

Property, Plant, and Equipment

(4)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

(in thousands)	September 30, 2017			December 31, 2016
Buildings and land	$	574		$	556
Enterprise hardware and software		1,648			1,532
Leaseholds		1,659			1,504
Equipment		960			940
Furniture		182			354
Property, plant and equipment, gross		5,023			4,886
Accumulated depreciation		(3,770	)		(3,803	)
Property, plant and equipment, net	$	1,253		$	1,083

XML 24 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2017

Payables And Accruals [Abstract]

Accrued Expenses

(5)	Accrued Expenses

Accrued expenses consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Clinical trial expenses		1,410		1,365
Compensation, excluding taxes	$	1,132	$	933
Professional fees		448		286
Short-term portion of lease restructuring		221		216
Other¹		544		607
Total accrued expenses	$	3,755	$	3,407

¹Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Restructuring Expenses

9 Months Ended

Sep. 30, 2017

Restructuring And Related Activities [Abstract]

Restructuring Expenses

(6)	Restructuring Expenses

The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2017:

(in thousands)	Lease Liability
Reserve balance at December 31, 2016	$	820
Charges		—
Payments/Utilizations		(155	)
Reserve balance at September 30, 2017	$	665

XML 26 R15.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Convertible Notes Payable

(7)	Convertible Notes Payable

Restructuring Agreement

Amendment to Restructuring Agreement

The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows:

	Number of Shares of Common Stock		Number of Shares of Preferred Stock		Applicable Conversion Price		Reduction in Principal
January 12, 2017		11,753		—	$	126.00	$	1,478,318
January 26 - February 1, 2017¹		4,857		—	$	112.00		544,000
February 10, 2017		43,882		—	$	70.00		3,045,817
February 23 - March 2, 2017¹		2,571		—	$	49.00		126,000
March 13, 2017		117,297		—	$	38.50		4,417,830
April 10, 2017		169,061		—	$	21.00		3,621,286
May 9, 2017		109,367		—	$	17.50		1,913,915
June 7 / July 2, 2017 Exchange Agreement²		689,796		4,200	$	6.09		4,200,000
July 7, 2017		114,286		—	$	17.50		2,000,000
August 4, 2017		38,906		—	$	24.50		1,015,848
August 28, 2017 Restructuring Agreement³		117,171		—	$	10.50		1,200,000
Total		1,418,948					$	23,563,014

The following table summarizes the convertible notes outstanding at September 30, 2017:

(in thousands)
Convertible notes payable, principal	$	11,437
Debt discounts		(1,701	)
Net convertible note payable	$	9,736

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Stockholders Equity Note [Abstract]

Stockholders' Equity

(8)	Stockholders’ Equity

Stock Issuances

Reverse Stock Split

On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-three hundred fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.]

Recent Preferred Stock Issuances

Series A Preferred Stock

On June 29, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series A Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series A Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series A Preferred Stock”). On July 2, 2017, we entered into an exchange agreement (the “Exchange”) with one of our investors which had purchased certain senior secured convertible notes (the “Notes”), convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock (the “Series A Preferred Shares”). The Exchange was made in reliance upon the exemption from registration provided by Rule 3(a)(9) of the Securities Act of 1933, as amended. The Series A Preferred Shares were entitled to the whole number of votes equal to $4.2 million divided by $1,288.00 (the closing bid price on June 13, 2016, the date of issuance of the Notes as adjusted for the reverse stock split effected in July 2016,) or 3,261 votes. The Series A Preferred Stock had no dividend, liquidation or other preferential rights to our common stock, and each share of Series A Preferred Stock was redeemed for the amount of $0.001, paid in cash pursuant to the Restructuring Agreement signed on August 28, 2017 and discussed in further detail in Note 7.

Series B Preferred Stock

Series C Preferred Stock

Warrants

Stock Incentive Plans

For the three and nine months ended September 30, 2017, the Company recognized compensation expense of approximately $3,000 and $48,000, respectively, relating to stock options granted to employees. For the same periods in 2016, the Company recognized compensation expense of approximately $24,000 and $0.1 million, respectively. There were 43 stock options awards granted during the nine months ended September 30, 2017. There were no stock option awards granted during the same period in 2016.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

(9)	Fair Value Measurements

Derivative Warrant Liability

	October 2016 Warrants		July 2015 Series A Warrants		February 2015 Warrants		October 2013 Warrants
Expected volatility		142.46%		165.32%		181.24%		227.68%
Risk-free interest rates		1.77%		1.59%		1.53%		1.33%
Expected life (in years)		4.02		2.81		2.38		1.08

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1		Level 2		Level 3		Balance at September 30, 2017
Liabilities
Derivative instrument liabilities	$	—	$	—	$	16	$	16

For the periods ended September 30, 2017 and 2016, there were no transfers in or out of Level 1, 2 or 3 inputs.

The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2017:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)	Warrant Liability
Balance at December 31, 2016	$	18,751
Total change in the liability included in earnings		(1,227	)
Extinguishment of convertible note warrant		(17,489	)
Fair value of warrants issued		—
Fair value of warrants exercised		(19	)
Balance at September 30, 2017	$	16

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net Loss per Common Share

(10)	Net Loss per Common Share

The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive:

	September 30,
	2017		2016
Stock options		155		118
Unvested restricted shares		289		54
Warrants		953		21,221
Total		1,397		21,394

XML 30 R19.htm IDEA: XBRL DOCUMENT

Taxes

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Taxes

(11)

Taxes

XML 31 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

(12)	Subsequent Events

As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,550 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75^th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period, (iv) the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes and (v) the conversion floor price on the notes is $0.05 and not subject to adjustments.

XML 32 R21.htm IDEA: XBRL DOCUMENT

General (Policies)	9 Months Ended
General (Policies)	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Liquidity and Operating Matters	Liquidity and Operating Matters The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $305.6 million at September 30, 2017. As shown in the accompanying financial statements during the three and nine months ended September 30, 2017, the Company incurred net losses of $12.6 million and $25.9 million, respectively and during the nine months ended September 30, 2017 used $11.7 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. As a result of issuing $35.0 million in senior secured convertible notes in June 2016 and effecting a reverse stock split on November 6, 2017 management believes that in its current reduced operating mode its capital resources will be adequate to fund operations through at least January 2018. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to clinical research, product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel.
Basis of Presentation	Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2017 and 2016; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018. Due to the nature of the Company’s revenue generating activites and the small number of customer contracts, the Company does not anticipate that this guidance will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Raw materials	$	328	$	346
Work-in-process		660		214
Finished goods		176		100
Total inventories	$	1,164	$	660

XML 34 R23.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2017

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Insurance premiums	$	61	$	501
Taxes		53		—
Security Deposit		50		50
Other¹		221		147
Total prepaid expenses and other current assets	$	385	$	698

XML 35 R24.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment (Tables)

9 Months Ended

Sep. 30, 2017

Property Plant And Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consist of the following:

(in thousands)	September 30, 2017			December 31, 2016
Buildings and land	$	574		$	556
Enterprise hardware and software		1,648			1,532
Leaseholds		1,659			1,504
Equipment		960			940
Furniture		182			354
Property, plant and equipment, gross		5,023			4,886
Accumulated depreciation		(3,770	)		(3,803	)
Property, plant and equipment, net	$	1,253		$	1,083

XML 36 R25.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2017

Payables And Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:

(in thousands)	September 30, 2017		December 31, 2016
Clinical trial expenses		1,410		1,365
Compensation, excluding taxes	$	1,132	$	933
Professional fees		448		286
Short-term portion of lease restructuring		221		216
Other¹		544		607
Total accrued expenses	$	3,755	$	3,407

¹Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Restructuring Expenses (Tables)

9 Months Ended

Sep. 30, 2017

Restructuring And Related Activities [Abstract]

Schedule of restructuring and related costs

The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2017:

(in thousands)	Lease Liability
Reserve balance at December 31, 2016	$	820
Charges		—
Payments/Utilizations		(155	)
Reserve balance at September 30, 2017	$	665

XML 38 R27.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Summary of Common Stock Shares Issued under Notes

The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows:

	Number of Shares of Common Stock		Number of Shares of Preferred Stock		Applicable Conversion Price		Reduction in Principal
January 12, 2017		11,753		—	$	126.00	$	1,478,318
January 26 - February 1, 2017¹		4,857		—	$	112.00		544,000
February 10, 2017		43,882		—	$	70.00		3,045,817
February 23 - March 2, 2017¹		2,571		—	$	49.00		126,000
March 13, 2017		117,297		—	$	38.50		4,417,830
April 10, 2017		169,061		—	$	21.00		3,621,286
May 9, 2017		109,367		—	$	17.50		1,913,915
June 7 / July 2, 2017 Exchange Agreement²		689,796		4,200	$	6.09		4,200,000
July 7, 2017		114,286		—	$	17.50		2,000,000
August 4, 2017		38,906		—	$	24.50		1,015,848
August 28, 2017 Restructuring Agreement³		117,171		—	$	10.50		1,200,000
Total		1,418,948					$	23,563,014

Summary of Convertible Notes Outstanding

The following table summarizes the convertible notes outstanding at September 30, 2017:

(in thousands)
Convertible notes payable, principal	$	11,437
Debt discounts		(1,701	)
Net convertible note payable	$	9,736

XML 39 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Schedule of fair value of the warrants

The fair value of the Warrants at September 30, 2017 was determined by using option pricing models with the following assumptions:

	October 2016 Warrants		July 2015 Series A Warrants		February 2015 Warrants		October 2013 Warrants
Expected volatility		142.46%		165.32%		181.24%		227.68%
Risk-free interest rates		1.77%		1.59%		1.53%		1.33%
Expected life (in years)		4.02		2.81		2.38		1.08

Assets and liabilities measured at fair value on a recurring basis

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1		Level 2		Level 3		Balance at September 30, 2017
Liabilities
Derivative instrument liabilities	$	—	$	—	$	16	$	16

Fair value measurements using significant unobservable inputs

The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2017:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)	Warrant Liability
Balance at December 31, 2016	$	18,751
Total change in the liability included in earnings		(1,227	)
Extinguishment of convertible note warrant		(17,489	)
Fair value of warrants issued		—
Fair value of warrants exercised		(19	)
Balance at September 30, 2017	$	16

XML 40 R29.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Anti-dilutive securities excluded from the computation of earnings per share

The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive:

	September 30,
	2017		2016
Stock options		155		118
Unvested restricted shares		289		54
Warrants		953		21,221
Total		1,397		21,394

XML 41 R30.htm IDEA: XBRL DOCUMENT

General - Additional Information (Details)			3 Months Ended		9 Months Ended
General - Additional Information (Details)	Nov. 06, 2017 $ / shares shares	Jul. 21, 2016 $ / shares shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) $ / shares	Jun. 30, 2016 USD ($)
Class Of Stock [Line Items]
Reverse stock split ratio		0.0625
Number of fractional shares were issued in connection with the reverse stock split \| shares		0
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01	$ 0.01		$ 0.01		$ 0.01
Net loss			$ 12,596,000	$ 1,004,000	$ 25,873,000	$ 9,485,000
Net cash used in operating activities					11,659,000	$ 10,597,000
Accumulated deficit			305,587,000		305,587,000		$ 279,188,000
Senior Secured Convertible Notes [Member]
Class Of Stock [Line Items]
Debt instrument, principal face amount			$ 11,437,000		$ 11,437,000			$ 35,000,000
Subsequent Event [Member]
Class Of Stock [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] \| OTCQB [Member]
Class Of Stock [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connection with the reverse stock split \| shares	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01

XML 42 R31.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 328	$ 346
Work-in-process	660	214
Finished goods	176	100
Total inventories	$ 1,164	$ 660

XML 43 R32.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 61	$ 501
Taxes	53
Security Deposit	50	50
Other	221	147
Total prepaid expenses and other current assets	$ 385	$ 698

XML 44 R33.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

XML 45 R34.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 5,023	$ 4,886
Accumulated depreciation	(3,770)	(3,803)
Property, plant and equipment, net	1,253	1,083
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	574	556
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,648	1,532
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,659	1,504
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	960	940
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 182	$ 354

XML 46 R35.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 100	$ 100	$ 198	$ 232

XML 47 R36.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Clinical trial expenses	$ 1,410	$ 1,365
Compensation, excluding taxes	1,132	933
Professional fees	448	286
Short-term portion of lease restructuring	221	216
Other	544	607
Total accrued expenses	$ 3,755	$ 3,407

XML 48 R37.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details)	Sep. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

XML 49 R38.htm IDEA: XBRL DOCUMENT

Restructuring Expenses - Additional Information (Details) $ in Thousands			9 Months Ended
	Aug. 18, 2014 USD ($)	May 22, 2014 USD ($)	Sep. 30, 2017 USD ($) Lease	Dec. 31, 2016 USD ($)
Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Number of sub leases \| Lease			2
Restructuring reserve balance			$ 665	$ 820
Sub-lease 1 [Member] \| Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900
Sub Lease 2 [Member] \| Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700
Other non-current liabilities [Member] \| Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			400
Accrued Expenses [Member] \| Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			$ 300

XML 50 R39.htm IDEA: XBRL DOCUMENT

Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) - Lease Liability [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2017 USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 820
Payments/Utilizations	(155)
Restructuring reserve balance	$ 665

XML 51 R40.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Additional Information (Details)																					1 Months Ended	3 Months Ended			8 Months Ended	9 Months Ended
	Nov. 06, 2017	Oct. 11, 2017 USD ($) d $ / shares	Oct. 10, 2017 USD ($) Investor $ / shares shares	Sep. 21, 2017 USD ($) $ / shares	Sep. 15, 2017 USD ($) $ / shares shares	Aug. 28, 2017 USD ($) $ / shares shares	Aug. 04, 2017 USD ($) $ / shares	Jul. 07, 2017 USD ($) $ / shares	Jul. 02, 2017 USD ($) $ / shares	May 09, 2017 USD ($) $ / shares	Apr. 10, 2017 USD ($) $ / shares	Apr. 02, 2017 USD ($)	Mar. 13, 2017 USD ($) $ / shares	Mar. 02, 2017 USD ($) $ / shares	Feb. 10, 2017 USD ($) $ / shares	Feb. 01, 2017 USD ($) $ / shares	Jan. 12, 2017 USD ($) $ / shares	Jul. 21, 2016	Jun. 13, 2016	Jun. 06, 2016 USD ($) Installment $ / shares shares	Dec. 31, 2016 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Sep. 30, 2016 USD ($)	Aug. 28, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)
Debt Instrument [Line Items]
Gain on warrant extinguishment																						$ 0		$ 0		$ 9,613,000	$ 0
Warrant liability fair value adjustment																						(27,000)		$ (8,680,000)		(1,227,000)	(9,171,000)
Debt instrument, conversion price \| $ / shares							$ 24.50	$ 17.50		$ 17.50	$ 21.00		$ 38.50	$ 49.00	$ 70.00	$ 112.00	$ 126.00
Reverse stock split ratio																		0.0625
Conversion of convertible notes							$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286		$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318								$ 23,563,014	26,199,000	0
Subsequent Event [Member]
Debt Instrument [Line Items]
Reverse stock split ratio	0.0029
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Conversion of convertible notes						$ 1,200,000
Restructuring Agreement [Member] \| Investor [Member]
Debt Instrument [Line Items]
Initial release of restricted cash						1,650,000
Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes						$ 11,444,637																			$ 11,444,637
Additional Restructuring [Member] \| Investor [Member]
Debt Instrument [Line Items]
Reverse stock split ratio					20
Additional Restructuring [Member] \| Investor [Member] \| New Warrants [Member]
Debt Instrument [Line Items]
Shares issuable upon warrants exercised \| shares					2.125
Warrants expiry period					42 months
Exercise price of warrants \| $ / shares					$ 122.50
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Exercise price of warrants \| $ / shares			$ 122.50
Warrants issued to purchase Common Stock \| shares			127,551
Series A and Series B Preferred Shares [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock																										2,360,000	0
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share \| $ / shares									$ 0.001
Series A Preferred Stock [Member] \| Restructuring Agreement [Member] \| Investor [Member]
Debt Instrument [Line Items]
Number of preferred stock \| shares						4,200																			4,200
Preferred stock redemption price per share \| $ / shares						$ 4.20																			$ 4.20
Series B Convertible Preferred Stock [Member] \| Restructuring Agreement [Member] \| Investor [Member]
Debt Instrument [Line Items]
Number of preferred stock \| shares						2,006																			2,006
Series B Preferred Stock [Member] \| Restructuring Agreement [Member] \| Investor [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock						$ 2,006,000
Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share \| $ / shares				$ 1,000.00
Conversion of convertible notes				$ 500,000
Series C Preferred Shares [Member] \| Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Redemption of shares outstanding for cash payment			$ 590,000
Securities Purchase Agreement [Member] \| Warrant Repurchase Agreements [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants												$ 7,900,000
Gain on warrant extinguishment												9,600,000
Warrant liability fair value adjustment												$ 17,500,000
Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																						11,437,000				11,437,000		$ 35,000,000
Debt discount on senior notes																						1,701,000				1,701,000
Senior Secured Convertible Notes [Member] \| Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price \| $ / shares		$ 0.05
Number of Notes investors entered into agreement \| Investor			2
Conversion of convertible notes			$ 279,015
Conversion price of debt instrument to purchase price of common stock percentage.		200.00%
Debt instrument, maturity description		The maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018
Debt instrument maturity date		Dec. 30, 2018
Debt instrument, deferred description		Until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period
Debt instrument, conversion treshold days \| d		75
Debt instrument, redemption description		The Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes
Redemption of outstanding debt instrument for cash		$ 7,300,000
Senior Secured Convertible Notes [Member] \| Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion of convertible notes									$ 4,200,000
Senior Secured Convertible Notes [Member] \| Series C Preferred Shares [Member] \| Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Cash held in the restricted accounts		$ 600,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																				$ 35,000,000
Debt discount on senior notes																				2,800,000		$ 35,000,000				$ 35,000,000
Interest rate upon default																						0.00%				0.00%
Rate of interest in event of default																										15.00%
Debt instrument interest rate computation terms																										The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable
Proceeds from issuance of notes available for general corporate purposes																				$ 3,000,000	$ 3,000,000	$ 2,100,000	$ 6,600,000
Amortization payments number of equal installments \| Installment																				14
Period after original date of issuance of notes for which amortization payment begins																			7 months
Debt instrument, original issuance date																										Jun. 13, 2016
Debt instrument, conversion price \| $ / shares																				$ 1,536.50
Debt discount amortization																										$ 33,300,000
Beneficial conversion feature																										4,400,000
Debt instrument, put options issued on default and change in control, value																						0				0
Debt issuance costs																						1,800,000				1,800,000
Amortization of debt issuance costs																										1,200,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member] \| Series A and Series B Preferred Shares [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock																						$ 2,400,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member] \| Restricted Cash [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants																										7,300,000
Restricted Notes [Member] \| Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes						10,092,857																			$ 10,092,857
Unrestricted Notes [Member] \| Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes						1,351,780																			$ 1,351,780
Cancellation Note [Member] \| Restructuring Agreement [Member] \| Investor [Member]
Debt Instrument [Line Items]
Aggregate principal of notes cancelled						$ 1,200,000
Redemption Notes [Member] \| Additional Restructuring [Member] \| Investor [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount					$ 4,000,000
Debt instrument, redemption price					6,436,852.80
Exchange Notes \| Additional Restructuring [Member] \| Investor [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount					$ 2,436,852.80
Exchange Notes \| Additional Restructuring [Member] \| Investor [Member] \| New Warrants [Member]
Debt Instrument [Line Items]
Common stock shares purchased \| shares					114,286
Series C Warrants [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants																										$ 7,876,000	$ 0
Series C Warrants [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Additional issuance of common stock purchase price per share. \| $ / shares																				$ 0.01
Series C Warrants [Member] \| Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants																				$ 32,200,000
Debt discount on senior notes																				$ 27,800,000
Shares issuable upon warrants exercised \| shares																				20,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Details) - USD ($)												8 Months Ended	9 Months Ended
	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Aug. 28, 2017	Sep. 30, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Applicable Conversion Price		$ 24.50	$ 17.50		$ 17.50	$ 21.00	$ 38.50	$ 49.00	$ 70.00	$ 112.00	$ 126.00
Reduction in Principal		$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318	$ 23,563,014	$ 26,199,000	$ 0
Exchange Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price				$ 6.09
Reduction in Principal				$ 4,200,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price	$ 10.50											$ 10.50
Reduction in Principal	$ 1,200,000
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of Shares		38,906	114,286		109,367	169,061	117,297	2,571	43,882	4,857	11,753	1,418,948
Common Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				689,796
Common Stock Issued [Member] \| Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of Shares	117,171
Preferred Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				4,200

XML 53 R42.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Parenthetical) (Details) - USD ($)												3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Sep. 30, 2017	Aug. 28, 2017	Sep. 30, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Reduction in Principal		$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318		$ 23,563,014	$ 26,199,000	$ 0
Loss on debt settlement												$ 2,952,000		$ 2,952,000	$ 0
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	$ 1,200,000
Loss on debt settlement	$ 2,000,000
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued		38,906	114,286		109,367	169,061	117,297	2,571	43,882	4,857	11,753		1,418,948
Common Stock Issued [Member] \| Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued	117,171
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued				4,200
Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal				$ 4,200,000
Loss on debt settlement				$ 1,000,000
Exchange Agreement [Member] \| Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued				689,796
Exchange Agreement [Member] \| Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued				4,200

XML 54 R43.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable - Summary of Convertible Notes Outstanding (Details) - Senior Secured Convertible Notes [Member] - USD ($)	Sep. 30, 2017	Jun. 30, 2016
Debt Instrument [Line Items]
Convertible notes payable, principal	$ 11,437,000	$ 35,000,000
Debt discounts	(1,701,000)
Net convertible note payable	$ 9,736,000

XML 55 R44.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Reverse Stock Split - Additional Information (Details)	Nov. 06, 2017 $ / shares shares	Jul. 21, 2016 $ / shares shares	Jul. 19, 2016 shares	Sep. 30, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares	Jul. 18, 2016 shares
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.0625
Number of fractional shares were issued in connection with the reverse stock split		0
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01		$ 0.01	$ 0.01
Common stock, shares authorized (in shares)			500,000,000	500,000,000	500,000,000	170,000,000
Minimum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.1
Maximum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.05
Subsequent Event [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] \| OTCQB [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connection with the reverse stock split	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01

XML 56 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Recent Preferred Stock Issuances - Additional Information (Details)														1 Months Ended			3 Months Ended	8 Months Ended	9 Months Ended
	Sep. 21, 2017 USD ($) Investor Vote $ / shares shares	Aug. 28, 2017 USD ($) shares	Aug. 04, 2017 USD ($)	Jul. 11, 2017 USD ($) Vote $ / shares	Jul. 07, 2017 USD ($)	Jul. 02, 2017 USD ($) Vote $ / shares shares	May 09, 2017 USD ($)	Apr. 10, 2017 USD ($)	Mar. 13, 2017 USD ($)	Mar. 02, 2017 USD ($)	Feb. 10, 2017 USD ($)	Feb. 01, 2017 USD ($)	Jan. 12, 2017 USD ($)	Oct. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Oct. 31, 2013 USD ($)	Sep. 30, 2017 USD ($) $ / shares	Aug. 28, 2017 USD ($) shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Nov. 06, 2017 USD ($)	Sep. 12, 2017 $ / shares	Jun. 29, 2017 $ / shares	Dec. 31, 2016 $ / shares
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																	$ 0.01		$ 0.01					$ 0.01
Conversion of convertible notes			$ 1,015,848		$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318					$ 23,563,014	$ 26,199,000	$ 0
Gross proceeds from the sale of shares														$ 1,200,000	$ 2,600,000	$ 7,500,000
Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes		$ 1,200,000
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																							$ 0.01
Number of Shares \| shares						4,200
Closing bid price \| $ / shares						$ 1,288.00
Number of votes \| Vote						3,261
Preferred stock redemption price per share \| $ / shares						$ 0.001
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																							$ 0.01
Closing bid price \| $ / shares				$ 65.35
Number of votes \| Vote				30,607
Sale of stock in private placement				$ 2,360,000
Cash purchase price in private placement				2,000,000
Gross proceeds from the sale of shares				$ 2,000,000
Conversion price per share \| $ / shares				$ 53.55
Deemed dividend amount																	$ 360,000
Series B Preferred Stock [Member] \| Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Redeemed share \| shares		2,360,000																2,360,000
Series C Preferred Shares [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																						$ 0.01
Conversion of convertible notes	$ 500,000
Number of Shares \| shares	590
Number of votes \| Vote	1,484,061
Preferred stock redemption price per share \| $ / shares	$ 1,000.00
Number of investors \| Investor	2
Redemption of preferred stock																					$ 590,000
Senior Secured Convertible Notes [Member] \| Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes						$ 4,200,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Warrants - Additional Information (Details) - USD ($)	1 Months Ended				9 Months Ended
	Oct. 31, 2016	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Sep. 30, 2017
Class Of Warrant Or Right [Line Items]
Sale of common stock, net of expenses (in shares)	1,215	1,715	440	234
Proceeds from issuance of private placement	$ 1,200,000		$ 2,600,000	$ 7,500,000
Net proceeds from issuance of private placement	$ 1,100,000		$ 2,500,000	$ 6,900,000
Sale of units to underwriter		1,715
Proceeds of common stock issued, net of related expenses		$ 6,000,000
Series A Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable per share price (in dollars per share)					$ 49.00
Number of warrants outstanding (in shares)					500
Number of warrants converted		1,140			285
Gross proceeds from underwriting offering		$ 7,000,000
Warrants expiry period					5 years
Warrants exercised (in shares)					285
Net proceeds from exercise of warrants					$ 15,000
Series B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants converted		1,715
Warrants exercised (in shares)					285
Net proceeds from exercise of warrants					$ 800,000
Remaining outstanding warrants expired					1,140
Warrants expiration date					Jan. 29, 2016
Series A and B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Value of warrants issued		$ 3,400,000
2013 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)				106
Value of warrants issued				$ 1,900,000
Warrants exercisable per share price (in dollars per share)					$ 39,424.00
Number of warrants outstanding (in shares)					100
Term period for warrants					5 years
February 2015 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)			197
Value of warrants issued			$ 800,000
Warrants exercisable per share price (in dollars per share)					$ 49.00
Number of warrants outstanding (in shares)					100
Term period for warrants					5 years
October 2016 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)	425
Value of warrants issued	$ 300,000
Warrants exercisable per share price (in dollars per share)					$ 49.00
Number of warrants outstanding (in shares)					200
Term period for warrants					5 years

XML 58 R47.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense				$ 48,000	$ 138,000
Restricted stock compensation expense				84,000	228,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 3,000	$ 24,000	$ 48,000	$ 100,000
Stock options granted				43	0
Stock Options [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, term				10 years
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				264	0
Restricted stock compensation expense		$ 20,000	$ 38,000	$ 100,000	$ 200,000
2004 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)		34		34
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	269	573		573
Increased number of shares (in shares)	304
Shares available for grant		55		55

XML 59 R48.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Input	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Fair Value Disclosures [Abstract]
Number of inputs used for valuation of warrants \| Input			6
Derivative warrant liability [Abstract]
Change in fair value of the warrant liability, net	$ (27,000)	$ (8,680,000)	$ (1,227,000)	$ (9,171,000)
Derivative warrant liabilities	$ 16,000		$ 16,000		$ 18,751,000

XML 60 R49.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value of Warrants (Details)	9 Months Ended
	Sep. 30, 2017
October 2016 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	142.46%
Risk-free interest rates (in hundredths)	1.77%
Expected life (in years)	4 years 7 days
July 2015 Series A Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	165.32%
Risk-free interest rates (in hundredths)	1.59%
Expected life (in years)	2 years 9 months 22 days
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	181.24%
Risk-free interest rates (in hundredths)	1.53%
Expected life (in years)	2 years 4 months 17 days
October 2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	227.68%
Risk-free interest rates (in hundredths)	1.33%
Expected life (in years)	1 year 29 days

XML 61 R50.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Derivative Instruments Liabilities [Member] - Recurring [Member] $ in Thousands	Sep. 30, 2017 USD ($)
Liabilities [Abstract]
Total Liabilities	$ 16
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 16

XML 62 R51.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 18,751
Total change in the liability included in earnings	(1,227)
Extinguishment of convertible note warrant	(17,489)
Fair value of warrants issued	0	$ 28,133
Fair value of warrants exercised	(19)	$ (245)
Ending balance	$ 16

XML 63 R52.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,397	21,394
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	155	118
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	289	54
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	953	21,221

XML 64 R53.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Details)															8 Months Ended	9 Months Ended
Subsequent Events - Additional Information (Details)	Nov. 06, 2017 USD ($) $ / shares shares	Oct. 11, 2017 USD ($) Conversion $ / shares	Oct. 10, 2017 USD ($) Investor d $ / shares shares	Sep. 21, 2017 USD ($)	Aug. 04, 2017 USD ($) $ / shares	Jul. 07, 2017 USD ($) $ / shares	May 09, 2017 USD ($) $ / shares	Apr. 10, 2017 USD ($) $ / shares	Mar. 13, 2017 USD ($) $ / shares	Mar. 02, 2017 USD ($) $ / shares	Feb. 10, 2017 USD ($) $ / shares	Feb. 01, 2017 USD ($) $ / shares	Jan. 12, 2017 USD ($) $ / shares	Jul. 21, 2016 $ / shares shares	Aug. 28, 2017 USD ($)	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Dec. 31, 2016 $ / shares
Subsequent Event [Line Items]
Conversion of convertible notes					$ 1,015,848	$ 2,000,000	$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318		$ 23,563,014	$ 26,199,000	$ 0
Debt instrument, conversion price \| $ / shares					$ 24.50	$ 17.50	$ 17.50	$ 21.00	$ 38.50	$ 49.00	$ 70.00	$ 112.00	$ 126.00
Reverse stock split ratio														0.0625
Number of fractional shares were issued in connection with the reverse stock split \| shares														0
Common stock, par value (in dollars per share) \| $ / shares														$ 0.01		$ 0.01		$ 0.01
Series C Preferred Shares [Member]
Subsequent Event [Line Items]
Conversion of convertible notes				$ 500,000
Preferred shares outstanding for a cash payment	$ 590,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] \| OTCQB [Member]
Subsequent Event [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connection with the reverse stock split \| shares	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price of warrants \| $ / shares			$ 122.50
Warrants exercise price description			On the 136th day subsequent to the date of consummation of the offering hereunder, there shall be a “true up” with regard to the issuance of shares upon exercise such that the difference between 382,650 shares and the number of shares that would be issuable if the exercise price were lowered to the average price per share of the variable weighted average price of our common stock for the five trading days commencing on the date which is 76 days after the date of consummation of the offering hereunder, but not lower than 33% of the variable weighted average price of a share of our common stock on the 81st date following the date of consummation of the offering hereunder.
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| On Or After 75th Day Subsequent To Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Shares issuable upon warrants exercised \| shares			382,650
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| After 76 Days from Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Number of trading days required to measure weighted average price of common stock \| d			5
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| On 81st Date Following from Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Minimum percentage of variable weighted average price of share of common stock			33.00%
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| On Or Before 135th Date Following From Date of Consummation of Offering [Member]
Subsequent Event [Line Items]
Warrants provision may buy out			$ 6,138,349.80
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| Senior Secured Convertible Notes [Member]
Subsequent Event [Line Items]
Number of Notes investors entered into agreement \| Investor			2
Conversion of convertible notes			$ 279,015
Registration statement on Form S-1 filed date			Oct. 11, 2017
Conversion price of debt instrument to purchase price of common stock percentage.		200.00%
Debt instrument maturity date		Dec. 30, 2018
Conversions during 75 day period from date of consummation \| Conversion		0
Redemption of outstanding debt instrument for cash		$ 7,300,000
Debt instrument, conversion price \| $ / shares		$ 0.05
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| Common Stock Issued [Member]
Subsequent Event [Line Items]
Shares issuable upon warrants exercised \| shares			127,550
Amendment to Restructuring Agreement [Member] \| Subsequent Event [Member] \| Series C Preferred Shares [Member]
Subsequent Event [Line Items]
Preferred shares outstanding for a cash payment			$ 590,000

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 198 236 1 true 69 0 false 11 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.delcath.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.delcath.com/20170930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.delcath.com/20170930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.delcath.com/20170930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) Sheet http://www.delcath.com/20170930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) Sheet http://www.delcath.com/20170930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) (Parenthetical) Sheet http://www.delcath.com/20170930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnauditedParenthetical Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.delcath.com/20170930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 100080 - Disclosure - General Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureGeneral General Notes 9 false false R10.htm 100090 - Disclosure - Inventories Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureInventories Inventories Notes 10 false false R11.htm 100100 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 11 false false R12.htm 100110 - Disclosure - Property, Plant, and Equipment Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePropertyPlantAndEquipment Property, Plant, and Equipment Notes 12 false false R13.htm 100120 - Disclosure - Accrued Expenses Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 100130 - Disclosure - Restructuring Expenses Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureRestructuringExpenses Restructuring Expenses Notes 14 false false R15.htm 100140 - Disclosure - Convertible Notes Payable Notes http://www.delcath.com/20170930/taxonomy/role/DisclosureConvertibleNotesPayable Convertible Notes Payable Notes 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 100160 - Disclosure - Fair Value Measurements Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 100170 - Disclosure - Net Loss per Common Share Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureNetLossPerCommonShare Net Loss per Common Share Notes 18 false false R19.htm 100180 - Disclosure - Taxes Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureTaxes Taxes Notes 19 false false R20.htm 100190 - Disclosure - Subsequent Events Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 20 false false R21.htm 100200 - Disclosure - General (Policies) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureGeneralPolicies General (Policies) Policies 21 false false R22.htm 100210 - Disclosure - Inventories (Tables) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosureInventories 22 false false R23.htm 100220 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 23 false false R24.htm 100230 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables Property, Plant, and Equipment (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosurePropertyPlantAndEquipment 24 false false R25.htm 100240 - Disclosure - Accrued Expenses (Tables) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosureAccruedExpenses 25 false false R26.htm 100250 - Disclosure - Restructuring Expenses (Tables) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureRestructuringExpensesTables Restructuring Expenses (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosureRestructuringExpenses 26 false false R27.htm 100260 - Disclosure - Convertible Notes Payable (Tables) Notes http://www.delcath.com/20170930/taxonomy/role/DisclosureConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosureConvertibleNotesPayable 27 false false R28.htm 100270 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosureFairValueMeasurements 28 false false R29.htm 100280 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureNetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://www.delcath.com/20170930/taxonomy/role/DisclosureNetLossPerCommonShare 29 false false R30.htm 100290 - Disclosure - General - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureGeneralAdditionalInformationDetails General - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 31 false false R32.htm 100310 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 32 false false R33.htm 100320 - Disclosure - Prepaid Expenses and Other Current Assets - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsAdditionalInformationDetails Prepaid Expenses and Other Current Assets - Additional Information (Details) Details 33 false false R34.htm 100330 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) Details 34 false false R35.htm 100340 - Disclosure - Property, Plant, and Equipment - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails Property, Plant, and Equipment - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 36 false false R37.htm 100360 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesParentheticalDetails Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details) Details 37 false false R38.htm 100370 - Disclosure - Restructuring Expenses - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureRestructuringExpensesAdditionalInformationDetails Restructuring Expenses - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureRestructuringExpensesScheduleOfRestructuringAndRelatedCostsDetails Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) Details 39 false false R40.htm 100390 - Disclosure - Convertible Notes Payable - Additional Information (Details) Notes http://www.delcath.com/20170930/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformationDetails Convertible Notes Payable - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Details) Notes http://www.delcath.com/20170930/taxonomy/role/DisclosureConvertibleNotesPayableSummaryOfCommonStockSharesIssuedUnderNotesDetails Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Details) Details 41 false false R42.htm 100410 - Disclosure - Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Parenthetical) (Details) Notes http://www.delcath.com/20170930/taxonomy/role/DisclosureConvertibleNotesPayableSummaryOfCommonStockSharesIssuedUnderNotesParentheticalDetails Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Parenthetical) (Details) Details 42 false false R43.htm 100420 - Disclosure - Convertible Notes Payable - Summary of Convertible Notes Outstanding (Details) Notes http://www.delcath.com/20170930/taxonomy/role/DisclosureConvertibleNotesPayableSummaryOfConvertibleNotesOutstandingDetails Convertible Notes Payable - Summary of Convertible Notes Outstanding (Details) Details 43 false false R44.htm 100430 - Disclosure - Stockholders' Equity - Reverse Stock Split - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureStockholdersEquityReverseStockSplitAdditionalInformationDetails Stockholders' Equity - Reverse Stock Split - Additional Information (Details) Details 44 false false R45.htm 100440 - Disclosure - Stockholders' Equity - Recent Preferred Stock Issuances - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureStockholdersEquityRecentPreferredStockIssuancesAdditionalInformationDetails Stockholders' Equity - Recent Preferred Stock Issuances - Additional Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetails Stockholders' Equity - Warrants - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureStockholdersEquityStockIncentivePlansAdditionalInformationDetails Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 48 false false R49.htm 100480 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Warrants (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfWarrantsDetails Fair Value Measurements - Schedule of Fair Value of Warrants (Details) Details 49 false false R50.htm 100490 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 50 false false R51.htm 100500 - Disclosure - Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) Details 51 false false R52.htm 100510 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 52 false false R53.htm 100520 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.delcath.com/20170930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 53 false false All Reports Book All Reports dcth-20170930.xml dcth-20170930.xsd dcth-20170930_cal.xml dcth-20170930_def.xml dcth-20170930_lab.xml dcth-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true ZIP 71 0001564590-17-023836-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-023836-xbrl.zip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�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
,F;QWYKKG#%[CEN\JAW$"H4> MA3Y>+!C6*%@LHFQU]B%)$93(A'/4=:L&!=?;&''!J_TF?IRK7Y];M/R^_PK+ MD"6>EJIZ!!.:(?]<:"^1J6'Q06MN-P M$%P0+\$B9G5X>62)1_S0ZX[23V7KPH4(KT-[HZ4VMR:\&Q],<=OE54=N+&F2 M(A%L)(">9R#6 ']8,2M,[ TLL8UE!$=/[*\\"5-PG.IEO[92,94C/I_3T=/K MWN8=;_:HJZ9E08NUM"I(IO-9HC?/Q%^NC=7F%:8\^0^OS*^^Z\Z MFG)W:7_VB?AK&#!-GB1"3B(4E<.E1O#HH_D?ST?Z!,(5CZ<_A.LL5I[KR9"Y MX[FK(;J>_RQ2.A_VR0.2N'1Z+.C4B-$>BCC$2/QB]R@.45I%MU;>?GS@U M8B3'(8X16SL]HUX8=M"?3(Q+4Z>&XW\DZAC]N,]&KQ9C&<.Q?FGBU'#=CT.< M?M(AGD^:J"5UC.G%.:N&0WD<\@P2SAK43'",IKW1Q4]/#2?O..09]B;)#]-: MY.E-^Z.+GYX:CLC!Y$FLII*[D$G%4W5[E'$]@36:3,?3T:6I6L/M.,ZA&_=& MR0_C?4JJ+D*>RKG<1R7/I-=/?AC4(0\@U[LX=]@R?U+Y2MTI7YQ4Z)R M[OAI')BZY!GHD^E@"A9FX8R*F>DU_%P"^L(1Q7= M?QN% 1IO9^>(L!TN:=%V=.-BV]DQ1FRG$UFPG7%5:^;3[F;GF+$=3E_1!;3I MQ7:S8P;93B^M8#?]R0E:8]3;SJ:LIN(-BGEZ'!CG&@.QT,M1#=.2ATAS]0Q&V#B^WF@':"!_[)[P798PJ+CH/AA/^IM5794+.F#].^V,LI!^^?HW!X&>_<\1W6>BWXOA,]?YTC[L3>ZV_1M3CJ*YXQ;%+ MNHN<8]L[C8"RX&EENX?SK7]GZ* LNEG5[4P?3LK#3,==_P$M?$_:V>8<>]^M M\$L"A!5GKS\<]7O8N/4H&Z@?%AQ4SB]O5@15W5FG'?% 7BZ,'9L_N?CU.Q:& MSL:]S4'E!/53;+>J8W(BM$H7?L!!KY'I.D5'GJI+7,=E] 9\4CFZ_=B9FS,0 M]9BYFSI,4V>J_"GV734U8 _>J3F:85!G8/S!98[''498-7AJQW37G?,5Y/[7 M@C>2SX'.6-K14B9="^8X[C$=JM_?K(+>292:X:77S&5S&^>99XS[GN$%(":3 MM<63'JMF=F_.R]F'3!L7SRKEW^,39GTB+GR?_5!:,L$5GZ, M8I.CK6\/M:FF1)YN_X3%@#J=\X&G\86W^[31/GY9IISR%$+<+]\P'HP#3).-123=T*7M MUIDS?[;M3L?]?'"Z9/W':CHZJ#,:_@MW:277YJ/MVLMHF6UQU!OKD^2'RO1Q M.L7Y6&U!#]E[#2M^>^_F]T/W+E\$.L+FRQK/?,%!SX'T+%F75HY3%YLQ>LD/ MM:ZJ;#9ZK;^L38[-VGR8_B=?S$'GEL-V"^I!Y83S.LLOOJJERQRX>CC)(7OB,QRH]5+1=_W-MTWRI6L-=2=X1$=Q[\9*FQG[G74O/1QSHG MX]2A3R[:1T;3:IG\Z:JWK?VC?&<9\'PX&?>(C1XW(=4@5EAG*//I*'+BX/@; MQPM 8+^V9[SR0]IVG>')Q]AV;K**WSQ2]\8Z1N]$OG2#QK8,*@SWO?H&)99N[)$+!>)]68E-%4.=6;K'C32 MX&+*H<3VXM_XC3WQO^08H$;@\'!*C/5>\D--:PRSIJ.\@*^UM?K4$+]^CRK. M?X2CE:-*C5C>A:BR:4$UVJ(\!K1P3CPPV2-LZ[-C6GQOFS&X.L-I3T>8VNF> M!INKI_R.9TQ6;KNIJS(:=OO#_95?#>/P?*=<4GX]<"G*M9_4/;)@%MA&[6J1 M\#^> 53[\4^TQ/8;W7V8HU)E1>=XS+PP%?3 9]$[A*-<9 M+7F,#3+"KG'UE6Z$=SS@L)X&NY\>D5UR:V>SO7KF/!FF2(J>X M;,.1"X,Z4P0+)Z.D!ECRLJ]/WM>%%P4F M6 KN[.O"!AG"W R\YD30L4-'@Z$)!_BIE:, *Q=?U>DRT3G[^9C9T:WS17DS M.ZYX[K69T;2WR5%UEB4APZVG;-"1P%)>=@U+Z6A'L?:^]:D,8N$>CCI0:U!G MHMQQR-"@E"2[6#\=&(.<4CG5<*O"(>.#.M/ M\Y-5R5NM844=:ZNY:JI?/@__%9_WPC4>J"TK!Y#!(H9X-3;^H>K*3)K*&M2M M)3A45]8P<>H!\I[=^Y'IK_/ O+?G>5S**5%Z%J?CLZG,'49/^>*KPK(C6=J> M3V563I[:>S.;/N?156:=(4_'/I&UMS^1H3R#XJPS..FHQ-A'?VZTV3FO\JPS MO^B\%#JU#JTS:.?(.SY E>)439?YP1MS98>F<@ZT!BK'I!R\A2;F0.7Q*Q\$^LZT%OG/RKL[ M*# DRJIX^814^+8Q+[4!:?3!+BYKLLT34NV@6%)&M=='H5KN0!V):EPB<,-% MM@F^X1"D)WR"^_ IF; DD>6@1&2#PU3"<%6ACIZL[&MMK([%)BU4HD/EU(A] M=S!*=E![10WLM#KS%&HA!RJGX:&NNH0XD$$[@X569W#"X0>X=699G9$))R!+ ML;@;[FF)%4V:E_=X4%ZP_A[+K*^BY4FKK[03LN^* Y#;UT'IO;JJJORZ6S&( MQB0I#6FVL7*9''\T^:1LP=692W!*$M1P0>OL2#H-7Y(Y8])1SQV@_!$XDHVW M:_^UD!P_+C+W*7XC/3^_=%!GF,#1(5BG<[_1Y?W:LG%.NW]ST>"7$YKV% J[NW= M5_;A1WY.4I&CS91*]:_J[E]^>+K7,<_69'LK(!_@EH MT3J7LK*G_B4(E&K@$P7Z*]ONGV3#AZ3,D1BOS0#OR2Y7S VXO2JU.GN]SC[R MV5SS>[9/IC]+K;C2V]?#RH[]\0) _+B_F4NIYPI7I""AW-!^1.GD DZ#/>#- ME:T=>Y=G)&(-TZT>$:=[$'$X[K>'BK>SF8U?,9TJ>M8(_#6FYR@)\XXV8YZE MI[-WS.-9OO,S'M0:5NH^A*U9I3J:MN>@QH]_-&T'6^* A%\^# \FLD4J6&W-Z3(OG>[>EL7@;<6 MWG1S-0SQYIN3)'OMS1F#$^RNAA6]#W3-(S:#R0EV5\-DW@<[O02[G8VK&^YO M7QD9=Y_\J_!.8Z;>B'@,*T=9G #Z\J'E1] *Y3L^*TEK&-7'/&]U.H^=FJ+\ M=K)MA?&]HVTFK#.RHY H&T\^3#,8>?8K7G73G=4P39ON;)^FG[U3[*V&I=AL M;_NHO/[D!#O;UWZKV-D>"F&S65>=O9U8>NUKQNUQG,O]K6/XKXIH@WTMQST. MVB4UP<8%^U44!M\"WF0'X^1QN_?M@.:P&_:_$/L-@@B<7T6T^T,L?B'Y\!W'3M"_1T[#*O2=%!D-^\:E*+)/J/6PHOR=Y)CH MQN!2Y-@G4EK)+CNO^^T@A]$UQJ/):4&4F,XO00U:ABIYY49G!3]2Y"BAEEZ7GF!I.B? MA!2)E,$,JTR"&I;D<:7$+Y\'_QJ_K2<2<;'[;ZU& /+X;/_+9^-?TX^&<98= M'F(>[GLGS_C7X*-^%@#K3(LX,GO^\EG_ES'=>W._VN8]:G X.ND7<5:&XP61 MW/-H6&<41/J$U^OTQ[_9S#=]:['^E3TR1_;LTH\(MX3_O9]/ DD/3!:ZYF4= M\G/>,EYE93\R,1O'-IVLEU4@;;#TV1^9B;OE(U)\]M^(N=:Z<*72!X,O6%J+ MI7=[CB[)3_*HQF%?S&I8ET3B(A(7+>>?=KCXYGKW ?,?,466], QON'+"A&QO5>!7;G(R'^2DX)UG]<0A4\H:_FK:+0Q@_ MN)83S; 9W3O3Q\L,F10P.O([WWW'FY>1'2QX M$6V\ KS-F!O3$"L>F<([:F7WH_!X,)GVTGK1B^[US%R^0/L>+U=M-_A M NYABO2GXW:18.=XQN;'H#\]K?!K>-UZ\XZ7O/LFO23$]$]=B:$1F'^G" M\,;DO0A\ 8RUA.\>X3^;I14;?]X8P $?_C27*B)2A74+_YKA;[YZ.Z=Q 'YU MNA@8X^%P_UY5FS3>KZ7Y$C#BXI;FK<$E4/[JL?=*!YL6 5GK)1HG]SWGK^\ MT]_;@%N^Q\2PS@REPT=1*D#ZWC3# 'MBF]S(GQNCHZGZC[9=T'MZRP/+MU8:D MJS612P&2YM3%)U<+%TS3^Z-PH,@$/_\:_>4F3 MR07S681-&COX>Y]I (WC:/=,,[7_]S\3P^C]#.MB6K3B_])_UIYL>*//'DQ_ MEKS)CMM!F+B0^+LQ;P23,4"[/Q[0R_<,_")\9<#0Y"!TY"\FW3 MG?%/NAQZZ;'\&4]>Y,QPB?R]H%@T6^PJ?=^*CV5\POTX'OY?NE03A+3YD'QB M!0_G3T[H\@ALR9_XQ/!$P??R7X"/>9$/)$4[6PMX?\JYY_/OSD'2:Z"P>4<& M@"3@'X-MXK\]-\/D:6$#.>Q &X_$YTQD_;TPNX]"S?5"L4ND#I"R_Z<&NS&S M_6]M+%[S1 ]"L;"YY\"+< G-U]K=ZL=7S)@%!LU705.0A\$7..+8O^RK%V<[ M_AGO[%9L+!;[A>U#AXU&T&W):%D^W]G?<37%ZEQEL2S+D KY'(4^FOP;)LY! M.$BX?K1=O+\+)A%>GH9/?YK_(SZIQ8_A+G@IJDV::!9HWG?X1M"X?A BEN^3 M,_YLP4VJ];!6[UAX%&C>S[[W:*,]_-%_'+2.]/^H-I=]+;D*G;)!>X?+_W'>>GN>>%H"O8K[;[ MN_;=@?_^Y'L.^\N+11BN?OKQQZ>GIRY^LNOY#S\:O5[_1_SSC_C!%_'G0]CI M7UX :+ M-GO!GYX^W_&LW,?@WR9.FXQ_N?!Q)__#\>^AS25^[9CWS(F/!?SZ MW\Z]\T+[,?_D9.6YQX,Y !K+8IL/^NTK?Q2VPZF_R>0-$TE[ 2 A&VZ-]_N M7OP"RW:8!<:^"0J1W<"INPE$F:CV4O])'[T"8P@]/Q9KS6#EV*'&X)1A!@>5 M*!9B:H;>T3!^R6V;[%$AD(5I"U"1:*3@W^9PDM?XZ/ZPM_O9OWF/_ AI(_[X M\9]_S).LF)"W?AXJT[<2:L&/.P@6?^+'N6F%-Q+A^-?GP'6;:,9O\O+@_'C MZ3&*3X]1>7K.M&GC5)L>%V]ZK,*FQZ?:]*1XTQ,5-CTYS:9US =M;QI^??E- MIXLX_J8'Q9L>J+#IP:DV/2S>]%"%30]/M>E1\:9'*FQZ=*I-%TIO^+4*FSZ1 M]-8'A=(;?JW"ID\FO:?%FYZJL.GIB38][!5N>MA38-/)(JHVO6DVHX\$?Q"_ M_N7_!U!+ P04 " #KBVY+T_=<%.,2 "=SP $0 &1C=&@M,C Q-S Y M,S N>'-D[5W=4^.XLG^_5>=_T.'AUDR=#4F ^8 [[*E 8(M;,.$0V#UO6XJM M)*IU[(QL SE__6W)EC]ERTZ@]."?O_[MO[[]O==#X^LI&AD>?29CZAJ6X_J, M?)C>?43_OGBX15-C2588C1W#7Q';0SVT]+SU6;__\O)R:,Y=PSDTG%5_3FUL M&Q1;/9>P9VH0MX]Z/=G$)2/8 VG0&'L$B;\S=#08?ND-A[WAR>/1T=GPT]GP MY/#HZ^?AT>#T'X/!V6"08/![H U*_ &#PT^'@\/3!-D]-O[""X)NQ@FR+U^. M1I?'7RZNA\.KDXO+XZN3KY]/!^/!U=?QY?> /Z^?CDZ'1[!Y?#+(,GQ MTEEO&%TL/?3!^"A$AJZP;6)99(.NI=*_H-O;RT,TLBSTP(E=]$!X/Q#S,.3E M!MT(R-CNF0T<_-7Y0:(G7V?,.G38HF]ZK.]MUJ0/1#V@(HP:![*>OE*Z H#- M;[M1K3EV9Z*&+.D+% ;#WO%05G*]-8LJB"9<8APNG.<^+^$5AND*-J:&JZXA MBA1MF(:W3*EB$LO WE+8TI$ X7@@B:G]3%Q/W4!0QJLH)*?4+4\4,#)3_+"4#5T(,\Q:.%Z8$E$TAN.;WMLHVXB M+%1(95'[KY)6>/$,NU$KKSGZEV-!/3P]/>V+TD@@GS'P(442A:4*DN7;8:DSFV+< ;M_^X6.+SBDQP>M9A/NL%$&B MV,-L0;SO>$7<-39(57M4]1CT[[#_[[O;P%L>P(A'Z!M=K1WFH6#HWSJ&<($E M^/!?/6D*/7ZK!R[I>'CXZH*TME+.(COJ[R""M).M1(B-;"L1Y-CD;7\J:E4] MF"NU)ZHJ!WB?6)XK[_1BPRP2HM1+5)&4VZ(P\^5##$_'>XB@V-_WU6,Y%1>WS22#E_^J("*=M+80I*D MHX]^U99%-5W4%R::0,1572%RTT]] 1*Q1WC=B^.02D(HHI?Z8L0Q5G!9MR?R M,5I]&>3DS"]Z\2Q=J?WLQ+Y%ZS(N%5>UV\]&M:$ V+8=3[0J?O,[ZS6UYT[X M$V[PR>Z,.19YA&&.J'E^\$A6:PL6.;.)%3P\WVLBBSPG[Z;KU0KI()BF5 M26!)1H7T?'T#BZGD&DXVA7A;W_K9&EEFODO,B?VKN%XS6-K80<N%="48&(]E/#V2.1&![AIG!:]3B+RYA((.;^@K 5-IM;Y/4-56/O+NE7VYAU\=VUEM A&ETY7_1[9Y98-@FQN82=A* M"'4@IHX'(/^S$GF9LQ\JO'UTB6T3!>Q0@E\]_[^U%]]^XMC=_^^*XA3$%KF$ M2\[HDQ',38-:II<-TR#&-&"*>F0QYHB13%')% M =L.VB:AO<>P;O&6Q*/04]OAG&:A _UH*]#1AU0K'SLCV-$(HE)W,I_ E"94 M=,$U7SHKT'H)%>@SN75<]\G&ODD]GEVL:!W;\-:9S7%%LXG;1LX2+5 M/N("H ^1")U-O8%-;>=^=FY(9VTG^[>VSJ/MT?JFGF/\M70LDS"7+XH,ZNWF MQDH9ZJSITU;6E&SRO_':=17W>IT5UGFF/%G:) MW>6UY;SL&%8IV.ALYLM6-L,;0J*ESNG42Y)$!X]^(S;$!4F7D2_3@?=5I#^B M:O CK-DA40.)&_L9E' 8):X2C62Y#I'3'"*)VATJ-5"Y9V2-J7GUNN;>B(?Q M$YA[V*784O5&KIO.0-6LJ,%Q.,CA&+)%DJ\(Y@5G%+)& >\.Y5HHB\SYYM[" M00KXAT_7?)HI@+:(6H?G4(%GP.L7)+C]$J2,)<,.Q!H@C@R#^20:<4KHLC0Z MP(YR@(4LPW/)]1>U$*E)I2!]=Q#JX4GPZT;4"# /R9;RO. M+/+=\8A[CS=XQK?N%+ 5T>J .\D!E^"$!"L4\NJPJX%=_8\LD=P?RW6.PJ05-3ZG#[G,.-\T&"$4IRZE"K M@=IWXO$<^CT$^,YJY=C3)69J#ZFFU*'V)8<:\ G2]FL>^@M62/#J<*N!VR-^ M+0A @A(=+OG4AZC785!GCO)G+OGA@R)7SX7.+D>D0R:? HE9H(!'AU+]1.&] M8U&C*$65I=%@=)1/;X0 2P=5 MTXG%$@QK5->!F\]Q5$XR=M WFFTLQ;N\C@[D?&:D///8(=M "K($3S6E#L5\ MFB2;CNQP:RPO68)>&;T.PWSB1)VC[)!L,%E9@F5Y#1V:^71*8>*R [2Q?%@) MG&7T.C#S69:"W%@'96-)LA(HR^AU4.83,X4)LP[,'?(!(],4 F$K\8#3F'B8 M6J4Y@M)Z.G#SN1V9-X" *&*A79FJK.O79)JW236L $5I,[X,U".'9Q9+R0JMZ(F..M,J7;JKH?B M]@,/59[IZZRJ2:O:PA=MPTEG-?E4H=9J.J^SOU1P',5D"LHLHRX/G4WD4X^Y M]'$ZMLEGESM;V*,MI!YM:\(PE QU5I)/:=:VDO0S>IW5-+.6[X&;X"MSF+RR=A"BTGZE301CU;" MQI%HO3.C)G?(:CN6;?CH#"6?V"W>3>N\R\\PBZF_6F&VF;@AQ$4(MH5<% B!?"Y%6+>S MK3>QK63R97M M*TN6:+TSHX8>J7L@_.,_0<%T;='Z*>H,*)]"+GQ83P3GHFWIEGCK7;2U M?R,R0*U[1N:$,?X^'2#@4P%_SV3]57^3_'7&E<\TEQL7EP-%@H16%HG26=J^ M+>T/S!BVM]@TW9*5SGYJ/$D,9;+)SD[V;2>!B[#Y<*7/A.\9-6$R=;GJK">? MK2ZSGM#9R.;%3EAG2@V;DO((;FW3J<]%9RK5C_=V!K%_@XA3S%'Q9"Z]>VW# MJ,1-9R#Y/'6Q@203U0DJ^!7-4)VQ-.<]@A-9MGE+\8S"@H02-RPW1UX,N0WA MI<_X?L$%=FE],]JQ'9V!Y?/;)1XH. S&MST2PD@J$V$O97DH7-IU3 P;\D^W,^$=H>1KFQE[[6WBQ'=O1F-^G?':\V/R*2H0T M*"$.2LJ# H$ZVVON 9D11*IC:OD\7IWR(2[\P-6K8?DF,:^9L^*G_?Q ]\G\ M"C,;$.),1/4R&]QG>SI;S.?,BQ_0 6<(0O6D5"@6"TFYT!P$0PG)^$PL94,@ MG'S6IS/,!E[14G\=6(>!SG3RZ?#_0,%TWO.! MF&2U%@*O^'=:P_/W4L.*Q$D5P5>!6;'-#DH&WY+VRG2<8TM\TDW4G07?(#H_ M,$!2ZA7KSGWJ! ;7S)L2SPM*I:KJLH8UJP*?6C63S,HTBY+8Q!R+0T+WHM5@ M(_7JE3"#NHEEH%2Z=K64,0?;QC^E-VKJ+:*UVFH7UFJ-%>@,7+'BE_J84OER MFG>CZHWM$3 _[\:&>9OP^(9/!W<@\N8.L[\(]\KAEW[LQ<@07Z&.#&#+RN^F M<\:AV^;[E[9/(KWS]UNCDL;! 5(,%E^PS!-G(:G!3U[RKVM L'M-;> AD(*@ M6$3#,= UJ[6F/W00/\ =[,ICJ;%B#KMZY5;K4W>9G-^JT[>F"S0F4:Q1'*CH MM4_2OA?-IX0_UWTIW?<=6NFU:5GHY'7GU+BR(2!)1=YU**9T]>?]MX[*B5PEE5=73M5&[ M6_K#I^"=-\DPX0Y[$%2XXG6=FYRBM:JT4>?)X^6_+M*#,G6K;2-O2FSJ,)$? M$]_G2II9UK?H*=NFW1U^I2M_!>L6OG^/%Q7?"2%5WKIZV _0">N@[D]9YA?U M0OBXW:5%;7X<^)%1;$D%,IF,2J3O)8^A@"_4(;$_%FI< GE)G7;A_-WGHW R MG_JS6Q[&17:L*$AB2&&9MR#LC5,4H6S#C-?)WFZ;BY$"'JGE/FJKW(F$>GB2 M,O6PP[W/C"7(?P^K "*W:B(OL57=U& 1]]YTM-PSQR#$=/D:-U9#A%?@U;.Y ML*K4[V=M)'?$)%JC!2."*#OM:PG;9MHA&@]DG94XLURJ0-@VW=)/UZHA*Z=I MI48BU2!&DT*5?&';='BR69D6A<5MTR/,&B2B^_36EBK;H*=NFY;?R8LZ)Z0H M:)OL\=2;&N5I/31$;=/IDL]85K!7GE]W%I6V38LX0ZKT8\K"MNEP]0K3H+T@ M"@V416V3?P0_3?&1 Z?*1%F9O&UZ/F!/O!M5;L^),RR3^9C,L6_%>QD:JB97 MKPVL ,M"[&=,!=-KASVYI$I0GJWQ7@+STF8^ATZ6M&1'Z;?HD0O?@H0VZ MQE9XNBH(#V)UJU*W1GV-0XA/GZPIVP0&G5G 9LK:9Z#2%PG7S-^Y[7H.9!H3%R#T=11BPJ$*?1_QI%8C6YR M"5 031<6MRUZYET?&U^8ON!>)9HT?&\B, B')C_P*F+FD6U>"AUO>#6/.98X M(IC$M&'&;=EKJW*P-O78-G?Q^!K]F4JA21; MJ&-Z9\L-]V3^3'3*GE(NEL,?R[J@IG"ND4O.WF[9GHV,"G[G44$V5 AOMFYG M4[U*A0Y^AI7(O84-00_2N)K=IH(J[R60+'9.)@M:-RT?"5D&XS1?]F?W>@L+V+:TRSR@$ M<874HJ"P+4&%;N$OY7Y\<1Z7CN]B&"&V^;BD$%416[F7JZ%M6R@JI;XF,^8# M"FGIK^F\6-%*5=JF;WA .;&4*SN=74;73LTN*FI61M=.S?BA\JK:Z6C;IJ$( MI)(QEWB]ZPL_]F(O)G,(.>"_5+$B\7N9PDN?;2Q\.JYNK;8ELAX(-SH.6/QZ MTU0R-9D^KT#:J'[-92 GAN? B$M/$5/Z6CRK5*G1MN&;?T/$' 7_?R!$X!XFH>GH9O!N&!.Q3@=00B'ER?%- M[LT(%2A;EA&3_1Y.]/_K6W5BUJJUVF:]I=ZQ?#U2J4K;]%6]5NH/ZBWS;Y)Z M((9C&V"SHL7T2\XB:TX_.OL;:"=>(Y%]TWG89;('WUB(U@1PNE7RD\BQ\*?5 MY3Z_XJRFAJAM!OA %I13&+#'+":#J^I!6$GW(Q#M&K4J>P-W&G' MIGB?+S2"DRM [O(7]BM1'AL6'5V!0/("7X*O]1R<,2/X@W$B(.0*?BQ>*8RI9][PCLV;/.37@H.^H MG7U8]G?,*.>E5D?DAY1=U BK)H\"-= ]<@EPSYQGRB?E.[RY\#<3W\LN$E04 M[VV31F;[!#Z* T]ZNK<\[_2M[QI+LL*__A]02P,$% @ ZXMN2[^"_"DZ M#0 O[4 !4 !D8W1H+3(P,3R,9YS((SMMWSHTN;)XH0 5(&WK_OH#*,HD)7X $$$9 M:OT2AR86^ULL%HO%8OGQEY>Y;ST!H1Y&%ZW>4;=E 7*PZZ''BU9(VS9U/*_U MR\___,?'?[7;UNCJSAHX@?<$(X\Z/J8A@1_OOOQD_?YI.C[@TW!&F$G MG ,*K+8U"X+%>:?S_/Q\Y$ZI@X\YD2, . M&#_6R [ BG[.K7ZW=]KN]=J]D_M^_[SW[KQW(928*A,#W M86E=K4'_Q[JY&1Y9 ]^W)OQE:DV RP'/'^A7N;MY^/UN[W.[U]N[IP9S.VVAVC 6$E:<3)Y[7IG9V>= MZ*_L5>J=TZC]#7:B\1'@RRI\@_^OO7ZMS1^UF42/>T/1LQF!Z47+=8)9NQ^-Q7&7M__A'MA;3'EN(LXYG6^3 MZPR[+O@,Q"S2QG73#G^QDVW;R;(B3"JP7S#"\^6*YEW "/(),<3(!43!9;]0 M['LN>^Y^LGT^&GG\HT,N*+X;EV+X3^M%@BI73T3V75*U5LW9IU9L\ M?]H9&P%A^L>]\!O/?O!\+_! 19SE='1/4,S,-PD\;@%Q /367G)KJ "CBE(A MD&WOBC_A:^)JB;\+L/-] B[S"+F+-)ASRRW!H PU_CZ>&<[\E@ MY8H/\7Q!8,:\D_ IB%91H91VA_+ M:ZW=?0YL#X%[:1/$/#Z:$BC3<,_QI)1+A)IN97-=CZ]%MG_+-H'7:&@OO,#V MI92JB(1V]V$^QTA-=;;;ZM^TIWP :7YSFVMF.>IJAGT7".6;@V IPW%>ZP84 MP@OFT:8,\3A3P"85((?9;EG=*"33W&*EN$HUR2(3SVY*4DWK%4PJ4#D@3J8/ MFSAK^NS7K2AE-NH46M[ ='JMZR0,D;Q8F4[6]8S\*. Z BF:R#PTFF3"*)_\(+(>RO! M?VP4?C'$N:M3 OGD "%O.Q )WG<'B+?0R4M@OS] V"(>>B*!TP.40-XF*T'\ M01QQVQC(TKOD1!YG1FE GK>9[\J\QCY>H3*P!P2U)#R5(#;6A\M#7!903" ; MZZUMAOJRTSLW#IR@-LM'$T9=%+E/@)OEJ94#ESEZ221@EN\F-O15IV,)>K-< M.#'TY4><"7:SG+>-DVF\^9<<@!*^VIL&6)ZXD. URQ?+SXA(SV*Q[)-7_'VS M'+1*_-+I18DDS'+<*B51GD"6P#;+>:N$G4WV2V":Y:U5PA3*QTS0F^6R5:*O MRJU-@"MZ:A\[&RG/#:1WO_Z5CJ=CMG9%?:^BY*G( H\I?$-VZ#+QO>9<[Y $ MOD.O;S!57 6-[N-&&HRG<<1 [H QTU#W,2Y;'FG,72J9)YK?7G^:,C"[ MPI?Y$>O:QY&#%]M$R:3D,D*Z90\^H_GX&1!36)_Q,'#G'O*8(Q-M2!3PB%+4 MG=2VFH'H,>Y0ZK0ZI[%F=C\39A?8OF$JEY^3:=9$FN!79@[7PED%FA54I(J2 M]KL< 1#FJRMPOM54-F^7F_\Q&L%#< =!X$?KA7":;GYCW9II>XCRGH'U??G" MAROTZ(SW/9YR7J3TM9J89CA7MD>B[=? _6](@U7/O[%]&=NJ2]F("D)-F;?D MM$?)P*6;-V$_"DZJKC!AGC!:^='.\IX)D=I.Y/@C-_I?O UXE;5*88E.S ML2K15JR:2BE9;R%OHQ*X@.=C:GY6(?82IU4I*<&V M]-#GQI--3;ZJ +L1ZE?*M&J_I>,K?NA^Y>-G;2=5Q1V\\4.I',9U!UH=GIL- M(UC]>XW6'D.1,+\*5+_^S3M+WB:Q@49VPJ/+C#U5O-,WBI6$-)>!V=!P/$B*R'#=;9= M8_7]HAL/:ADSN12:J#8QCC8_/+%;)36F@,+?YX=IC^(:91.I5;R2;1JZJZ?8 MRVB7=8\'SI^A1Z#P#H ,'!FJ^HLZ.@ NO2)X?DUIR'-?QX2'2L93^;(:(M0: M!)2Z?R2[!I>2:4CIKC"9P"(DSHRI_GB:O5+&M&3U '@=8_Y$10.ENY!U!B?@ M0T0Z.W&C?M=WXH1]/S%B^Y@Q]0Z.8@_[44L5M["25'UJEO6?:U"U38(-JAN3 M52RX+;[66\?H"PG2H:@=.I'?'>8OY;QK111J=#6/V^5T"@[;[%R^,.5&CS"Q M QBC_!MDJYI%(6,PN6 @,WR[]Z7?5>5L,#5[\EQP/RV_47"O4]E(L_A:(A]W-8*Q4OJ44W?VF(JJ( -);8U,+%&K0NJJ A[&5#?7.4)GPEZFINHU-SW20U-1RBHU- M30E]DTD1/OPINW5:8FHZ<4.6;>-XS-1\Y)HB6SD34^24=/?\YH,16_%9N5*Q MR3F:EU,>N72T46 MH5(!S<,TSZ+7R0TKL*E'I42OG\N4Y3PLM=HE<5RIW.N.HMK$2"YM6DT"["O/MZB< .(^Q>J\ RUS4324FX M\7\528E=W'T5X?%!Q-QKE6#93>]$;HKNOI[:!7Q9]S$-":0FRITS S?D =W4 MPQ'_F)O_*HG2@@7*5/=2I4">6]V7C>)2_5>\J MC(RKT(7?5*)^"]EM2<;>_ M8?*=+_?8 ;E;7444FF)\8C]_L=D6R[,W=5*0[RR!IMB6+$J>;;=7LYP+(>^S M%5G!FIKM* QW0_]-S5(4QKMAJ';.+M2]6F:_,T+7>YCX8QNKK4RRA(B\K;:^ M:N=CSRNR/GP-%)3.LK/YW1;1HM %5+1_?(%YL6S"C2 *\LMPO=54^^VR2$#W M]HOLA;%TNV:8O$9,JWG*A *CJ;;-,%O^%25I_LO)[76=D@&\_;6IU,"8ZICL M)H!X"IGJI2B"W[)SIMZ)4,1?MCKM?,E!OP-7D(?%Z\-CM,JG+WQ)U5FKL<^] M.V9U8-%<[2SY%'TZG8/][D,TP9";/O6JI2Q*?7WJOY.?WW-4E%5N>2^GM"\@ MDE&1BIP M>QPHC>;M%2B-114EW25:V-3"2V V)#)SN^F5 #'94CFQ>(;L38]-_'L>P%]/ M.PD.Q6DUHSB[R5EDZN[E ].5X+#,4)CJ9@B)06+.F!H7D9)#E1TT-3@B)832 M)Q. M*-(TM'^1-5=99'@O)+'G;Y*6 \,BPC?53FG=CVV;,^UDG-*OF6]Y1GYDSW)>4O1)&3Q M"T4XO'BL[]ST>@;NG_YK]>5=_""@M#%_J_O M)N^/WQT@W\:.ZS_]^BX.#ZW0=MUW__6?__-__/*_#@\/+J_O#Z9VY+Z@2S>T M/1S& ?KW^V__S@Y^3KY\'5R]O[D\\?)R?&7_WU\_/7X. ?@]X2>@]P_!,#[#^^/ MWW_)_>S.LO^RGM#!S67N9Y\^G4PO3C^=7T\F5V?G%Z=79Y\_?CF^/+[Z?'EQ M=G;Z\?"8_//YT\F7R0GY<_+I. _Q C^O _=I&1W\N_T?#&7""M]'GH?6!]G1^D/WR6__/H:NH5?_SQ-?SLY^N]OM_?V$JVL0]NX,-X!_SFUV:73\Z8W1^R!(W4(D;603P7[T$$+*_8B M&'HEC^M!%J\LUY?&=?.T2E39$H,8R*SVZA M(@PJLEZQCU?K!.9]1 #2H^<"^PZA$CGDCQ![KD,^=\XMC^J]^R5"47AG!>1W M2Q2YMN4UT3DGP/]L"[S(V W!9#.ZODN5).5#X9?H-4)D(2=]GE*HC2$,.X*? MA^TRB65RMK#"1R9LQ%)XLJQGAL01\J(P_81Q\?!XLE'7_[;YF+ 2VW\ML>>0 MH_KJ[]B-UM]QA-BG]\^>2['=6"5S>H!,BBSTZ+&"@_1#SWI$'C-7)&$?J27V M@1@TQ%):)R@L"9M#"#VECRM&^0*O5MC/K3B+(VHT4,,0@GL]'-U$W(1AS+>3 M%/XI"-VH3^-HB0/W7RW1SX/11P+1++. :2+G=\N+T1T*&#J2I%2#4TS2'8&% M@@ Y[3=&(Z@>2(%OCSHH/1 @MTF:(&DEI(NM(@I1,6'W\6.(_HZ)37'U0O[U M;6,D P[R<@!ZT7X@B%YNG!!IU/- !HW^GR=]$#!]=4$64R4(U:BGQO:#]>B! MMNSVD[H0)3X'NB%_PMA;\G2&,/=GIH%= $H\T13@QBD5C*DDSRP"O*K'8;,8 MKF8K#HA3\.N[R?'QY/C]\?&[@^? )6H^6O_ZC@AV'!*,\#/%G3EMS 7_:F,_ M(I[8E<< $?\-/=$_^/<>)E[5K^^B($;*^%#JO=?RI2B"6&!S<.:<-3-'$9TE M0:I2*AMT1#VY7)5QDC^80')!3W=/<9[>3_W16XR9"1*[=895DYM:"9S4+T:3 M*J3'1"VZC.C)R=B(WK7+.;$?QTELZDEEA)XWQ&.J*6J&H!:?X M\Z@HKMFRIR/03Y6Q04[E"!13?00W(_5L!*JI--#.*1R!.H*G1CCYPKKIEZ-B M3DM#8B_[-IPM9L138D4'X=0G/UH]!VA)#>P7=(O#\(=OQ8Y+'NDZ_=<5"N8E M"5M3MD\E[F.J8XNI[D.2^Y#D/B3YQD*2^_C+!>[W# ]E 4!>YC M'%&]_( 3HQURZK9>2K%-07#@"$$(VWJP$LU=2:>?_'EMN0&+\*,,]WC M70E6L:1>NB\NT2A.6 R/7UCA$B*WM6"4&_ UDL /P-DB^3MRB2:X1S;Y:>3" M"F+;KM0/(YAHZ>"#Z$)]RL,0\L*.-@$Y_6H'#3HQK'"R0&\7 &ND.%NM1 M*C1Q ["68F9,G7_&8<1LI0<\=1PWL73O+->Y\2^L9S>R//;NSBUF9*V>B7G! MXHX,Z1FSC,E[):9V2$RJ^^0684+E'-GX*3$"(3S3AI)J.6M3E:R_#GG7^]'%]=UK@")<\ MK!C=1&70'89]C+U^HXQ4DY\69]98%2R!7FC)J M,GD3YUF+Y#KGU-CW7VVQ1<8&LV^ZM6"#5!E-QI8/8[6,Y*JB.%]&+2[U-6T9 M$SZ._33:JB_,"/\\=IW9NF(T9=6)>%S7X+IIE9<0P>L.MZ)Z?]UPW\-Q?X-R M?X-RGPW?9\/?:#9\?X-R4 GA_0W*ZL3W&VEOUN+.J'@?L)Y]'QH+N_;PSU#5 M3='J!\=:U'\DVTOD=1E)R=("-#)1:*K:N.46?!P3YYER*@^F(C M>LQILEG@/KE$/=%/IRL<^Q'(/Q8 IOI&,6$LV;HW!(R$S23ULQV[;4UD%5_7E@,4"V=%L?BWU#0XH&G^!KA2+0-!*4R[33LTZ6DATPJDFPULPTN\;!'#W' M =E#-.E9S):3C91\@.@<,OH)B#S9):!=*.;(0PPTKZMA)CQ=UT&K9]';Q@!@ M?>R8;E^.Y K]B"6D@X@PJ.[$[.J56H:Q&RY7@DUZ@ UBAOAU89Q.WCM'B>R M$@=&H3PRY A,N$=='ZSB,:G)Q.U-Q[%E6Y,E"-%M,.]R]XQ7X8L\%$ MP_X57DE[0Q-6I$6#4G$0L"Q&$C($'L8PN-J)G-HV#1F&9*_2R"G9E.23($9. M9^2*K:"=<+H1?4)':_H*@'I[?W-D(_<%6IHA!D\[4<07>K98=P6!PFE+^I/,X1T2F"B;&*!^&>7(0" M8IHDAL!3-X M$C3(VQV">Q-6VFT[@KR MEEEMQ !M6%-:.6+SI!K=QZ/&><) OU1B/+BY-_*ZBBED3/E@=#/;CH,VS>UM MCC\:W0I5'3_4A!XY6WNT IO9JC3NNWV?MB2LS9MG&KT;=;&I*FW!V63TQ7E= M;"HFHS+F?#9:@^EB3D-^D7-KKYB:D\J<6T:W<= I6PW5!+QK[9O6Z&WJ2S@+ MW[2VKR@AROHQBG04&B]WX&5?G'%O6O/75/UQ#NVU/;!FDW>6-EKM2Q2WUC)$ MK&(W8X[9XT:Z9DY9U39GA=%*J&M6%,KQ.0^,5C.JQ*'^R@7OS?ZF%$G=]1O. M$J/M0:4ARU:7M#(&GAFM?UL%PL%7^#A3C-;$'=^1S#$2W9ERER^ MNPCGW1 56%M1$V]"PP>A&*VG%,I84TL?8MF&\Y MEO'([,2*]NT'D"ZS\REZMN5.HT$^M.FMJG6!AI*<26]4L[=M,>S=AA=KI$<#P$J 4Q)]UH;=R&],H>TQGM9B>"Y%IR0]F29\<(E *@47Q& MM^$!?7 __4*-7N,X@(P-AD>@V[!!T6 (SCJC=XY)K"O,(\GX)Q[/5S*MAY;G M>)A2]QORB7G@31W'3=:]\1#PQ1]8-0;GPB MBC&5CVO+1HF2*O*G>?Y).0SEW7((BWSDT/I"(O7AU+;C5>S1J4:;6:P0,D2@ M&=VP!$*LX=T_!])@9HR#:.MFQ--:U"#,38,#7OP'@M9!JODSDRL;I?CDX+ZG M1SX;Z);&MN@ZX*XIS: T#.3B9\AW:R4Q1[@:QH"1U] VI;@TM%]*V=-069X] M7/SC'"BTA6>$.!0B^_T3?B'6K$N9(B>FJ1%VBI^O6;\" M>*NF.C :V]/M1O2 '>IN^^O>5$\'%F3V&QC0+B"R^VGM^VGM/4]K[UJ>FRP+ M/J_="'$N:W0D:%[A*CN/DVA$*[:2'=N&PCQ]1N[0&I,=E[DOG)SQ[,(Z_S"C M]\38'2C@'%<26?3>.;&F[L5N:,U3:N2N% [78$!P\PEO^T;$8#6EW:22ZH*@1L= M21K*4RJQ.%_+Y(^%P&G+)5>S6#ZQW 2SK_>UZYRT>5VW_>6? 126)J.;7A!/ MR@G4Z \\,RVX 3!P W,6&C&4IR[# -%O(FPH*F0@6 =RP@+!_-,A_ X/\69#M;Z*+8CEFK> MM-$..[P,*PV_WPP&'&W5=TUS^)#_0<$+R#TO?U[Y!=GL!9[0Q# ZX#! %J)RN8OI#SE$;?KG%0Q$D^A0 " M_^9(UIA%$<)*-J<" *Z8W.JI$O"-V@Q+,3'GED=;,]XO$8IN*:K4Z@7+91V4 M@1.@8?^4+0[=)M4PU%^":ABJS;[ \L,%"L)D[/>+2WMH90/?J"N8 MEC2&U+@+R[^2L!0[77?/I,9U->SBDL6AF[@2A+::@1H7O,U]= &P_?E'NR&_ M=D[2;7_5 R J2^L'!-[46[K<+KX?L, V-NRR>UWE0),VP^KT-.>2Z9<:>V*2 M(947S5D6)98#%K$;32C*T*5NJDU_GK 5SDCUI6\:?: &@LOZ$_18C2*D/KJA M>3"%* *>.H9$1DRH.]&UQR6B8)P]@RE3A <095E4IBZ&4L2HFTN#*_R1";[7 MLJ@T><(+@@91]2C)E/)\&*?=Z!.G2]I/=FD?_['3F HVHD&'V"$CFB'/.VUU M"7U.>H][0.C@Z)+R/-U&E_LV5W04IF*4ULQP4HUVLZ%1OZK*)EZ[:72)JVR0 M4[B\;" UK)WP(2L7Y-6KPK')/JI7Q0ZT#LM9I18TL+X51H?B@I'\T-$<,J"Z MD$H8;['P]0T7(N^+Y]YD\=SPZ\CV6?=]UGV?=3:>8K]F MW_E7Y"%.]N&!WA-KZOA0[5CQR+'!'>ZX3N\XMIBA7Z# #*(JS4& M_R"B0@[WQ6QQB1:([B?6-38,8UH6 /691: I'VZ7+)P4+;$UPXND7 'OH0'?18T2U!^W:?!>@ ME1NO(!0* -/A:[HV/;*M< GV*G-/:A6V.7J. WM)S?:6T[%W(6DFQ$&KY^0X M">W 97^VH:847%^*X(&L$M(.2 ^!17MA75KK%J-,&P'+*'L.GI^(H! M@0*;_,1Z$K<*.EI-=0PZ[_VD^I1&I!R$5M2 )L=9LB489M(9*Q'0T/?YAQ4$ M%EF@:L",\*MJ!J1A!W%YF07N$S&+/?IIOSVZP3@08O >*#ZM."=&-SY6#Y!Z&0.O)UG7R(V+:&[P%<#K>$6B*&?"- M@6 K3\GFCR1ND[--RB=V0=*P0@#;V;\$F&^[SY:7B,0%C:AX'A+?_*+@H&@6 M/^$*8,"%5Y R#%9/QFD3=,ATD2Q>I?O=+T=.R&RP0+*B@04@2 ]>-SR[R7 M1E!]N$Y9J3V=]IL,PK2H_7"^WG9R6CM1D*7Z>:M% W#J.\D'B-X,[BBBTKP$ M^&@(L(V0$UX'>,55,G/5\U4F/T+Q-7BK<]&JVG!O ],;A9 R+)PJ U4K@3]\*SGVD9-F >7I*@76 MY0;V'+J)#.4! QV\D)6SQOX!<. M:L&H)B%^#-'?,>$;4XD2R)<#T(LVO>P)OP-1 T0_^M#[#)4@X'X?\ITD UO=JL-HBI62!2I<_"HW=IM%(&A8JGP4G;)/IHI8" 6%0] MKD53GG>C*2O R!^V!3F%BGL]%'!F$?U,S0<@(B5/*GZI288B&_L.5\ 5 )0G M<(AQ3!71UO(A6 77 P)/*TB$.Q>6E=TN('!:=OZTFYU? 0;*Z1]^D&529%1Y MY?/R^2"Y$P6&1#@&.VT*@7[JP@6L/EHNSI@2&L9> 27Y3UN;5L M=J/A?)W_!CY[21RJU&'3UKOKUJ7;&*RYRO44(O0L%("D^CH%1> I67+JDR/9 MM_@G^7-Q')X0?=T!0 Y]V":M-(N>L&LQ$;*/6@&IR=A MRLQYN.8O>UJ7]YA?6]ISW 6BFM]6N(3OROQ36J]QT0N!Y#_4P7ZQ/*H4RC^% MD]1NG3T3=*A>.?2DYEU*K@)7XFE=QMVVG0+6WXV0=,R%2DYCR>%.Q8<'A:X. MPX.O*>,CESX.EU??Q0&3-=K^HM!2 "RPS:"T)IN_6RN)J$DU#*W(0Z6A[&DY M"_1",C]1\70?!7G2AF8YF#Y(@+[_&B!:Y1;@6&@'#:>/7+,N::)X8'WA1/0_KC^A3&CVUK4PEYD#1O1W$Y+B M&E.HDL:\I6;"Y"@!V6TT5S' M#9ASE'74ESJXO N=4:(<=U(DCH/KYS,DO$C M?8[@$=JMLE2:,6I'=,QE:60!BP=K.*WCV9]M(FM\'L5G$^2[<;)0NS!E:Z;Q MF"QG7(^]:<7G$AG!MQS7/AH]S:V3Q$#>Q,\E=C@+^CM1NM9 -8DV3J[I3EMS MRG'7:2ND1#FI0_#5RG+!&)BUYA2/QV>KJ"/(2/UBOKU;6TJ1'^P-KP+A;##> M'E;$A3P/C+:79$T1JO+2?JJ_%2)DR&,*E4V*40+Y#D]!L_ 5NB MFK2"*;L1@DF/'J6H(] M]7G:#1_045GWG"-PNWH\(^ZT/U^EWW!A.2-Y.!&QVBO< M./"9Z.Y %'3%2TP4DI/)D9G M,81/WJIN)9Q.H_8O/NJ M9E49L1^,"-'5F1P-+;OJJ=TV.$[Z3,X+.+V-[=6JR=V18[,SZI!3MZ)%'Z?4 MZ)[ZB8TGIZ)CP#UE!:6_3$Y$PP>A*R*!-$NYERLGOT#Q7*>6FG64ZT MT=.>I8FN;QN<4?_!:"4N*NE-;: YN4;;HIV\[$U#;DZRT9&]+G39=EOUC/2/ M0S_+TI]*-\3/6/&IQVK;3EG1>CQ"QI+/ XHQR$A'R0%O=OT0@&2!X2:DKFQS%631T]Z;""BK.">/DCM.MJ9WSQHD? MIWNS/;8OH_=DZ X-+U#9&;"8$=EC"+E+KZUB[&5&YN#C$:"AHYSLL6Q9P:&P MG/"Q."GP>;\9#SZ,\VRNF.G,R1Z+S(L,Y\ZH'GR HF:D.B=R+!(M.=Z>,V(4 MQUGJ@['86UK"'EZQ"*1SXTIW84"J_XN\O-1J]XOV/1 M>)6AI8@!AO)\&(5O5O1.-DR@7ED6?8RC&:-G8\[/_$V-#&TNQ&JX;^AC$4&, M91KS'!I+<"X]T:^)Y^;;Z *'47@1DT_\Z+< A_G3[6PL*N$/@CVQTQ>L)FIC MSSQF"3/*@CS5PD;-+T><:++^7\F'%/\Y6AS0__Z8WV2T_OSY\[V#/-N*EN]M MO#I*.Y$?1=8K]O%J?<0HI\K*PR'9GULM+],[N/?Q:F4%ZX+;D?BBB5#_\ DA M[(%+%%FNEW&DJ@OZG"S[I[IE$R$(W=4S[W']2Y%QA5^BUP@16$[Z?$%@^F.B M^M[<#8&5/(^:NW0W -/::KPV50LC2Q"H!O)J#YJ\*+5X=*Q$2RW8<5H_O-^B<.Z!L-$U^)6,))RI87 MD\*E&P!TU.1I&*L+#O^(NP M=6IZ@N3.HFFO)8I!ITY*20-&A^DM5YJF?8SN411YF\I:P=!P M^K@>PSY?M,^3Y5MD^5[5-E8I%A M,])B:B/#9N=UNH@,]YC"Z6,.:Y\-F33/89T8?1NJPWDQ?>9O^J].Z+.GDHFI M>+-S0,I2\3VVFM(]@[C/')YVX1ZCJCGG^M#G1N3YR]PL+*2 MCFBI1J<,IKI,CJ5R"M(-C*2RE?W56\@E<8;CVH M&DVB&>70+#ZH&,TY347 D2P\9CR*&KI=L-6@08G<0]# U.SAXA_GP A4X1DA M?H3(?O^$7X@]Y%)6G-$_*#)G.0Z0C[+:&O%P4ME3W:+D1T17W;HAG4$79L4_ M@F^H"8)JA5X^XAN@M#HBA."J,(B+!UOL:RP2&*!K3"FRK*@+83+33+#NV;4V)ZXS.@UH3)2B;*=EXCDB1$B6=>K:]=IVB:) M^V]&E/L)G1JB5 VF>J_, <>5 0M.E-$)LR:BBL$B7G)H9$8,:LO*!__N/,MFX;C-V"%!K$$P^TE^LX,\^?B:%H$%+X2+ M7:2^JP#W2.9W])-]TQEY.8!:QTMPW0S>34" LCK_=UIQ!=;WFZ? 6H>3% MG+L.PUYRHV7Q?54*(0M33JNNBF45<%F+?7"7'?0DJ/W)YW M([<58/8]\O8]\LKMP<\HRWOJ;P4:D7K66;D?QQ5/1&DB]W'45402;>R^SB*8J+R M5)/A8]FDB-Q*XW$2C6Q)V(T>J\R<C&=+E)<+?^&&) MX] BBL%W[EU"$?*!R5T(2%#'#)=M8\JYT\W?E*#37'XT^?3/9+_3@SW%Y>KU MV0T2/I%S7X0485#PBB&Z^XDQENL178 MUG1+');RV&L,K5 M>CA2Z>"J^U"<10E\<89#P4+1+KR\=0(\LC L3^!,FA($2H M,#Z@8)7L2^)XI]M56/@JGNY#V'+G36M9*L#J@YA47S,_./LRW'P;@LJ_)1> M"A(+X7!(R8DD+$@53_=R4FR'8MH?%[L0QW.YJL%LJ+),P"9$-: ^FYYV>2-J M!R*\')95:!"?YCQGH*0,!!?$B@"30[$S]+I';=H9YV10V]>5&U%7GKZO:_08 MQ%:P+@8,KMU%BQB$$$Q9A(M 'Y9NT +3>F!]F$72PEP.I@\2H%)= Z0/],$C M=^J@]$' ;LQ:EHC;_N;P"%*V6YU:^AK&6X0/$.4F7@VM&K]9^311/+"Z?)$# M X-..!.*\Q41+F2$\$KG_C+-BK:XR/6$4]/G0'=W/>'4R 2[6$6PH,O%:1V" M%FNFM<[SY;0.07$)O->&(,2P*ML!5IMHH,CP0E$X P0C?[PZSL@:8$FZ)0L$ MC:SUEI=]T4@ZKQ(SLN9?4@8J\B&\5LS(FNB._=/F))5$$=F ^5%(2V:DFSUO M$BCW%0EE3NS8M)Q@6C]C@)F7(3H6=%@M1\:;SR-1 I"ZGHSX+R-1 X#"*T[[ M2#9%3%9% [ M1])6%)X39;2ET$14,0/";ZCME5=U.HO?:S-:GA4YU=UG-3-^?C"ZC-)0?M:E MU_G$$:-K%0WE;&7AA^$S3C2PM9OJ(\['MZA(*RK6^,W1_9[MIGB17T5]@]NU MJ@B6,T5X[RFNX[ZVW(#=K_V&+/K_S)#C?E?V-;]Q*E>_W7J=?NNVY=%7F^7* M%IZ&89S,E*!W)Q 5/7I]%)+#:H:E.&57AL#<#?^Z#A"Z\2-$[()H+C@? ZS M!^)2[OZ./:)V/*('NB"O"JIL'\72"RHMVRD*P7PSG2HWG5W^7^QUBK,HV$X% MPY"A)/W7J>RK5+85%(I"\C9O7>N1:B4BFIO#U)GY[WUZN4):$KGF0WI8-&:4BQCD'3B(<9.:\8+;94-3C%)%TB MUJ_=?4'7KF_YMDO[NQ'K)68;H6"50K<6&+2NMU?OYS$#^X>/'T,4O-#X+SN. MR=>8D."YK!3G?)W"6+/NBBT$6ATR>W9VB(Q>[5+$H(5>*0,T@.SA/KFZ3Z[N MDZMO-;G:H+\,R[;67)M(%U< ME##A9)<)@SMH6C/A=)<);[MZ3K3V@?/+Z,HY8'&(,"/RW4&$&:"XO.L[BF[I MT$(4;,;TT5O$4S]R+UTOIFX;G^=X]6I[L8,<.N^,WD*.(^8+SA975D!'@E$@ M['&Y,B\-F/1;[J620,6=N F2CCR2TQ4=D J)3'>TH.+ _:;2&IX'W7H0>K'Q M!YM#AQSID1PB4/9S$. [0NX^9C.L$1&C8VY .^5QOBX' )Y"H!(-;4W;6U+1 MHG-[-RN;+6M2:=ONUM2=L>V<6Z4-W;L1G/%G;!5MX6M.F!'9K-O04.H%G&#C$@KJGG96U[H0%*'*FV(CL(.$NDTU6/0 MX\>095>CJQ=VR;##B><2H/N-PX$P5NL^; *!5.'<6<$LN">BA1P6-DZ%"N(9 M"('3,:[[)@QCY%S&-'V0M-M,^N7.T0L*PN1XN7_VW @VO0H*6@>I2^R1W1Y> M_1V3#?X=1SD,+K!/<2+2-*S%F:+G,P+X]W) M6E "T\[1#X'E$-F]M-9$9LF;#9#S@#=9N/+594CL:#59H;IZ);QUPP3F)0KM MP&4G'EBTJ@$IWMRLKC'KDSH+YI17!6QX$]7-MR%HATLNH/SVUV/$"S03+1.Y M9&-PA<-P Y$* *J5O#EZC@-[:842*:HF2++J@;,D3 ZY>T2ME/4UL4G)+DZ. M/&J*7I*SG?T\C%>)S0)6#JW6TOJFOED1M<;7E\#&LW50H&]H2UAGBR+P!WRW M$8%=1X M?:6^6LV9(@&MYJD -T=]\AW<<"L)SK*)W.$Z8D.E'P14%I]-+F" ML6H86I&'RD/9TZIM?^[AP4LE2QY67>')HM8T889]PB*X9%0 T*4IMI8'U_\U M %)-!FOS?5%T5^%B4PM&CZ_+EH1+3]G3ND0GO[:TV.P"48U^,2\J(2SE /2B M30?X2M@FU4#THP\6F2H08$>$R)V31!=9.4QL1RPLG(45H&Z'*#S55;JYZ<_) MY3:+?_) _@HMFS7CALL\&+1B4NG+GRUR6$&%J0* YET +ALO?5XOTKS/S.I6K-=@<94/^ZX]((SQNC36)PQ M+:IM."^,CHY A*1M-15GB='.!VS?=%9&EW'GTP@H90W?H: M!.>)T4U/(3QIN@23DCPY[M&3Z7#CB]YBXG3W>#YU2'='=] X6T:E"ZON%7)R M!Z\$N[LMRIDR&BW8= ,X([G/7*=*DFLO;SGB_'-'5'XFI]9__'U!+ P04 " #KBVY+ M@HV&H )F #JM04 %0 &1C=&@M,C Q-S Y,S!?;&%B+GAM;.V]:W/DN)4H M^'TC]C]@>S8<[=VJKE>WVVV/?2/UZM&NJE)74KOO1,>&@THB)8Z91)IDJBK] MZQ?/G[^+M\4&?;=!NS?;)(NR31*EKPN8OR0;6+P!KU]72,YS&)680' 1 ME1#0__T)O'_[[L?7[]Z]?O?]P_OW?WKWPY_>??_=^S_^^.[=3S_]WV_?_NGM M6P' W]@"@? _#."['[Y[^]U/PI_=1IM_1$\07%$?_;CC^]7YQ]^/+MZ]^[R M^[/S#Y??__$//[V]>'OYQXOS[[__\(?7;_'__OCC^Y_>O<<_OOOQK0CQ'.V/ M>?+T7()O-[^G)&-69!E,4W@$5]6B7X&;F_/OP"I-P1WYXP+<0<('&'_'8:45 M([&XLN(OWPA,_/*8I]^A_.G-^[=O/[RI_O ;]I=_(O\V^/,OO;___('^->;J M3V_H;^L_+1+9'V*P[][\CX\W]YMGN(M>)QE1G0U!4"1_*NB'-VA#Q:E!%U#^ M!?G7Z^K/7I./7F,!?'CWW9M1/?3&_(7;S+X MA-4KOHD>88K));#_])S#K?Q[:9ZWOD9(^(F0\.X/A(1_DT$KCWML/T6RVZ>8 M(6^F4/D)EFX)[0)T2.LMS!,47V:.62L'ZYSN^S+*'?-:!=@A[0_8XT&W5/=! MNJ07E5'JF-X>2#?T6BA#V2=10_(I^0NRA?(_(L &?";%Q3VT !1^*6$60^X4 M"5BTD=%.@15P\]T3>GD3PP0#??<]^>$U^>'UVW?0!$!C.G?WU!:6E2O\DT+=Y1O*K3XQQ', M_"_>;!#>,/?EZU34D&V.=H/LXVC1*&_>J!0AWI3/1-@XA/GPEHD:?_+W*G9; M93&#>IUM4;ZC6_CJL< (-J66Z/6!F:F"+EPWJA%S3!3T-W^M(UL<(./0F:I* MTN#^;A$M,18;,F9CR")B+&E$@S$";L4"3O!;A?7_ZPK)F8>\@T$P9&5GZ(= M-'.0W>]:^L%"?9D^%9^[5[@:/"#PE](X.6>1D@,A<#'5 M8:!#'U?G:9CW1_?-Y:^DQWF/1KE34A\[CK)$1;K/6K?XE_" M/(E#Y X=LI)?^VJ_:FM",W\SU0+LY5V[Q@P*>F62U[A!1)&# M#<.^W NWF0R1.4N5F1*B.]Q&Q2.E_5"\?HJB/?&)/[Z!:5E4GU#U$YPC__CO M]YC7D+!\O:U306]1D9@F5IC!,U)"$]!.K;U&"-;;)E$65#@'WN[G4#\K"2(; M=GI6P551P+*P4;;N-ZW4J@W$0Y!(X2^I(0H&HV$>!,/,5.2C7<+,5.7D'ME> M1WL )G"W \O? W\4B.:JN-]38"EG0N-T6YTK7L^LUN=1\;S*8O*?RW\>DIP\'<&E/9F%9I"KS88>OX9:*H6N"L>*X!V4>"$$<+(,-;T ,)(JBKN^\ CNDF0D06+ U;8&E; M4APA#80H2M ^ZL]B5A?\?8'=[,)S5-2+-G3]8Y"L9#,,U,/3:/6.Q'M\X#!T M0W N:32:(D)F7 M6'&E'$AP7H,CJ:["YMAWK#<;%5N+!!Y5-GX&_TIX# >T. MH_N *X_OS[7F\Q>NFY;)3 M]N"-9]&SFR1Z3-*D3&"!%9UFZSRC-,:A)='Y\FCS(JP/TXKANN#=1]D"9NJC M1=R_B_:H^#/ X5^R21;UU\8B1;:\/0'QI7W)K3J2 PSOW"_4 DD3LB^&H$P5 MSVQY&&F#,Q##TK;H0)KV2M(%Y?*G: M,T0A/% I1"!YFI)Q)SAV=Y^C.(Y9#[<8>7Z <=^<#15AZ!QE+S O$_+VCTHX8<\=@V2763<(U$/8V> #&4%8;<;TJ@V@ M+8CA8PGBI* [R*+9D'J20V;,#%9*:5] %-_@%=D,O$>FZ/VT;'X9C^9ZE M!NG>7GZ-?833>PC?]P^S9HW8'? ^EFUL_+D2R*3DA!X\CVDB.<,50GJ(6A:2 MS! %CT+D>]IA.4<#&CRSJ#S-T!+LS4[GAZ!8,5\-T+W6LR2U#&6O W/L&K)! M^BP+4@ZI* +1[<]L!@)JR^!E^D[J*UP)1)ME+);')VX"$U\1R4Q7,KM=4NYH M\5(6XP-OF61/,-L8ZN<@&,MCOA*BCYN8&AE]4&^A6_;>95P\R(!I88HB[4MA M-28%3TU:7.2=.,\TF3.W1))+$B^?2V*6/>(E7V2F#)$ ,D+:SQ3&-=32K]M6 MEG0AN5?X3N^K5^#__.[M.["/(7/ MP\4>T@FKZ:*WFT,J@#0$%):X%8]A\Q5("_WOS1M^]+YKO8F+8/P$42A36=$/ M;P?-Z-VK[]__X=6['SY0RWCW[M4?W_X@,2SR9S^\^N,?WE=_]N,/-3@G1O=_ M+1WM2=4$C[],>VPD2<)V!:P.Z1D)"Y/ 3=1?1UHEHU3Q@#[J&<2L(1PB#&0%3)G7=!RX<92 MH0,5/B"*2%&SX,5N'G(8%8?\:!>3R;YMQ?\^H(G\EHVW_VN%I8K-<'1$JK)Q MU,5BIQ,-EP9DB,99'(:\ND-6N*!F#YL:,Z1/)#AZV^?P&68%%O-UMD$[>(.* MXA,LU]N'Z(M1.&4*VC:WU02+ETSCVI'QMB$B"2"A-"R/_N^=@ZB M[M?RD5P!RTNAZ S/Z304"],4M 5H4-WKL:IW[FK>F78%/F'@@22GF^T([6]. MFQ=!@?AXDJS&0_Q&,80Q!:+-:]F\!X$=P? UU62I'ST]/!;PGP>,]I*T/WS MJUA]28P2390@[#@LA^9!A6M$@&):;'*>KBB0)I/"8WLZP''P&\&SF+)?H%V4 M9!/5O0+BBO,,WO^<*M\1R+#2BXP*D?G#BL\P+:+Z'^D-X@2UKP"XX#J#-8.Z M_\8P+1NL# I"K>XBDT)CNDK-5?SV&W'?)!F\QC^:!3&2;T^+$&M 7J-O@@50 M-&&$X'WFR\+P#F^"8G0_'!_@\0S)?K=1OLXI-3%]?+B%^3UY(3+1;EV(#G+$ M5,!GR!*L4YO MTD&8I2F$3[T[V'.GM1^'T[VWJA,E0E]P^P-7GYI5W3L50TC M!>L<,+3LC8V,F044\P(V1_$6JSH9SM[6^I *#Q+AB9H2QSE.DMU?P^3C!2@PCK^#(F MG"%#F'QP\2J( 0.8\648CAON>SVI2&TAP&.*EL"&K,+- <6_< ;L M8^ZC2:O.A-%@8AO2KT\O>&&0W%N"HCZI,8!%]7](%JHZ(Y%38?$][;!<5/.% M2AA(:V6VSGV:E*SI@K>Z02;2@ C(01 R5#!JC9O?WIPUMJ M='3L "E46F<7\+&\AV69TD0#':L:^+(1PY5PW' T1IL#@48XE'WS5UJ6A3E& M>^<7-:[OEK",N.63%;G8!BT^],"<+*+!70G%H?K^ 3TFZ4';;F M=*!CLD":7/*L,O=1"@O>1OAGA.+"<%*N_/MV/EP"RL]NNW"7ZD&>(QV&!,;? M:A\D".J>U!3%;+-MR43T]9;C-KMZ:'W1\C@KP/!QN5#0"3)/E*,%#C26O4*0 M<1H-T@.F-G3)1^E9Q,I#@"QZQJO@N>A>7^%JIXE M^*=%6_:/B@-ILRE$UJ==KE=HYFZ&>P]3#//I9YAA2M)5%J_B79(EA 32 HF3 M913^:D*T"]BT@/N8E4CQO@)/##/M6!"U<"\:/IM)$=DQ-'B)I2UA 8Z3]BYH M8ZW,;:8>A@7$LGS&9%S@Z"I%>W*DM;"L$4"6'?(&8/HX:C)TU'[B!N&R?0MU MY(.,>!:J+-*.&%:T!UZ-:U:[Z&VQDT(M5_N\KW8WJ!=@!15?:<55+N,ISW'4 MO!K<=&RSTF'QZ].XVT!RK\<-DU,,/PCME?!=IK]=KH3%XYX."PWX9E'CJRC) M:1+M*OZO0T$GU*RW?!JMD4*/ +)B^R!,']UDSY\Q3:2A)=ABU#PK'&U!^0S! MY^Z(7CK*>DE3T),=,N)G<')J&PK!Q).^&USD[K+"-L_E991D!3%16*RSRR_$ M< ])\W904F+$'9*HOIOU*:^-[<]-@, MZ?%%@7.%LB?&O8/AM( -)P:4#7X0U00L^Q+@5[4T?=!4J7UU:J3IJRH-J^@$ M J'T:5H@5;SKG7DJD83)-DYH$(QMS; *HOLH_;P7:2QF>C9KW3$*4+0L%XHAGCM"'N�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